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A B S T R A C T
Background
Asthma is a common long-term respiratory disease affecting approximately 300 million people worldwide. Approximately half of
people with asthma have an important allergic component to their disease, which may provide an opportunity for targeted treatment.
Sublingual immunotherapy (SLIT) aims to reduce asthma symptoms by delivering increasing doses of an allergen (e.g. house dust mite,
pollen extract) under the tongue to induce immune tolerance. However, it is not clear whether the sublingual delivery route is safe and
effective in asthma.
Objectives
To assess the efficacy and safety of sublingual immunotherapy compared with placebo or standard care for adults and children with
asthma.
Search methods
We identified trials from the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov (www.ClinicalTrials.gov), the
World Health Organization (WHO) trials portal (www.who.int/ictrp/en/) and reference lists of all primary studies and review articles.
The search is up to date as of 25 March 2015.
Selection criteria
We included parallel randomised controlled trials (RCTs), irrespective of blinding or duration, that evaluated sublingual immunotherapy
versus placebo or as an add-on to standard asthma management. We included both adults and children with asthma of any severity
and with any allergen-sensitisation pattern. We included studies that recruited participants with asthma, rhinitis, or both, providing at
least 80% of trial participants had a diagnosis of asthma.
Data collection and analysis
Two review authors independently screened the search results for included trials, extracted numerical data and assessed risk of bias, all
of which were cross-checked for accuracy. We resolved disagreements by discussion.
We analysed dichotomous data as odds ratios (ORs) or risk differences (RDs) using study participants as the unit of analysis; we
analysed continuous data as mean differences (MDs) or standardised mean differences (SMDs) using random-effects models. We rated
all outcomes using GRADE (Grades of Recommendation, Assessment, Development and Evaluation) and presented results in the
’Summary of findings’ table.
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Main results
Fifty-two studies met our inclusion criteria, randomly assigning 5077 participants to comparisons of interest. Most studies were double-
blind and placebo-controlled, but studies varied in duration from one day to three years. Most participants had mild or intermittent
asthma, often with co-morbid allergic rhinitis. Eighteen studies recruited only adults, 25 recruited only children and several recruited
both or did not specify (n = 9).
With the exception of adverse events, reporting of outcomes of interest to this review was infrequent, and selective reporting may have
had a serious effect on the completeness of the evidence. Allocation procedures generally were not well described, about a quarter of
the studies were at high risk of bias for performance or detection bias or both and participant attrition was high or unknown in around
half of the studies.
One short study reported exacerbations requiring a hospital visit and observed no adverse events. Five studies reported quality of life,
but the data were not suitable for meta-analysis. Serious adverse events were infrequent, and analysis using risk differences suggests
that no more than 1 in 100 are likely to suffer a serious adverse event as a result of treatment with SLIT (RD 0.0012, 95% confidence
interval (CI) -0.0077 to 0.0102; participants = 2560; studies = 22; moderate-quality evidence).
Within secondary outcomes, wide but varied reporting of largely unvalidated asthma symptom and medication scores precluded
meaningful meta-analysis; a general trend suggested SLIT benefit over placebo, but variation in scales meant that results were difficult
to interpret.
Changes in inhaled corticosteroid use in micrograms per day (MD 35.10 mcg/d, 95% CI -50.21 to 120.42; low-quality evidence),
exacerbations requiring oral steroids (studies = 2; no events) and bronchial provocation (SMD 0.69, 95% CI -0.04 to 1.43; very low-
quality evidence) were not often reported. This led to many imprecise estimates with wide confidence intervals that included the
possibility of both benefit and harm from SLIT.
More people taking SLIT had adverse events of any kind compared with control (OR 1.70, 95% CI 1.21 to 2.38; low-quality evidence;
participants = 1755; studies = 19), but events were usually reported to be transient and mild.
Lack of data prevented most of the planned subgroup and sensitivity analyses.
Authors’ conclusions
Lack of data for important outcomes such as exacerbations and quality of life and use of different unvalidated symptom and medication
scores have limited our ability to draw a clinically useful conclusion. Further research using validated scales and important outcomes for
patients and decision makers is needed so that SLIT can be properly assessed as clinical treatment for asthma. Very few serious adverse
events have been reported, but most studies have included patients with intermittent or mild asthma, so we cannot comment on the
safety of SLIT for those with moderate or severe asthma. SLIT is associated with increased risk of all adverse events.
P L A I N L A N G U A G E S U M M A R Y
Sublingual immunotherapy for asthma
Review question
We assessed the evidence on the use of sublingual immunotherapy (SLIT) for people with asthma compared with placebo or with
normal treatment for asthma. We focused on whether SLIT is a good treatment for asthma and whether it is safe.
Background
Asthma is a long-term condition that causes breathing problems and cough, which sometimes develop into asthma attacks. This may
lead to the need for patients to take extra medication, visit a clinic or a hospital for treatment or even be admitted to the hospital.
Approximately 300 million people worldwide have asthma, and allergies may be an important trigger of asthma symptoms in about half
of these people (e.g. house dust mites, pollen). The aim of SLIT is to reduce the body’s allergic response that causes asthma symptoms;
this is done by giving repeated doses of what the person is allergic to in liquid or tablet form under the tongue. Currently, it is not clear
whether SLIT is more helpful or safer for people with asthma, when compared with placebo or just continuation of normal asthma
treatments.
Study characteristics
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We included 52 studies involving 5077 people. These studies lasted between one day and three years. Most of the people included in
the studies had mild asthma. Both males and females were included, and about half of the studies included only children.
Most studies involved people with house dust mites or pollen allergy. The evidence presented here is current to 25 March 2015.
Key results
Very few studies recorded the number of people who had asthma attacks leading to a hospital visit or the need for additional medication,
so we do not know if SLIT reduces asthma attacks, possibly because most of the patients included in these studies had mild asthma. A
few studies reported quality of life, but they used different scales, so we could not really tell if SLIT had a positive effect. Some studies
reported that people taking SLIT had fewer asthma symptoms and had a reduced need for asthma medication compared with controls,
but studies measured this in different ways, some of which may not be accurate.
People receiving SLIT were no more or less likely to experience serious unwanted side effects, but these were generally very rare. We are
not confident that this finding would apply to people with more severe asthma. People receiving SLIT were more likely to experience
any unwanted side effect, but many of these were mild.
Guidelines for asthma treatment suggest that SLIT should be used only for people with asthma that is difficult to control with standard
treatments. However, many of the studies in this review included people with mild asthma, so trials looking at the effects of SLIT for
people with more severe asthma are needed. It would be helpful if these studies used standard scales to report their findings, so that
results can be combined in the future.
Quality of the evidence
The evidence presented in this review is generally of moderate or low quality, and very few studies have reported outcomes that are
important to people with asthma, such as asthma attacks and quality of life. Most studies did not clearly explain how investigators
decided which people would receive SLIT and which individuals would receive placebo or normal care, and in some studies, both
participants and trial organisers knew which treatment they were getting. This may have affected the results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Subgroup and sensitivity analyses compared with placebo for asthma
Patient or population: adults and children with asthma
Settings: outpatient
Intervention: sublingual immunotherapy
Comparison: placebo or usual care
Weight mean duration of all included studies: 54 weeks (Fadel 2010 and Rodriguez 2012 excluded, as duration not reported)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control SLIT
Exacerbation requiring ED
or hospital visit
Study duration:
4 weeks
No events No events Not estimable 47
(1 RCT)
⊕⊕©©
Lowa,b,c
Quality of life No meta-analysis possi-
ble
Not applicable - (0 RCTs) Not applicable 5 studies reported quality
of life outcomes but we
were not able to perform
a meta-analysis
Serious adverse events
Weighted mean duration
of studies: 49 weeks
14 per 1000 12 per 1000 (0 to 24) RD 0.0012, (-0.0077 to
0.0102)
2560
(22 RCTs)
⊕⊕⊕©
Moderated,e,f
Exacerbation requiring
OCS
Weighted mean duration
of studies: 25 weeks
No events No events Not estimable 77
(2 RCTs)
⊕⊕©©
Lowa,b,c
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All adverse events
Weighted mean duration
of studies: 60 weeks**
222 per 1000 327 per 1000
(257 to 404)
OR 1.70 (1.21 to 2.38) 1755
(19 RCTs)
⊕⊕©©
Lowg,h
Bronchial provocation Mean bronchial provoca-
tion in control group was
1020 mcg (PD20) and 5.
45 mg/mL (PC20)
Mean bronchial provoca-
tion in intervention group
was 0.69 standard devi-
ations higher (0.04 lower
to 1.43 higher)
- 139
(4 RCTs)
⊕©©©
Very lowi,j,k
3 studies reported out-
come as PC20 and 1
as PD20. We combined
the different scales using
standardised mean differ-
ences
ICS use Mean ICS use in control
group was 255 mcgl
Mean ICS use in inter-
vention group was 35.1
higher (-50.21 to 120.42)
- 174
(2 RCTs)
⊕⊕©©
Lowm,n
Both treatment and con-
trol groups in both stud-
ies included in this anal-
ysis showed significantly
decreased ICS use at end
of study compared with
baseline but no intergroup
difference was detected
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; ED: emergency department; OCS: oral corticosteroids; PD20: provocative dose of methacholine required to produce a 20% fall in forced expiratory volume in 1
second; PC20: provocative concentration of methacholine required to produce a 20% fall in forced expiratory volume in 1 second; ICS: inhaled corticosteroids.
**All adverse events was not a prespecified outcome, but we have included it in the ’Summary of findings’ table, as substantial data were contributed to this outcome. We have left out the
asthma symptom scores outcome, as we were able to perform only a limited narrative analysis
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aOnly a small number of included studies reported this outcome, suggesting lack of relevance in this study population. Treatment period
in Calderon 2006 was just 4 weeks and exacerbations requiring ED/hospital admission/OCS are rare events. Downgrade once.
bNo events but could be a product of the asthma severity of the recruited population. No downgrade.
cFunnel plot not possible as no one outcome shows > 10 studies contributing events. Many reports are conference abstracts without
associated peer-reviewed full publication. Downgrade once.5
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d5/21 studies included in this analysis were assessed as having high risk of performance and detection bias, but none of the 5
contributing events. No other serious issues.
e5/21 studies included a mixed population of participants with asthma and rhinitis (but all > 80% with asthma), but the 5 studies
contributing events to this analysis recruited exclusively participants with asthma.
f Events rare. Participants had largely mild to moderate asthma and may have been less at risk of serious adverse events. Downgraded
once for indirectness.
gTwo studies contributing events assessed as having high risk of performance and detection bias, with 3 others at high risk but not
contributing events. Study contributing greatest weight (41%) to the analysis reported only as a conference abstract with uncertainty
about attrition bias. Downgrade once.
hSix out of 19 studies included mixed rhinitis and asthma populations, and of those contributing events made up approximately 25% of
the analysis weight. Most of these events were mild and transient and did not lead to participant withdrawal. Downgrade once.
iTwo out of four (contributing >50% of analysis weight) studies assessed at high risk of performance and detection bias. Downgrade
once.
jHigh level of heterogeneity (I2 = 76%) and combines PC20 with PD20 scores using SMDs. Downgrade once.
kPossibility of benefit in control group not excluded by confidence intervals. Downgrade once.
lCalculated as the weighted mean of control group scores of the included studies.
mImprecise estimate with confidence intervals including the possibility of a clinically important harm or benefit from SLIT. Downgrade
once.
nMany participants in included studies had mild asthma and so would be less likely to be using ICS. This was a predefined outcome,
which may have less relevance to the study population.. Downgrade once.
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B A C K G R O U N D
Description of the condition
Asthma is a common long-term respiratory disease that affects
both adults and children. It is characterised by reversible airflow
limitation, typically leading to recurrent wheezing, chest tightness,
shortness of breath and cough. Symptoms may vary over time and
in intensity and can be triggered by factors including allergens, vi-
ral illnesses and exercise (CDC2013;GINA2014). Airflow limita-
tion is a result of several factors including bronchoconstriction, air-
way oedema, bronchial hyper-responsiveness and airway remod-
elling, which may become irreversible over time (NAEPP 2007).
Asthma therapy generally aims to reduce smooth muscle constric-
tion through the use of inhaled agents such as long- and short-
acting beta2-agonists (LABA and SABA) and to reduce airway
inflammation through therapies such as inhaled corticosteroids
(ICS) and leukotriene receptor antagonists (LTRA) (BTS/SIGN
2014).
Although estimates vary between populations, it is increasingly
recognised that for asmany as 50%of thosewith asthma, their con-
dition has an important atopic component (Agache 2012; Arbes
2007; Normansell 2014; Pearce 1999), defined by a positive skin
prick test to a recognised allergen, which may provide a therapeu-
tic target for immunotherapy.
Atopy is defined as the production of specific immunoglobulin
(Ig)E in response to common environmental allergens; it can be
identified through skin prick testing. Total serum IgE has also
been associated with asthma. Up to 95% of adults and children
with asthma are skin prick test positive for one or more allergens
(Craig 2008), but it should be noted that more than 50% of non-
asthmatic children and adults are also skin prick test positive (Arbes
2007).
Description of the intervention
The aim of immunotherapy is to build up tolerance to an aller-
gen through repeated exposure to the causative allergen. Subcu-
taneous immunotherapy (SCIT) is well established in the United
States, whereas survey data from 2011 suggest that only 11.4% of
US allergists prescribe sublingual immunotherapy (SLIT) (Sikora
2013). In Europe, SLIT represents approximately 45% of im-
munotherapy and up to 80% of new prescriptions for im-
munotherapy (Cox 2009; Linkov 2014). SLIT is available as
tablets or as a solution and is usually taken in the morning, once
daily, on alternate days, or twice weekly, according tomanufacturer
instructions. The drops or tablets are kept under the tongue for
one to two minutes before they are swallowed. A build-up phase
of gradually increasing doses is usually followed by a maintenance
phase at the maximum dose. It is currently thought that a SLIT
course should last for three to five years, which is consistent with
evidence derived from trials of SCIT (Passalacqua 2012). Consid-
erable inconsistency can be seen in the literature about safe and
effective dosing of SLIT, and a recent World Allergy Organization
position paper states that a regimen will have to be established in-
dividually for each allergen extract formulation (Canonica 2014).
How the intervention might work
Recognition of the important allergic component for many peo-
ple with asthma has led to interest in the use of immunotherapy
directed against specific allergens; although the efficacy of sub-
cutaneous immunotherapy for asthma has been established, evi-
dence for SLIT is conflicting (Incorvaia 2010; Passalacqua 2012).
Allergen-specific sublingual and subcutaneous immunotherapy is
thought to work primarily by inducing T-cell tolerance and pro-
moting regulatory T-cells, which secrete the suppressive cytokines
interleukin (IL)-10 and transforming growth factor (TGF)-beta.
This in turn leads to production of the non-inflammatory im-
munoglobulins IgG4and IgA, thus directing the immune response
away from the inflammatory, atopic IgE response.(Fujita 2012).
The hope is that targeting the dysregulated underlying immune
response and thus desensitising the immune system to the spe-
cific allergen will permit those with allergic asthma to experience
improvement in symptoms (Jutel 2014). The sublingual route of
administration may offer advantages over the subcutaneous route,
not only in terms of acceptability to patients. The oral cavity is
a naturally ’tolerogenic environment’, as it frequently encounters
foreign proteins without the provocation of a local or systemic
immune response and therefore may be an appropriate site for
delivery of a treatment intended to produce immune tolerance
(Canonica 2014). Pharmacokinetic studies suggest that the aller-
gen extracts are retained for some time in the oral mucosa before
they drain to local lymph nodes. This may account for the relative
frequency of local reactions and infrequency of serious, systemic
reactions (Marcucci 2007).
Why it is important to do this review
Asthma is thought to affect approximately 300 million people
worldwide (Partridge 2006)-between 1% and 18% of the popula-
tion indifferent countries (GINA 2014). The burdenof the disease
is considerable; in the United States alone, asthma costs approxi-
mately $56 billion a year and in 2009 led to 479,300 hospitalisa-
tions and 3388 deaths (CDC 2013); more asthma-related death is
thought to occur in middle- and low-income countries (WHO).
Many people with asthma remain inadequately controlled despite
treatment and therefore are at high risk of exacerbation (Partridge
2006). Allergen-specific immunotherapy may represent an impor-
tant addition to the more established asthma therapies and thus
may help to reduce the morbidity and mortality associated with
this disease. Indeed, it is the only treatment that specifically targets
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underlying causes of allergen-triggered asthma, and it may lead
to long-term desensitisation (Di Rienzo 2003). Moroever, SLIT
may represent a more acceptable and safer route of administration
than SCIT (Linkov 2014). However, the position of SLIT as a
therapeutic option for asthma has yet to be established. Most na-
tional and international guidelines do not recommend its routine
use for asthma because evidence of efficacy and safety is robust,
or they recommend use only in those with symptoms difficult to
control with standard treatments (BTS/SIGN 2014; GINA 2014;
NAEPP 2007).
O B J E C T I V E S
To assess the efficacy and safety of sublingual immunotherapy
compared with placebo or standard care for adults and children
with asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel randomised controlled trials (RCTs), blinded
and unblinded, of any duration that evaluated sublingual im-
munotherapy versus placebo or as an add-on to standard medical
management of asthma. We excluded cross-over trials because of
the long-term effects of treatment. We included studies reported
as full text, those published as abstract only and unpublished data.
Types of participants
We included both adults and children with asthma of any sever-
ity, diagnosed by a clinician or according to validated national
or international guidelines (e.g. BTS/SIGN 2014; GINA 2014).
Participants could have any allergen-sensitisation pattern. We in-
cluded participants with a dual diagnosis of asthma and allergic
rhinitis. As a pragmatic decision, and in a change to our protocol,
we chose to exclude studies in which less than 80% of participants
were reported to be diagnosed with asthma at baseline, as findings
for patients with asthma were rarely presented separately. We ex-
cluded patients with other respiratory co-morbidities.
Types of interventions
We included trials evaluating any type or dose of SLIT (including
single-allergen and multiple-allergen preparations) versus placebo
or as an add-on to standard medical management of asthma.
We included trials that allowed the use of short-acting reliever
medications such as salbutamol, provided these medications were
not part of the randomly assigned treatment. We also included
trials that allowed participants to continue their usual preventative
asthma medication (e.g. LABA/ICS/LTRA), again provided this
was not part of the randomly assigned treatment.
Types of outcome measures
Primary outcomes
1. Exacerbation requiring emergency department (ED) visit or
hospitalisation (participants with at least one).
2. Quality of life* (measured on a validated scale, e.g. Asthma
Quality of Life Questionnaire).
3. Serious adverse events (all-cause).
Secondary outcomes
1. Asthma symptom scores* (measured on a validated scale,
e.g. Asthma Control Questionnaire).
2. Exacerbations requiring systemic corticosteroids
(participants with at least one).
3. Response to provocation tests*.
4. Required dose of ICS.
Reporting by trial authors of one or more of the outcomes listed
here was not an inclusion criterion for the review.
*If more than one validated scale measuring the same construct
was reported within a study, or if different scales were used across
studies, we analysed them together using standardised mean dif-
ferences.
Outcomes were selected to reflect those most important to people
with asthma after a check of the existing literature (Busse 2012;
Sinha 2012).
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Spe-
cialised Register (CAGR), which is maintained by the Trials
Search Co-ordinator for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative In-
dex to Nursing and Allied Health Literature (CINAHL), the
Allied and Complementary Medicine Database (AMED) and
PsycINFO, and through handsearching of respiratory journals
and meeting abstracts (see Appendix 1 for further details). We
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searched all records in the CAGR using the search strategy pro-
vided in Appendix 2. We also conducted a search of ClinicalTri-
als.gov (www.ClinicalTrials.gov) and the World Health Organi-
zation (WHO) trials portal (www.who.int/ictrp/en/) for relevant
studies. We conducted the most recent search on 25 March 2015.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.
We searched on 14 March 2015 for errata or retractions
from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (RN and KMK) independently screened titles
and abstracts to consider inclusion of all potential studies identi-
fied as a result of the search and coded them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We retrieved the
full-text study reports and publications, and two review authors
(RN and KMK) independently screened the full texts to identify
studies for inclusion. We identified and recorded reasons for ex-
clusion of ineligible studies, resolving disagreements through dis-
cussion or, if required, by consultation with a third person. We
identified and excluded duplicates and collatedmultiple reports of
the same study, so that each study rather than each report was the
unit of interest in the review. We recorded the selection process
in sufficient detail to complete a PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flow diagram
(Figure 1) and a Characteristics of excluded studies table.
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Figure 1. Study flow diagram.
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Data extraction and management
We used a Microsoft Excel data collection form that had been pi-
loted on at least one study in the review to document study char-
acteristics and outcome data. Two review authors (RN, KMK or
ALB) extracted the following study characteristics from included
studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, dates of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (RN, KMK or ALB) independently extracted
outcome data from included studies. We resolved disagreements
by reaching consensus or by involving the third review author.
All three review authors transferred data into the Review Manager
(RevMan 2012) file. We double-checked that data were entered
correctly by comparing data presented in the systematic review
with data from the study reports.
Assessment of risk of bias in included studies
Two review authors (RN, KMK or ALB) independently assessed
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion or by consultation with
a third review author. We assessed risk of bias according to the
following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report together with a justi-
fication for our judgement in the ’Risk of bias’ tables within the
Characteristics of included studies table. We summarised risk of
bias judgements across different studies for each of the domains
listed. We considered blinding separately for different key out-
comes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for a
patient-reported symptom scale). When considering treatment ef-
fects, we took into account risk of bias for studies that contributed
data to that outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol
(Normansell 2014a), and we report deviations from it in the
Differences between protocol and review section of the systematic
review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous
data as mean differences (MDs) or standardised mean differences
(SMDs). For rare events, we used risk differences (RDs) to account
for trials with no events in either arm. We entered data presented
as a scale with a consistent direction of effect. We used change
from baseline scores when possible.
We undertookmeta-analyses only when this wasmeaningful (i.e. if
treatments, participants and the underlying clinical question were
similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges and explained when meta-analysis was not
considered appropriate.
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two (or more) comparisons (e.g.
drug A vs placebo, drug B vs placebo) were combined in the same
meta-analysis, we halved (or divided by the appropriate number to
reflect the number of treatment arms) the control group to avoid
double-counting.
If trials reported outcomes at multiple time points, we used the
end of treatment time point. As the benefits of immunotherapy are
intended to persist beyond the treatment period, we also looked
for primary outcomes reported at follow-up off treatment and
described them, when available.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of participants admitted
to hospital at least once rather than number of admissions per
participant).
Dealing with missing data
We planned to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
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data when possible (e.g. when a study is identified as an abstract
only), but owing to the large number of studies included, we at-
tempted to contact study authors only to clarify whether a study
did or did not meet our inclusion criteria.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity, we re-
ported this and explored possible causes by performing prespeci-
fied subgroup analysis.
Assessment of reporting biases
We were not able to construct a funnel plot because the only
primary outcome that was included in more than 10 trials was
serious adverse events (SAEs), and only five studies contributed
events.
Data synthesis
We used a random-effects model for all analyses, as we expected
variation in effects due to differences in study populations and
methods. We performed sensitivity analyses using a fixed-effect
model when we encountered substantial heterogeneity.
Summary of findings table
We created Summary of findings for the main comparison using
data from seven outcomes. In a change to our protocol, we did
not include asthma symptoms as we did not perform a meta-anal-
ysis for this outcome and instead included all adverse events. We
used the five GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to
studies that contributed data to the meta-analyses for prespecified
outcomes. We used methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011) with GRADEpro
software. We justified all decisions to downgrade or upgrade the
quality of studies by using footnotes, and we made comments to
aid readers’ understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
When possible, we intended to carry out the following subgroup
analyses for primary outcomes, using the formal test for subgroup
differences in Review Manager (version 5.3) (RevMan 2012).
1. Age of participants (adults vs children).
2. Asthma severity (as defined by baseline severity reported in
the trial or by review authors’ assessment according to the asthma
medication used).
3. Type of target allergen for sublingual immunotherapy (e.g.
house dust mite (HDM), grass pollen).
4. Study duration (> or < one year).
Sensitivity analysis
We carried out sensitivity analyses while excluding the following.
1. Studies at high risk of bias for blinding.
2. Unpublished data (i.e. no peer-reviewed full paper
available).
R E S U L T S
Description of studies
Details of methods, participants, interventions and outcomes for
all included studies can be found in theCharacteristics of included
studies tables.
Results of the search
We identified 372 records through initial database searching and a
further 61 from searches of clinicaltrials.gov and theWorldHealth
Organization (WHO) Clinical Trials Register. After removing du-
plicates, we screened 401 records, checking title and abstract only,
and excluded 177. We assessed the remaining 224 full texts for eli-
gibility and excluded 150 records (referring to 111 unique studies,
plus seven ongoing studies and 12 studies awaiting classification)
at this stage. Of those excluded, the majority included a mixed
study population of participants with asthma, rhinitis or both,
and results from participants with asthma were not presented sep-
arately (n = 53). As a pragmatic decision, and in a change to our
protocol, we chose to exclude studies in which less than 80% of
participants were reported to be diagnosed with asthma at base-
line. We excluded 12 studies because we were unable to ascertain
the percentage of participants with asthma at baseline.
We included 52 individual studies (74 records) in the qualita-
tive synthesis; 34 contributed data to at least one meta-analy-
sis, but 27 of these appeared only in the adverse or serious ad-
verse events analyses. Three studies appeared only in the narrative
synthesis of unvalidated symptom or medication scores (Cooper
1984; Lewith 2002; Reilly 1994). Fifteen studies did not re-
port any data relevant to this review (Almarales 2012; Hanna
2013; Inal 2009; Karakoc-Aydiner 2011; Keles 2009; Marcucci
2003; Mosges 2010; Muratore 1993; Orefice 2004; Radu 2007;
Rodriguez 2012; Rodriguez Santos 2004; Tian 2014; Virchow
2014; Yukselen 2013). A study flow diagram is presented in Figure
1.
12Sublingual immunotherapy for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Fifty-two studies met our inclusion criteria, given the pragmatic
change to the protocol described above. These studies included a
total of 5256 participants, and 5077 were randomly assigned to
comparisons of interest in this review. The largest included study
randomly assigned 834 participants, and the smallest just 15. The
median total number of participants across all 52 studies was 56.
Thirty-seven were reported as full peer-reviewed articles, 14 were
published as abstracts only (i.e. we did not identify a linked full-
text article) and one was found only on clinicaltrials.gov.
Methods
As per our protocol, all included trials were RCTs with parallel
design and compared SLIT versus placebo plus conventional ther-
apy (n = 39) or conventional pharmacotherapy alone (n = 13). Six
studies (Eifan 2009; Hanna 2013; Karakoc-Aydiner 2011; Keles
2009; Keles 2011;Mungan 1999; Yukselen 2013) included one or
more arms that were not relevant to this review, for example, SCIT
or SCIT plus SLIT. Trial duration varied greatly across studies,
with the shortest lasting just one day and the longest 156 weeks.
Several studies included a run-in period, and 10 included a period
of post-treatment follow-up ranging from two weeks to two years.
Outcomes data were extracted at the last time point reported,
which was end of treatment in six studies and post-treatment in
three studies; in one study different outcomes were reported at
different time points. Trials were conducted in a variety of coun-
tries worldwide, but most were carried out in Europe (including
Turkey) (n = 33) and Asia (n = 8). Only one study recruited par-
ticipants in the USA.
Participants
We included studies involving both children and adults. Eighteen
studies recruited only teenagers and adults and 25 studies children
only; two studies included mixed populations of adults and chil-
dren. In seven studies, the age range of participants was not re-
ported. Most studies did not specify the ethnicity of participants.
Most of the included studies (n = 44) recruited exclusively par-
ticipants with asthma, although severity of the condition ranged
from mild and intermittent to moderately severe. Eight stud-
ies stated that participants with asthma ’and/or’ rhinitis were in-
cluded, meaning that investigators recruited participants with a
diagnosis of asthma or rhinitis or both. As has been mentioned, we
included these studies only if we could confirm thatmore than80%
of participants had an asthma diagnosis at baseline. We excluded
53 studies because less than 80% of participants had asthma; we
excluded12 because we were unable to confirm the percentage of
participants with asthma at baseline despite attempts to contact
the trial authors.
The inclusion criteria of most studies stated that participants must
have had a positive skin prick test to the allergen of interest and/
or serum allergen-specific IgE above a specified threshold. Usually,
participants were also required to have a clinical history consistent
with allergic asthma or rhinitis or both. Some studies stated that
they excluded participants sensitised to other common aero-aller-
gens and those with severe asthma or with other co-morbidities.
Most studies excludedparticipantswhohad received immunother-
apy in the past.
Interventions
More than half of the included studies (n = 34) targeted house dust
mite (HDM) allergy, with the remainder targeting grass pollen (n
= 6), birch pollen (n = 3), cockroach (n = 1), cat dander (n = 1),
Alternaria (n = 1), Parietaria (n = 1), olive pollen (n = 1), Artemisia
(n = 1) and a combination of HDM and Parietaria (n = 1). The re-
maining two studies involved homeopathic SLIT compared with
placebo:One usedHDMhomeopathic SLITand the other various
allergens according to participant allergic response, withHDMthe
dominant allergen (84% of participants). As homeopathic SLIT
represents a different entity from standard SLIT (with the aller-
gen far more diluted), we intended to exclude these studies in a
sensitivity analysis. However, neither study (Lewith 2002; Reilly
1994) contributed data to a meta-analysis, so this was not nec-
essary. Dosing also varied across studies; when possible, we have
extracted this information and presented it in the Characteristics
of included studies tables.
Typically, SLIT interventions targeting perennial allergens, such as
HDM, were administered continuously, while those targeting sea-
sonal allergens, such as grass pollen, were administered before the
start of the pollen season or during the pollen season. Most studies
stated that participants were allowed to continue using specified
rescue medication for asthma and rhinitis symptoms throughout
the study, and in some trials the frequency of use of rescue medi-
cation was an efficacy outcome. Most studies made no changes to
baseline preventer medication, such as ICS.
Outcomes
Outcomes reported were not consistent across reviews, and vali-
dated scales were rarely used. Asthma symptoms were reported by
a large majority of included studies (n = 42), as were medication
use scores (n = 36). Many studies also reported outcomes not spec-
ified in our protocol, including lung function such as peak expi-
ratory flow rate (PEFR) (n = 32) and laboratory immunological
outcomes such as serum allergen-specific IgE and IgG levels (n =
31). Adverse events were reported by just over half of the included
studies (n = 27). Outcomes less frequently reported included skin
prick tests (n = 16), bronchial provocation tests (n = 11), quality
of life (n = 6) and exacerbations (n = 5). Despite the large number
of outcomes reported in the included studies, meta-analysis was
somewhat hampered by the wide range of unvalidated measures
used; two out of our three primary outcomes of interest were rarely
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reported (exacerbations and quality of life). We have presented the
data extracted for symptom scores and medication use by using
unvalidated or incompatible scales in Analysis 1.8 and Analysis
1.9.
Subgroup and sensitivity analyses
Studies contributing data to our primary analyses were insufficient
for us to complete the planned sensitivity and subgroup analyses.
In a post hoc change to the protocol, we chose to investigate the
subgroups of age, target allergen and study duration for all adverse
events; these results are presented in Analysis 2.1, Analysis 2.2
and Analysis 2.3. We chose to perform a sensitivity analysis by
excluding studies assessed to be at high risk of performance bias
for all adverse events (Analysis 2.4).
Summary characteristics of the included trials including informa-
tion about potential effect modifiers (e.g. age, treatment duration,
allergen) are presented in Table 1, and full details of each included
study are given in Characteristics of included studies.
Excluded studies
We excluded studies that did not meet the criteria specified in our
protocol or in which less than 80% of participants had received
a diagnosis of asthma. We excluded 12 studies because we were
unable to ascertain what percentage of the participants had asthma
despite an attempt to contact the study authors. Reasons for exclu-
sion of studies after the full text had been retrieved can be found
in the Characteristics of excluded studies tables.
Risk of bias in included studies
For details on the risk of bias rating for each study and the reasons
for each rating, see Characteristics of included studies. A summary
of risk of bias judgements by study and by domain (sequence
generation, allocation concealment, blinding, incomplete data and
selective reporting) can be found in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Overall, a lot of uncertainty surrounded allocation procedures be-
cause of insufficient reporting, and about a quarter of the studies
were at high risk of bias for blinding because they applied open-
label designs. Participant attrition was high or unknown in around
half of the studies, and selective reporting is likely to have had a
serious effect on the completeness of this evidence base.
Allocation
We assessed one study (Lewith 2002) as having low risk of bias
for both random sequence generation and allocation concealment.
Investigators used sealed envelopes followed by randomisation by
minimisation according to age, sex, smoking status and asthma
severity.
We considered 11 further studies to be at low risk of bias for ran-
dom sequence generation. Seven studies (Caffarelli 2000; Eifan
2009; La Grutta 2007; Marcucci 2003; Mosbech 2014; Stelmach
2009; Yukselen 2013) used computer-generated lists. Keles 2011
used the table randomisation method. Two studies (Pajno 2000;
Pajno 2003) used a key code for random sequence generation.
Reilly 1994 used a restricted technique of permuted blocks, strati-
fied for intended allergen and daily dose of steroid. For these stud-
ies, no details were given on allocation concealment, and theywere
considered to be at unclear risk of bias in this domain.
Thirty-nine studies stated that theywere randomised but provided
no specific details about sequence generation nor allocation con-
cealment and were assessed to be at unclear risk of bias for both
domains.
One study (Tian 2014) was at high risk of bias for random se-
quence generation, as participants were divided into treatment
group and control group in order of admission. No details were
given about allocation concealment; therefore we assessed risk of
bias as unclear in this domain.
Blinding
We assessed most included studies (n = 37) described as double-
blind and placebo-controlled as having low risk of bias in both
performance bias and detection bias domains.
Two studies were assessed as having unclear risk of bias in both do-
mains. Although Mungan 1999 was placebo-controlled and sin-
gle-blind, no details were provided about who exactly was blinded.
Radu 2007 was also single-blind and did not include details on
who was blinded.
La Grutta 2007 was rated as having high risk of performance bias,
as the study was open-label. Assessor blinding was not described
for some outcomes, so we considered detection bias to be unclear.
We assessed 12 studies as having high risk of bias for both domains.
Eight studies (Criado Molina 2002; Eifan 2009; Marogna 2005;
Orefice 2004; Rodriguez Santos 2004; Shao 2014; Zhang 2013;
Zheng 2012) were open-label, which may have introduced bias.
Hanna 2013 was a prospective study, with participants randomly
assigned to three parallel groups with no mention of blinding. We
made the assumption that three studies (Karakoc-Aydiner 2011;
Keles 2009; Keles 2011) were open-label, as participant or assessor
blinding was not mentioned.
Incomplete outcome data
Participant attrition was adequately described in 27 included stud-
ies, and we considered risk of attrition bias to be low. In 12 of these
studies, no dropout was reported. In 14 other studies, withdrawal
rates were low (no more than 20%), with similar rates reported in
control groups. Pham-Thi 2007 performed data analysis accord-
ing to the intention-to-treat principle.
Altogether, we considered 16 studies to be at unclear risk for at-
trition bias. Of these, 13 studies provided no information about
withdrawal rates. Cooper 1984 excluded three participants from
its treatment group and four from the placebo group who were
not included in the analysis. However, the paper does not report
whether these exclusions were part of the asthma series and did not
attempt to impute results for dropouts. One study (Radu 2007)
was stopped after six months and also did not report dropout rates.
Shao 2014 had a balanced and low dropout below 20% but did
not include these data in the efficacy analysis.
We assessed nine studies (Alvarez-Cuesta 2007; Bousquet 1999;
Criado Molina 2002; Marogna 2005; NCT00633919; Orefice
2004; Pajno 2000; Stelmach 2009; Wood 2014) as having high
risk of bias in this domain because of high withdrawal rates and/or
unbalanced dropout between treatment and control groups and/or
because only completers were analysed.Orefice2004 also excluded
individuals with more severe asthma during the trial; however, it is
not clear whether this was baseline exclusion or exclusion during
the study.
Selective reporting
Only 14 studies reported all stated outcomes and were assessed as
having low risk of reporting bias.
We considered six studies to be at unclear risk of reporting bias.
The numerical reporting of CriadoMolina 2002 was inconsistent,
and data could not be included in the meta-analysis. Marcucci
2003 reported outcomes well (although mainly non-clinical) but
did not report a trial registration to check whether all prespecified
outcomes were included in the write-up. Pajno 2003 reported sev-
eral outcomes narratively or gave ’ranges’ of P values. Some dis-
crepancies between reports appear to be related to the same par-
ticipant group. All stated outcomes were reported in Rodriguez
Santos 2004, but numerical data were not well presented; within-
group outcomes were reported rather than comparisons with con-
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trol. Wood 2014 and Zheng 2012 did not clearly report adverse
event outcomes.
We assessed 32 included studies as having high risk of bias for this
domain. Fourteen studies were provided only as conference ab-
stracts, with minimal information and details regarding the con-
duct of the study as well as data that could not be meta-anal-
ysed. Fourteen studies did not report data for all outcomes, se-
lectively reported outcome data or lacked numerical supporting
data (Bousquet 1999; Calderon 2006; Cooper 1984; Corzo 2014
(a); Corzo 2014 (b); Eifan 2009; Gomez Vera 2005; Mosbech
2014; Mosges 2010; Mungan 1999; Pham-Thi 2007; Tian 2014;
Wang 2014; Yukselen 2013). Most outcomes were reported with
a level of statistical significance in only three studies (La Grutta
2007; Lewith 2002; Vourdas 1998) and could not be included
in the meta-analysis. Although Marogna 2005reported all stated
outcomes, several were provided only in graphical form or with
inexact P values that also could not be meta-analysed.
Other potential sources of bias
We considered three studies as having other potential sources of
bias. Alvarez-Cuesta 2007 had an unbalanced male-to-female ra-
tio, and Radu 2007 was stopped after six months (planned for
36 months) because of statistically significant differences in out-
comes that favoured the active treatment. Reilly 1994, a study of
homeopathic SLIT, stated that “both doctors (homeopathic and
asthma clinic doctor) could also veto any patient they considered
unsuitable”, which may have introduced bias.
Effects of interventions
See: Summary of findings for the main comparison SLIT vs
control
Primary outcomes
Exacerbations requiring ED or hospital admission
Only one short study of 43 participants, involving four different
SLIT dosing arms (Calderon 2006), included this outcome and
reported no events during the four-week treatment period nor
during the five- to six-week follow-up period (Analysis 1.1; low-
quality evidence).
Quality of life
Quality of life (QoL) was a stated outcome in five included stud-
ies (Bousquet 1999; Inal 2009; Lewith 2002; Mosbech 2014;
Pham-Thi 2007), but none presented data in a manner that al-
lowed for meta-analysis. Bousquet 1999 reported increased QoL
scores using the Short-Form Health Status Survey (not specific
for asthma) in the SLIT group compared with the placebo group
after 25 months of treatment, and improvements were statistically
significant in several domains, including general mental health,
general perception of health and physical pain. Inal 2009, a con-
ference abstract, also reported significant improvement in QoL
scores after two years of SLIT treatment when compared with
placebo, but the scale used was not reported. Lewith 2002, a study
of homeopathic SLIT versus placebo, reported asthma QoL using
the ’asthma bother profile’ and did not find a statistically signif-
icant difference between groups. Mosbech 2014 narratively and
graphically reported the Asthma Quality of Life Questionnaire
(AQLQ) after a year of SLIT treatment (including three different
dosing arms) and did not find a statistically significant difference
between active treatment and placebo. Finally, Pham-Thi 2007 as-
sessed QoL using two forms of the Childhood Asthma Question-
naire (CAQ). The severity dimension showed statistically signifi-
cant improvement in the SLIT group compared with the placebo
group, but in all domains, average changes were not statistically
different between groups. We have presented in Analysis 1.2 the
numerical data extracted from Bousquet 1999 and Lewith 2002.
Serious adverse events
Occurrence of serious adverse events (SAEs) was a reported out-
come for 22 included studies involving 2560 participants, but only
five studies (Mosbech 2014; NCT00633919; Niu 2006; Pajno
2000; Wang 2014) observed any events. Although events were
infrequent, analysis using risk differences (RDs) suggests that no
more than one in 100 are likely to suffer an SAE as a result of
treatment with SLIT (Figure 3; Analysis 1.3; RD 0.0012, 95%
confidence interval (CI) -0.0077 to 0.0102; moderate-quality ev-
idence).
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Figure 3. Forest plot of comparison: 1 SLIT vs control, outcome: 1.3 Serious adverse events.
In total, 22 participants receiving SLIT and 12 in the control
groups experienced an SAE. Mosbech 2014 reported that 15 par-
ticipants receiving active treatment experienced an SAE: six in the
1 standard quality (SQ)-HDM group, three in the 3 SQ-HDM
group and six in the 6 SQ-HDM group. Of these events, only two
were deemed by investigators to be possibly related to SLIT and
were described in detail: One was a case of migraine and the other
dizziness. Four participants receiving placebo experienced an SAE.
InNCT00633919, two participants receiving active treatment ex-
perienced an SAE (one road traffic accident and one femur frac-
ture) and two in the placebo group (one perianal abscess and one a
diagnosis of obsessive-compulsive disorder). Five participants ex-
perienced an SAE in Niu 2006 (one in the SLIT group and four
in the control group), but these events were not further described.
In Pajno 2000, a ’serious asthma attack’ led to withdrawal of a
participant from the control group. In Wang 2014, six SAEs oc-
curred involving five participants (four in the SLIT group and one
in the control group) and included a knee fracture, Arnold-Chiari
Syndrome, contact dermatitis, ovarian cyst rupture, pneumonia
and traumatic brain injury. None of these events were thought to
be treatment-related, and none of the included studies reported
any deaths.
Secondary outcomes
Asthma symptom scores
Most included studies (n = 42) reported asthma symptoms as an
outcome, but a variety of often unvalidated scales were used and
numerical data were not always presented. Details of the scoring
systems used are presented in Analysis 1.8.We judged that a meta-
analysis using standardised mean differences of those studies pre-
senting numerical data would not be a sound methodological ap-
proach, and so the data extracted from the included studies are
tabulated in Analysis 1.8 but were not meta-analysed. In sum-
mary, of those presenting numerical data, five studies found no
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statistically significant differences in asthma symptom scores be-
tween groups (Bousquet 1999; Dahl 2006; Lewith 2002;Mungan
1999; Pham-Thi 2007). Alvarez-Cuesta 2007 reported a marked
reduction in asthma symptoms during cat exposure for the SLIT
group, with no significant improvement observed in the placebo
group. Caffarelli 2000, Eifan 2009, Ippoliti 2003,Marogna 2005,
Niu 2006, Pajno 2000, Reilly 1994, Stelmach 2009 and Zheng
2012 reported statistically significant reductions in asthma symp-
tom scores in the SLIT group compared with the placebo group at
the end of treatment. Cooper 1984 reports a ’small advantage’ in
favour of SLIT in number of days with asthma symptoms and in
symptoms graded according to severity. Lue 2006 found improve-
ments in both daytime and nighttime asthma symptom scores in
the SLIT group, although the between-group difference for the
former was not statistically significant.
Medication use scores
Similarly, 12 studies reported numerical medication use scores,
which were frequently unvalidated aggregate scores including res-
cue medication use and use of inhaled corticosteroid (ICS) and
oral corticosteroid (OCS). Details of the scoring systems used are
presented in Analysis 1.9. Although medication scores were not
a predefined outcome, as many of them incorporated ICS use
(which was an outcome of interest), we extracted the data and
have presented them, again without meta-analysis (Analysis 1.9).
Seven studies did not find a statistically significant difference be-
tween medication use scores for SLIT and control groups at the
end of treatment (Bousquet 1999; Dahl 2006; Lewith 2002; Lue
2006; NCT00633919; Niu 2006; Pham-Thi 2007). Four studies
found a statistically significant difference favouring SLIT when
compared with control in asthma medication scores at the end
of treatment (Eifan 2009; Marogna 2005; Pajno 2000; Stelmach
2009). Mungan 1999 reports a statistically significant decrease
from baseline in asthma medication scores in the SLIT group but
no decrease in the control group.
Exacerbations requiring systemic corticosteroids
Both Calderon 2006 and Pajno 2003 included this outcome, but
neither study observed any events (Analysis 1.4; low quality).
Response to provocation tests
Response to bronchial provocation using the methacholine chal-
lenge testwas included as an outcome in 11 studies, and four (Keles
2011; Marogna 2005; Pajno 2003; Stelmach 2009) contributed
to the meta-analysis. Marogna 2005 reported this outcome using
provocative dose (PD)20 and the remaining studies provocative
concentration (PC)20. Studies targeted a variety of allergens in-
cluding HDM (n = 1), birch pollen (n = 1), Parietaria (n = 1) and
grass pollen (n = 1). All four studies were at least a year in duration.
Reilly 1994 reported change from baseline (rather than endpoint)
PC20log and for this reason could not be reliably pooled with the
other measures in the meta-analysis. This study reported a small
benefit for homeopathic SLIT over placebo, which was not statis-
tically significant.
Heterogeneity between the four studies that contributed to the
meta-analysis was significant for response to bronchial provocation
tests, and the confidence intervals were too wide to allow a clear
judgement of SLIT benefit (Analysis 1.6; SMD 0.69, 95% CI -
0.04 to 1.43; participants = 139; studies = 4; very low quality) with
a high level of heterogeneity (I2 = 76%).When a fixed-effectmodel
was used to further investigate heterogeneity, the effect suggested
a small benefit from SLIT (SMD 0.72, 95% CI 0.37 to 1.08).
If Marogna 2005, the only study reporting PD20, was removed
from the analysis, heterogeneity was somewhat lower (I2 = 55%),
but the pooled effect remained imprecise and was not statistically
significant.
Required dose of ICS
Three studies (Bousquet 1999; Niu 2006; Pham-Thi 2007) re-
ported ICS use numerically at the end of treatment: Bousquet
1999 in beclomethasone mcg/d, Pham-Thi 2007 in budesonide
mcg/d (equivalent) and Niu 2006 in puffs/d. Differences between
groups in puffs per day of ICS were not statistically significant
(Niu 2006) at the end of treatment. We have not included these
results in the meta-analysis. Although ICS use significantly de-
creased from baseline in both treatment and control groups in
Bousquet 1999 and Pham-Thi 2007, pooling of ICS use at the
end of treatment yielded an imprecise estimate with wide confi-
dence intervals including the possibility of both benefit and harm
from SLIT (Analysis 1.7; MD 35.10, 95% CI -50.21 to 120.42,
low quality) with no heterogeneity (I2 = 0%).
Both Mosbech 2014 and Virchow 2014 also assessed ICS reduc-
tion and reported that participants taking higher-dose SLIT treat-
ment experienced a significant reduction in ICS use compared
with those given placebo at the end of treatment, but neither study
presented data in a way that allowed for meta-analysis.
All adverse events
In a change to the protocol and as a result of the infrequency of
SAEs, we chose to include an analysis of all adverse events. We
extracted data for all adverse events, not just those deemed to be
treatment-related. Nineteen studies including 1755 participants
reported all adverse events, and 11 contributed more than 500
events to the meta-analysis. Pooled results demonstrated increased
risk of experiencing an adverse event in the SLIT group compared
with the control group; this finding was statistically significant
(Figure 4; Analysis 1.5; odds ratio (OR) 1.70, 95% CI 1.21 to
2.38; low quality) with a low level of heterogeneity (I2 = 13%).
This translates into an absolute increase from 222 per 1000 people
in the control group to 327 per 1000 (257 to 404) and is presented
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graphically in Figure 5 by way of a Cates’ plot. However, most
adverse events were reported to be mild and transient and rarely
led to withdrawal from the trial.
Figure 4. Forest plot of comparison: 1 SLIT vs control, outcome: 1.5 All adverse events.
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Figure 5. Cates plot illustrating all adverse events (created at: www.nntonline.net)
Subgroup analyses
In a change to our protocol and as described above, we chose to
perform subgroup analyses on adverse events, rather than serious
adverse events, as so fewdata contributed to this primary outcome.
Participant age
We examined subgroups of children (mean participant age < 18)
versus teenagers and adults (mean participant age ≥ 18) versus
mixed age study populations or those for which the age range was
not specified. The effect for adults and teenagers was more precise
than for children because of the numbers of participants in the
trials and the numbers of events observed in either group (Analysis
2.1; OR 1.48, 95% CI 1.06 to 2.06 vs OR 2.13, 95% CI 0.83
to 5.47), but results of tests for subgroup differences were not
statistically significant (I2 = 0%, P value = 0.72).
Target allergen
More than half of the included studies targeted SLIT at HDM (n
= 34); the next most common target allergen was pollen (n = 13).
We chose to examine the subgroups of HDM versus pollen versus
other ormixed allergens; no events were observed in studies within
the other or mixed allergen subgroup, so this subgroup did not
contribute statistically to the analysis. Participants receivingHDM
SLIT and pollen SLIT were more likely to experience adverse
events than those in the control group (Analysis 2.2; OR 1.47,
95% CI 1.10 to 1.97 and OR 5.48, 95% CI 1.99 to 15.05),
and results of the test for subgroup differences were statistically
significant (P value = 0.01), suggesting that those receiving pollen
SLIT experiencedmore adverse events than those receiving HDM
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SLIT. However, we cannot conclude that this finding is a result
of the different SLIT target allergen, as additional confounding
between studies is likely.
Study duration
We chose to use a cutoff duration of less than 52 weeks versus
52 weeks or longer for this subgroup analysis. As we might ex-
pect, a smaller percentage of participants in the shorter studies
experienced an adverse event during the study (Analysis 2.3; OR
1.53, 95% CI 0.38 to 6.19 vs OR 1.77, 95% CI 1.22 to 2.58),
but results of tests for subgroup differences were not statistically
significant (P value = 0.84), so we cannot draw any conclusions
from this analysis about the interaction between study length and
all adverse events.
Asthma severity
We did not perform the planned subgroup analysis according to
baseline asthma severity as the majority of studies included par-
ticipants with mild or intermittent symptoms, or did not describe
baseline asthma severity in sufficient detail.
Sensitivity analyses
We chose to perform only two sensitivity analyses. First, we ex-
amined the effect of removing studies at high risk of performance
or detection bias, or both, from the adverse events analysis. This
analysis demonstrated a consistent direction of effect despite the
removal of open-label and unblinded trials (Analysis 2.4;OR1.47,
95% CI 1.10 to 1.96).
Second, we removed studies that recruited a mixed population
of participants with asthma and rhinitis from the adverse event
analysis. As above, this had minimal impact on the pooled effect
(Analysis 2.5; OR 1.42, 95% CI 1.06 to 1.91).
D I S C U S S I O N
Summary of main results
Fifty-two studies met our inclusion criteria, randomly assigning
5077 participants to comparisons of interest in this review. Most
of the studies were double-blind and placebo-controlled, but stud-
ies varied in duration from just one day to three years. The largest
study included 834 participants, and the smallest 15. Just over half
were conducted in Europe (including Turkey), and half recruited
children only. Participants with severe asthma were excluded from
most of the included studies, resulting in a study population con-
sisting largely of participants with intermittent or mild symptoms.
With the exceptionof adverse events, reporting ofmeaningful clin-
ical outcomeswas generally poor.Only 22 studies contributed data
to the primary outcome meta-analyses: 22 to the serious adverse
events outcome (with only five contributing events) and one to the
analysis of exacerbations requiring hospital visits (no events). Al-
though five studies numerically reported quality of life outcomes,
the data were not suitable for meta-analysis. This scarcity of evi-
dence limits our ability to draw any conclusions about the effect
of SLIT on exacerbations or quality of life. It would appear that
SLIT is probably safe, at least in the population studied; although
events were infrequent, analysis using risk differences suggests that
no more than 1 in 100 are likely to suffer a serious adverse event
as a result of treatment with SLIT.
Evidence from meta-analysis is again lacking for secondary out-
comes. Although many studies reported asthma symptom scores,
a variety of largely unvalidated scales were used, and a narrative
synthesis of those studies presenting numerical data did not reveal
a consistent effect. However, no study reported statistically signif-
icant worsening of asthma symptoms with active treatment.
Similarly, a narrative synthesis of asthmamedication use scores did
not reveal a consistent effect; some studies reported improvement
and others no improvement. Asthma medication use scores were
generally unvalidated aggregate scores including, for example, res-
cue medication use, ICS use and OCS use. Again, no study re-
ported significantly increased asthma medication use in the SLIT
group. We were able to pool reduction in ICS use from two stud-
ies, which reported this in micrograms per day; no difference was
found between active treatment and control, with wide confidence
intervals including the possibility of both benefit and harm from
SLIT. Two studies reported exacerbations requiring OCS, but no
events occurred.
Eleven studies reported response to bronchial provocation testing,
and four contributed to the meta-analysis. The benefit of SLIT
over control was not statistically significant, again with wide con-
fidence intervals and a high level of heterogeneity.
All adverse events was not a prespecified outcome in our protocol,
but we chose to extract these data because of the very infrequent
occurrence of serious adverse events. Meta-analysis of 19 studies
with 11 contributing more than 500 events revealed a significant
increase in participants reporting an adverse event on active treat-
ment compared with control. However, the clinical importance of
these events is doubtful, as they were usually transient and mild
and rarely prevented participants from continuing in the trial. In
addition, inclusion of respiratory symptoms as adverse events may
have masked or minimised differences between groups, as an ex-
pected benefit of SLIT would be reduction of these symptoms.
Subgroup analysis of all adverse events according to participant
age and study duration did not reveal significant subgroup differ-
ences. Findings suggest that those receiving SLIT for pollen allergy
may experience more adverse events than those receiving SLIT for
HDM allergy. Similarly, sensitivity analysis excluding those stud-
ies at high risk of performance and detection bias did not signifi-
cantly alter this outcome.
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Overall completeness and applicability of
evidence
Despite identifying 52 unique studies that met our inclusion crite-
ria, we were able to perform a very limited meta-analysis. Fourteen
of our included studies were reported as abstracts only and there-
fore provided minimal numerical data. Use of largely unvalidated
symptom and medication scores also impeded quantitative syn-
thesis of findings. Although a pooled analysis of composite asthma
symptom and medication use scores using standardised mean dif-
ferences would have been possible, we considered this approach
to be not methodologically sound and believed it might result in
misleading conclusions. We decided to include exacerbations, se-
rious adverse events and quality of life as our primary outcomes,
as these have been identified as important to people with asthma
(Busse 2012; Sinha 2012). However, we recognise that this deci-
sion is also a limitation of this review, as most study participants
had intermittent or mild persistent asthma and therefore were un-
likely to be experiencing frequent exacerbations. In addition, we
recognise that although treatment-related adverse events are im-
portant in immunotherapy, risk of attribution bias is present if
trialists are making this judgement, and unanticipated treatment-
related adverse events might not be identified. For this reason, we
chose to include all-cause adverse events.
Insufficient data contributing to the meta-analysis also restricted
potential subgroup analyses, resulting in difficulties in reaching
any conclusions about SLIT efficacy in different age groups, for
different allergens or for different treatment durations. As only a
small minority of studies (n = 3) reported outcomes during post-
treatment follow-up, we cannot comment in this review on the
lasting benefits of SLIT for asthma.
The position of both SCIT and SLIT as potential therapeutic
options for asthma has yet to be clearly established within in-
ternational asthma guidelines. The Global Initiative for Asthma
Guidelines (GINA 2014) state that the efficacy of allergen im-
munotherapy for asthma is limited, and that potential benefits of
immunotherapy must be weighed against risk of adverse reactions,
cost and duration of treatment. The UK guidance adopts a similar
position and does not routinely recommend immunotherapy for
asthma in adults or children (BTS/SIGN 2014). The organisation
that advises theNational Health Service (NHS) in theUK on cost-
effective treatments (theNational Insitiute of Clinical Excellence -
NICE) currently does not provide guidance on asthma therapies.
The British National Formulary states that “desensitising vaccines
should generally be avoided or used with particular care in pa-
tients with asthma” because of the risk of life-threatening adverse
events (BNF), and indeed both SCIT and SLIT are absolutely
contraindicated in patients with severe or uncontrolled asthma
(Slovick 2014). However, somewhat at odds with this, US Guide-
lines for the Diagnosis and Management of Asthma (NAEPP
2007) state that immunotherapy (SCIT) should be considered
only in patients for whom standard pharmacological methods are
insufficient (which implies that symptoms are not well controlled)
and for whom a clear relationship between allergen exposure and
symptoms is not evident. A more recent task force report in the
USA (Cox 2011) further supports this by stating that “candidates
for immunotherapy are patients whose symptoms are not con-
trolled adequately by medications and avoidance measures”, but
does go on to specify that asthma must be controlled at the time
of immunotherapy administration. Cox 2011 also highlights the
investigational nature of SLIT in the USA at the time of the report
and conflicting available evidence regarding its benefits. Until last
year, no Food and Drug Admiistration (FDA) approval had been
provided for any SLIT products in the USA; the first SLIT prod-
uct (’Oralair’) was approved in April 2014 for the treatment of
allergic rhinitis (FDA Press Release 2014).
In the light of all information provided above, the applicability of
our findings is somewhat limited, as most participants recruited to
the studies included in this review had mild or intermittent symp-
toms, and so would not be likely candidates for immunotherapy
for their asthma symptoms, at least according to current guidance
(BTS/SIGN 2014; Cox 2011; GINA 2014; NAEPP 2007). Many
of the included studies stated that participants must have a positive
skin prick test or serum-specific IgE to the allergen in question,
but investigators did not necessarily specify that asthma symptoms
must be linked to allergen exposure, again raising doubts about
the appropriateness of the study populations. In addition, patterns
of allergen sensitisation and association with asthma may vary ge-
ographically, limiting the generalisability of the findings of this
review, given that most of the included studies were conducted in
Europe (ISAAC 1998).
Quality of the evidence
We assessed the quality of the evidence presented in this re-
view using GRADEpro software and present this information in
Summary of findings for the main comparison. Overall, evidence
was assessed to be of moderate, low or very low quality, and ev-
idence was downgraded for several reasons. Heterogeneity varied
across individual outcomes, ranging from I2 = 0% for decrease
in ICS use and serious adverse events to I2 = 76% for bronchial
provocation.
We assessed evidence on exacerbations requiring ED visit or hos-
pital admission and exacerbations requiring OCS to be of low
quality. Neither outcome had any contributory events, and these
outcomes were reported by very few studies (n = 1, Calderon 2006
for exacerbations requiring ED/hospital admission; n = 2 for ex-
acerbations requiring OCS, Calderon 2006 and Pajno 2003). In
addition, Calderon 2006 was a short study of just four weeks’ du-
ration, during which differences in rare events, such as exacerba-
tions, might not be detected. The small number of studies report-
ing this outcome might also represent a publication bias.
We did not assess the quality of evidence for the quality of life
outcome, as no study contributed numerical data to this outcome.
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We assessed evidence for serious adverse events and all adverse
events to be of moderate quality.We downgraded quality to reflect
risk of performance and detection bias in contributing studies and
mixed study populations including patients with asthma, rhinitis
or both. Recruiting a ’mixed’ population may have resulted in a
population of patients with very mild and intermittent asthma
symptoms, leading to concerns that adverse eventsmight be under-
represented compared with those expected in a study population
including participants with a diagnosis of more severe asthma.
We also assessed evidence for reduction in use of ICS to be of
low quality. Only two studies contributed to the meta-analysis
(Bousquet 1999; Pham-Thi 2007). We downgraded the evidence
for imprecision and possible publication bias. Both studies re-
ported a statistically significant decrease from baseline ICS use in
both treatment and control groups with no intergroup differences
at the end of the treatment period.
Finally, we assessed evidence for bronchial provocation to be very
low in quality. Only four studies (Keles 2011; Marogna 2005;
Pajno 2003; Stelmach 2009) contributed to this analysis. We were
required to use standardised mean difference (SMD) analyses to
combine PD20 and PC20 data, and we found that levels of het-
erogeneity and imprecision were high, as was risk of performance
and detection bias, in two of the contributing studies.
Potential biases in the review process
We conducted this review in accordance with established
Cochrane standards. Two review authors independently screened
search results and resolved discrepancies by discussion and, if nec-
essary, consultation with a third person. We did not restrict the
search by language and as a result included four studies published
in languages other than English (three in Spanish and one in Chi-
nese). We attempted to contact study authors when it was not
clear whether a study met our inclusion criteria. We may have
missed some unpublished data as, owing to the large number of
manufacturers, we did not search individual manufacturers’ trial
registers for possible included studies.
At least two review authors extracted all study characteristics and
numerical data and resolved discrepancies through discussion. The
same was true for risk of bias ratings. In a change to our protocol,
and as a result of the large number of included studies (14 of which
were abstracts), we did not attempt to contact study authors to
clarify methodological and outcome information, relying instead
on what was presented in the report.
We adapted the protocol in two other ways that may have in-
troduced bias. First, we had not anticipated how many studies
had recruited mixed populations of patients with rhinitis ’and/
or’ asthma. As outcomes for participants with asthma were rarely
presented separately, we had to make a pragmatic decision as to
whether or not to include these studies. We decided, after consul-
tation with a third person, to include studies in which at least 80%
of participants had received a diagnosis of asthma. If this was not
clear from the report, we attempted to contact study authors to
confirm this. We excluded these ’mixed population’ studies from
the sensitivity analysis for adverse events, although this exclusion
did not substantially alter the outcome.
Second, we had not planned to extract outcome data for all adverse
events, instead opting to include the more clinically important
serious adverse events as a primary outcome. So few serious adverse
events were reported that we decided to extract all adverse events
additionally. Analysis of this additional post hoc outcome was the
only analysis with enough data to allow exploratory analyses with
subgroups, and so these results should be interpreted with caution.
None of the review authors have reported conflicting interests.
Agreements and disagreements with other
studies or reviews
Several published systematic reviews have addressed the question
of whether SLIT is effective and safe in asthma (Calamita 2006;
Compalati 2009; Lin 2013; Penagos 2008; Tao 2014) and have
reached somewhat conflicting conclusions. Tao 2014 reported
findings from 16 double-blind placebo-controlled trials that ran-
domly assigned 794 participants with asthma. Lin 2013 is a sys-
tematic review that reported on SLIT for allergic rhinoconjunc-
tivitis and asthma but without a formal meta-analysis. This review
synthesised findings from 63 studies, including 5131 participants.
Calamita 2006 included 25 studies that randomly assigned 1706
participants. Penagos 2008, a systematic review of SLIT for al-
lergic asthma in children three to 18 years of age, included nine
studies assessing 441 participants. Compalati 2009 reported the
findings of nine double-blind placebo-controlled studies of SLIT
for allergic asthma that assessed 452 study participants.
All four meta-analyses used SMD to meta-analyse composite
asthma symptom scores. Compalati 2009, Penagos 2008 and Tao
2014 reported a statistically significant reduction in asthma symp-
toms favouring SLIT, but with a high level of heterogeneity (I2 ≥
90%). Calamita 2006 reported a statistically significant ’general
improvement’ in asthma, but this conclusion appears to have been
reached from a combined analysis of asthma symptoms, need for
reliever medication, lung function tests and lung hyper-reactivity.
Study authors reported improvement in asthma symptoms alone
when data were analysed using SMDs, but this finding did not
reach statistical significance. Lin 2013 narratively reported im-
provement in asthma symptoms favouring SLIT in all placebo-
controlled studies included in the review and rated the strength of
this evidence as ’high’.
Similarly, all four meta-analyses reported composite asthma med-
ication use scores. Compalati 2009, Penagos 2008 and Tao 2014
reported a statistically significant reduction in medication scores
favouring SLIT, but again using an SMD analysis and with high
heterogeneity (I2 ≥ 90%). Calamita 2006 found no statistically
significant differences between groups in asthma symptom scores.
Lin 2013 narratively reported benefit of SLIT over control in 40
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out of 41 studies that reported medication use scores but did not
present findings for asthma separately from those for rhinocon-
junctivitis.
Calamita 2006, Tao 2014 and Penagos 2008 reported adverse
events and, consistent with our findings, observed very few serious
events. Tao 2014 concluded that participants receiving SLIT ex-
perience more adverse events overall than those receiving placebo,
but that most of these events were considered to be mild in sever-
ity, again in keeping with our findings. Lin 2013 concluded that
adverse events were insufficiently reported to allow further com-
ment on the safety of SLIT.
None of the four meta-analyses included quality of life or exacer-
bations as a prespecified primary or secondary outcome. Lin 2013
found that validated disease-specific quality of life was reported in
only eight of the 63 studies included in the review; half reported
a statistically significant benefit of SLIT over control, but none of
these eight studies met our inclusion criteria.
In contrast to the meta-analyses described above, and as per our
protocol, we chose not to combine different, unvalidated symp-
tom and medication scores in a meta-analysis. We believe that het-
erogeneity across measurements would lead to a potentially mis-
leading outcome. As in Lin 2013, we reported these findings only
narratively.
InNieto 2009, review authors evaluatedfivemeta-analyses of SLIT
for respiratory disease and recommended that as a result of dis-
crepancies, inconsistencies and lack of robustness in the included
meta-analyses, evidence at that time did not support its use. Sim-
ilarly, Incorvaia 2010 presented an overview on the position of
SLIT for treatment of allergic asthma and called for additional
research to resolve conflicting results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our findings are consistent with the current international position
that SLIT should not be prescribed routinely for the treatment of
asthma alone. Lack of studies reporting important outcomes such
as exacerbations and quality of life and use of different, unvali-
dated symptom and medication scores have reduced the quality
of the evidence presented in this review, thus limiting the conclu-
sions that we can reach. However, at least in this study population
(largely comprising participants with mild and moderate asthma),
SLIT does appear to be relatively free from serious adverse events,
although participants receiving SLIT are more likely to experience
any adverse event than those in the control group. This finding
supports continued use of SLIT for people with other respiratory
allergies, such as allergic rhinitis, who may also have well-con-
trolled mild to moderate asthma.
Implications for research
Further research using validated scales such as the Asthma Con-
trol Questionnaire and the Asthma Quality of Life Questionnaire
would be greatly beneficial for future meta-analyses and would
increase confidence in the quality of the evidence. In addition,
inclusion of participants with more severe asthma might result in
studies reporting less frequent, but nonetheless, important events
such as exacerbations requiring oral corticosteroids or hospital vis-
its. Larger trials with explicit reporting of serious adverse events
would increase our confidence regarding the safety of SLIT in pa-
tients with asthma.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Almarales 2012
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 52 weeks
Setting: Cuba
Participants Population: 120 participants randomly assigned to HDM SLIT group or placebo group
(n for each group not reported)
Age: not reported
Inclusion criteria: asthmatic symptoms and a positive predominant skin prick test to
D. pteronyssinus, D. siboney and Blomia tropicalis house dust mites
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT daily for 3 weeks then twice weekly until 12 months. Main-
tenance dose 2000 BU
Co-interventions: not reported
Outcomes Symptoms/medication diary cards, PEFRs, skin sensitivity to investigated mites, adverse
reactions
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no specific details about
sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled
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Almarales 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals not reported
Selective reporting (reporting bias) High risk Conference abstract only. Data not consis-
tently reported and could not be included
in meta-analysis
Other bias Low risk None noted
Alvarez-Cuesta 2007
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 52 weeks
Setting: Spain
Participants Population: 50 participants randomly assigned to cat dander SLIT group (25) and
placebo group (25)
Age: 14 to 55 years; mean age 29.1 (7.4) years in SLIT group and 27.8 (7.3) years in
placebo group
Inclusion criteria: positive clinical history of respiratory allergic symptoms related to cat
exposure andmono-sensitisation to cat allergens; positive skin prick test to a standardised
cat dander extract (wheal ≥ 7 mm) and specific IgE to cat dander
Exclusion criteria: use of immunotherapy during the past 5 years and any contraindica-
tion for the immunotherapy according to criteria of the European Allergy and Clinical
Immunology Immunotherapy Subcommittee
Percentage withdrawn: 32% withdrawal from cat dander SLIT group and 36% with-
drawal from placebo group
Percentage with asthma: 81.8%
Co-morbidities: persistent moderate to severe rhinitis
Allowed medication: antihistamines, local corticosteroids (nasal and bronchial budes-
onide), nedocromil and salbutamol
Disallowed medication: beta-blockers
Interventions Control group: placebo SLIT
SLIT group: cat dander SLIT once daily. Total accumulated dose 17.1 mcg
Co-interventions: not reported
Outcomes Exposure to cat in a cat room scoring symptoms (conjunctival, nasal and bronchial
symptoms), PEF values, skin reactivity, adverse events
Notes Type of publication: peer reviewed
Funding: Laboratorios LETI, S.L., Tres Cantos, Madrid, Spain
Risk of bias
Bias Authors’ judgement Support for judgement
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Alvarez-Cuesta 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no specific details about
sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind - “At the end of the study
and when the code was opened”, “the qual-
itative and quantitative composition of the
placebo was identical to the experimental
product, but without the active ingredi-
ents”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind - “At the end of the study
and when the code was opened”
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was high (32% and 36% in ac-
tive and placebo groups, respectively), and
these participants were not included in the
descriptive or efficacy data
Selective reporting (reporting bias) Low risk All stated outcomes reported, although
non-parametric tests used (appropriately),
so unable to use in meta-analysis
Other bias Unclear risk Unbalanced male/female ratio
Bahceciler 2001
Methods Design: ’randomised’, double-blind, placebo-controlled trial, 8-week run-in period
Duration: 26 weeks
Setting: outpatient clinics at 1 hospital, Turkey
Participants Population: 15 participants randomly assigned to HDM SLIT group (8) or placebo
group (7)
Age: 7 to 18 years; median age 12.4 (range 7.8 to 18) years and 12 (range 7.3 to 15)
years in placebo group
Inclusion criteria: require ICS for control of asthma symptoms, positive skin prick test
toD. farinea andD. pteronyssinus plus negative response to all other aero-allergens tested,
older than 7 years, ongoing respiratory symptoms in spite of mite avoidance measures
and appropriate ICS treatment, FEV1 greater than 70% of predicted
Exclusion criteria: not reported
Percentage withdrawn: 0% withdrawal in both HDM SLIT group and placebo group
Percentage with asthma: 100%
Co-morbidities: rhinitis
Allowed medication: SABA, ICS, intranasal steroids
Disallowed medication: not reported
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Bahceciler 2001 (Continued)
Interventions Control group: placebo SLIT
SLIT group: HDM SLIT daily for 4 weeks then twice weekly for 4 months. Average
cumulative dose 7000 IR
Co-interventions: ICS
Outcomes Symptom scores, use of rescue beta2-mimetics, compliance with ICS and intranasal
steroid therapy, skin prick test, lung function test, methacholine bronchial challenge test,
serum total IgE level
Notes Type of publication: peer reviewed
Funding: Say Tip and Stallergenes supplied D. pteronyssinus and D. farinea extract and
placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no specific details about
sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind - code not broken until after
6 months of treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind - code not broken until after
6 months of treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk None noted
Bousquet 1999
Methods Design: ’randomised’, double-blind, placebo-controlled trial; 4- or 8-week run-in period
Duration: 108 weeks
Setting: France
Participants Population: 85 participants randomly assigned to HDM SLIT group (42) and placebo
group (43)
Age: 7 to 42 years; mean age 21 (10) years in SLIT group and 22 (10) years in placebo
group
Inclusion criteria: at least 1-year history of moderate ormoderately severe asthma due to
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Bousquet 1999 (Continued)
HDM, diagnosis based on clinical history, positive skin tests using standardised extracts
and the presence of specific IgE as shown by RAST (with class 2 as a cutoff ), FEV1 >
70% predicted
Exclusion criteria: sensitisation to Alternaria or Cladosporium, sensitisation to animal
danders if animals were present in the home, received immunotherapy tomite in previous
2 years; using oral or parenteral steroids (more than 15 consecutive days), intramuscular
steroids, ICS (> 1000 mcg/d), inhaled beta2-agonists (> 4 times/d) and/or oral beta2-
agonists or methylxanthines
Percentage withdrawn: 45.24% withdrawal fromHDMSLIT group and 37.21%with-
drawal from placebo group
Percentage with asthma: 100%
Co-morbidities: rhinitis
Allowed medication: ICS up to 1000 mcg/d, ’rescue medication’
Disallowed medication: oral or parenteral corticosteroids for more than 15 consecutive
days, depot steroids, ICS dose > 1000 mcg/d BDP, SABA use more than 4 times/d, oral
beta-agonists, methylxanthines, immunotherapy for mite in the previous 2 years
Interventions Control group: placebo SLIT
SLIT group: HDM SLIT once daily initially then decreasing to three times per week
for 24 weeks. Maintenance dose 20 drops of 300 IR/mL 3 times a week
Co-interventions: usual medication
Outcomes Diary card, asthma severity, vital capacity, FEV1, PEFR, methacholine bronchial chal-
lenge, QoL, assessment of mite exposure, drug consumption, blood IgE and IgG4
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no specific details about
sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled
Incomplete outcome data (attrition bias)
All outcomes
High risk 45% attrition in treatment group, 37% in
placebo group (but all included in safety
analysis)
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Bousquet 1999 (Continued)
Selective reporting (reporting bias) High risk Selective reporting of QoL outcomes
Other bias Low risk None noted
Caffarelli 2000
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: 13 weeks and 9 weeks post-treatment follow-up
Setting: outpatient clinic in Parma, Perugia and Brescia, Italy
Participants Population: 48 participants randomly assigned to grass pollen tablet group (24) and
placebo group (24)
Age: 4 to 14 years; mean age 8.7 (3.3) years in SLIT group and 8.1 (2.7) years in placebo
group
Inclusion criteria: had rhinitis and/or conjunctivitis and/or bronchial asthma in the
grass pollen season, serum grass-specific IgE antibodies, positive skin prick test with grass
pollens including pollens contained in extracts for immunotherapy
Exclusion criteria: Sensitisations to allergens other than grass pollens (mites, pellitory,
cat and dog dander, birch, mugwort, Alternaria and Aspergillus) were excluded on the
basis of clinical symptoms andnegative skin prick test reactions; also, thosewith perennial
asthma and/or rhinitis who had received specific immunotherapy in the 3 years before the
beginning of the present study were excluded, as well as those undergoing treatment with
systemic steroids and those with contraindications for immunotherapy of the European
Academy of Allergy and Clinical Immunology (EAACI)
Percentage withdrawn: 0% withdrawal from grass pollen tablet group and 16.67%
withdrawal from placebo group
Percentage with asthma: 89.6%
Co-morbidities: rhinitis and/or conjunctivitis
Allowedmedication: ;local (both nasal sprays and eye drops) or systemic antihistamines,
inhaled beta2-agonists, ICS, theophylline
Disallowed medication: not reported
Interventions Control group: placebo tablet
SLIT group: grass pollen tablet (33% Holcus lanatus, 33% Phleum pratense and 33%
Poa pratensis) 3 times per week. Cumulative dosage 37,250 AU
Co-interventions: usual medication
Outcomes Symptom and medication diary cards, adverse events, nasal levels of ECP
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly assigned by a computer gener-
ated list”
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Caffarelli 2000 (Continued)
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% completion in intervention group, >
80% completion in placebo group
Selective reporting (reporting bias) Low risk All stated outcomes reported, but non-
parametric tests appropriately used, so not
possible to meta-analyse
Other bias Low risk None noted
Calderon 2006
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: 4 weeks and 5 or 6 weeks post-treatment follow-up
Setting: unclear
Participants Population: 43 participants randomly assigned to grass pollen SLIT group 1 (9), grass
pollen SLIT group 2 (9), grass pollen SLIT group 3 (9), grass pollen SLIT group 4 (5)
and placebo group (11)
Age: 18 to 65 years; mean age 22.1 (3.2) years in grass pollen SLIT group 1, 23.2 (2.8)
years in grass pollen SLIT group 2, 28.0 (9.5) years in grass pollen SLIT group 3, 25.8
(5.5) years in grass pollen SLIT group 4 and 24.5 (5.5) years in placebo group
Inclusion criteria: clinical history of significant grass pollen-induced allergic rhinocon-
junctivitis and mild to moderate grass pollen-induced asthma of 2 years or longer; well-
controlled seasonal asthma in accordance with British Thoracic Society criteria; positive
skin prick test and specific IgE to Phelum pratense
Exclusion criteria: significant asthma outside the grass pollen season; FEV1 < 70% of
predicted value; significant allergic rhinitis (requiring medication) caused by allergens
other than grass pollen during the planned treatment period; conjunctivitis, rhinitis or
asthma at screening or randomisation visits; history of anaphylaxis; immunosuppressive
treatment; hypersensitivity to excipients of trial medication or of rescue medication;
received immunotherapy with grass pollen allergen within the previous 10 years or any
other allergen within the previous 5 years; pregnancy or lactation
Percentage withdrawn: 0% withdrawal from all groups
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinoconjunctivitis
Allowed medication: reliever medication
Disallowed medication: not reported
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Calderon 2006 (Continued)
Interventions Control group: placebo SLIT
SLIT group 1: grass pollen SLIT (Phelum pratense) once daily. Dose 75,000 SQ-T
SLIT group 2: grass pollen SLIT (Phelum pratense) once daily. Dose 150,000 SQ-T
SLIT group 3: grass pollen SLIT (Phelum pratense) once daily. Dose 300,000 SQ-T
SLIT group 4: grass pollen SLIT (Phelum pratense) once daily. Dose 500,000 SQ-T
Co-interventions: not reported
Outcomes FEV1, PEF, adverse events, medication use
Notes Type of publication: peer reviewed
Funding: ALK-Abelló A/S, Denmark
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no specific details about
sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk No clinical data reported, just says ’No clin-
ically significant changes were observed in
FEV1 or PEF values during the trial period’
Other bias Low risk None noted
Cooper 1984
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: > 8 but < 16 weeks, 10 weeks post-treatment follow-up
Setting: outpatient allergy/respiratory clinic, UK
Participants Population: 19 participants randomly assigned to grass pollen SLIT group (11 com-
pleted) and placebo group (8 completed)
Age: 5 to 15 years; mean age not reported
Inclusion criteria: seasonal symptoms poorly controlled on conventional therapy, pos-
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Cooper 1984 (Continued)
itive allergen test to mixed grass pollen solution
Exclusion criteria: received oral hyposensitisation within 3 years of enrolment, took
oral steroids with 1 year of enrolment
Percentage withdrawn: not reported
Percentage with asthma: 100% (in asthma series presented separately)
Co-morbidities: hayfever
Allowedmedication: antihistamines, sodiumcromoglycate, topical steroids, salbutamol,
aminophylline, ICS
Disallowed medication: OCS
Interventions Control group: placebo SLIT
SLIT group: grass pollen SLIT (12 grass pollens (B2 grasses, Bencard)) once daily
decreasing to twice per week for maintenance. Dose not reported
Co-interventions: usual medication
Outcomes Adverse events, peak flow, symptom diary cards, medication usage, respiratory infection,
days taken off school
Notes Type of publication: peer reviewed
Funding: Beechams Research Laboratory
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stratified before random allocation - no
further details given
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double-blind study’ with ’matched
placebo’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double-blind study’ with ’matched
placebo’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 grass pollen SLIT patients and 4 placebo
patients were excluded from the study and
were not included in the analysis. Study au-
thors do not report whether these exclu-
sions were part of the hayfever or asthma
series and did not attempt to impute results
for dropouts
Selective reporting (reporting bias) High risk Some stated outcomes were not reported
at all in the paper (e.g. school absence) or
were not reported for asthma and hayfever
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Cooper 1984 (Continued)
separately (e.g. adverse events)
Other bias Low risk None noted
Corzo 2014 (a)
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 4 weeks
Setting: UK and Denmark; phase 1 clinical trials unit
Participants Population: 71 participants randomly assigned toHDM SLIT group 1 (9), HDM SLIT
group 2 (9), HDM SLIT group 3 (9), HDM SLIT group 4 (9), HDM SLIT group 5
(9), HDM SLIT group 6 (9) and placebo group (17)
Age: 18 to 65 years; mean age range 25 to 32 years across arms
Inclusion criteria: clinical history of HDM-induced mild to moderate asthma of at least
1 year before trial entry; use of appropriate medications for control of asthma symptoms
(in accordance with GINA guideline); positive specific IgE (≥ class 2) and positive skin
prick test (wheal diameter ≥ 3 mm) to D. pteronyssinus or D. farinae
Exclusion criteria:history of severe asthmawithin the past 2 years; history of anaphylaxis
Percentage withdrawn: 0% withdrawal from groups 1 to 4; 11.1% withdrawal from
group 5; group 6 (32 DU) discontinued before end of trial because of severe adverse
event in 1 participant
Percentage with asthma: 100%
Co-morbidities: rhinoconjunctivitis
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group 1: HDM SLIT once daily. Dose 1 DU
SLIT group 2: HDM SLIT once daily. Dose 2 DU
SLIT group 3: HDM SLIT once daily. Dose 4 DU
SLIT group 4: HDM SLIT once daily. Dose 8 DU
SLIT group 5: HDM SLIT once daily. Dose 16 DU
SLIT group 6: HDM SLIT once daily. Dose 32 DU (discontinued before end of trial)
Co-interventions: not applicable
Outcomes Adverse events (according to MedDRA, lung function (FEV1 and PEFR), physical and
oral examination, laboratory safety assessments and immunological measurements
Notes Type of publication: peer reviewed
Funding: ALK
Risk of bias
Bias Authors’ judgement Support for judgement
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Corzo 2014 (a) (Continued)
Random sequence generation (selection
bias)
Unclear risk ’Participants were allocated to 6 dosage
groups and randomised 3:1 to active or
placebo’ but no specific details about se-
quence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled; ’active
and placebo were identical in appearance,
smell, and taste’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled; ’active
and placebo were identical in appearance,
smell, and taste’
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 withdrawal in this trial (from the 16 DU
group) due to occurrence of oedema under
the tongue and itching throat, but the 32
DU group discontinued because of a severe
AE
Selective reporting (reporting bias) High risk Lung function and laboratory results not
reported numerically. Adverse events not
reported in a way that allows meta-analysis
(only those occurring in > 5%and numbers
of events rather than participants affected
reported)
Other bias Low risk None noted
Corzo 2014 (b)
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 4 weeks
Setting: 4 centres, Spain; ’specialised allergy centre’
Participants Population: 72 participants randomly assigned toHDM SLIT group 1 (9), HDM SLIT
group 2 (9), HDM SLIT group 3 (9), HDM SLIT group 4 (9), HDM SLIT group 5
(9), HDM SLIT group 6 (9) and placebo group (18)
Age: 5 to 14 years; mean age range 7.9 to 10.6 years across arms
Inclusion criteria: clinical history of HDM-induced mild to moderate asthma of at least
1 year before trial entry; use of appropriate medications for control of asthma symptoms
(in accordance with GINA guideline); positive specific IgE (≥ class 2) and positive skin
prick test (wheal diameter ≥ 3 mm) to D. pteronyssinus or D. farinae
Exclusion criteria:history of severe asthmawithin the past 2 years; history of anaphylaxis
Percentage withdrawn: 0% withdrawal from all groups
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinoconjunctivitis
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Corzo 2014 (b) (Continued)
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group 1: HDM SLIT once daily. Dose 0.5 DU
SLIT group 2: HDM SLIT once daily. Dose 1 DU
SLIT group 3: HDM SLIT once daily. Dose 3 DU
SLIT group 4: HDM SLIT once daily. Dose 6 DU
SLIT group 5: HDM SLIT once daily. Dose 9 DU
SLIT group 6: HDM SLIT once daily. Dose 12 DU
Co-interventions: not applicable
Outcomes Adverse events (according to MedDRA, lung function (FEV1 and PEFR), physical and
oral examination, laboratory safety assessments and immunological measurements
Notes Type of publication: conference abstract
Funding: ALK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Participants were allocated to 6 dosage
groups and randomised 3:1 to active or
placebo’ but no specific details about se-
quence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled; ’active
and placebo were identical in appearance,
smell, and taste’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled; ’active
and placebo were identical in appearance,
smell, and taste’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk Lung function and laboratory results not
reported numerically. Adverse events not
reported in a way that allows meta-analysis
(only those occurring in > 5%and numbers
of events rather than participants affected
reported)
Other bias Low risk None noted
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Criado Molina 2002
Methods Design: randomised, parallel, open-label, pharmacotherapy-controlled trial
Duration: 52 weeks
Setting: Allergy and Immunology Unit, Spain
Participants Population: 44 children were randomly assigned to Alternaria SLIT (22) and placebo
(22)
Age: 18 to 65 years
Inclusion criteria: clinical history compatible with asthma and/or fungus-induced
rhinoconjunctivitis; Alternaria alternate specific sensitisation/sensitivity alone or in com-
bination with pollen and/or epithelia shown by IgE and positive prick test; positive
bronchial provocation test with Alternaria extract
Exclusion criteria: systemic immunological disease; severe atopic dermatitis; severe
asthma for which daily medication was needed; corticoid long-term treatment; yeast/
fungus/mould extract treatment in the past 2 years
Percentage withdrawn: 27.3% in each group
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinoconjunctivitis
Interventions Control group: pharmacotherapy only
SLIT group: Alternaria SLIT, 3 times per week as maintenance at 29,848 PNU/mo
(mean accumulated dose was 280,000 PNU)
Co-interventions: not reported
Allowedmedication: green zone: loratadine 5 to 10 mg/24 h or Budesonida 100 to 200
mcg/24 h (taken only if nasal symptoms persisted after loratadine was taken);
yellow zone: terbutaline sulfate 0.5 to 1 mg/6 to 8 h. If not returning to green zone, add
Budesonide 200 to 400 mcg/12 h;
red zone: terbutaline sulfate double dose and add deflazacort ¼ mg/kg
Disallowed medication: not reported
Outcomes Symptom medication score, skin prick, bronchial challenge test, peak flow, total and
specific IgE and IgG4
Notes Type of publication: peer reviewed, original publication in Spanish (duplicate transla-
tion)
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Criado Molina 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk Apparently high dropout but not clearly re-
ported and no participant flow diagram
Selective reporting (reporting bias) Unclear risk Numerical reporting inconsistent and not
possible to include data in meta-analysis
Other bias Low risk None noted
Dahl 2006
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 19.5 weeks (mean 84 days preseasonal exposure, 53 days seasonal exposure)
Setting: Denmark and Sweden
Participants Population: 114 participants were randomly assigned to Timothy grass SLIT group (74)
or placebo group (40)
Age: 18 to 65 years; mean age 36.5 (SLIT) years and 34.1 (placebo) years
Inclusion criteria: age 18 to 65; clinical history of significant grass pollen-induced
allergic rhinoconjunctivitis and mild to moderate grass pollen-induced asthma of 2 years
or longer; well-controlled seasonal asthma in accordance with GINA guideline; positive
skin prick test and specific immunoglobulin E to Phleum pratense
Exclusion criteria: significant asthma outside the grass pollen season; FEV1 < 70% of
predicted value; significant allergic rhinitis (requiring medication) caused by allergens
other than grass during the planned treatment period; conjunctivitis, rhinitis or asthma
at screening or randomisation visits; history of anaphylaxis; immunosuppressive treat-
ment; hypersensitivity to excipients of trial medication or rescue medication; received
immunotherapy with grass pollen allergen within the previous 10 years or any other
allergen within the previous 5 years; pregnancy
Percentage withdrawn: SLIT 10.9%, placebo 9.9%
Percentage with asthma: 100%
Co-morbidities: rhinoconjunctivitis
Allowed medication: loratadine 10 mg once daily, levocabastine eye drops (0.5 mg/
mL; 1 drop in each eye twice daily), Budesonide nasal spray (up to 32 mcg; 2 puffs per
nostril twice daily), prednisolone (up to 50 mg once daily), salbutamol (200 mcg per
inhalation; 1 to 2 inhalations twice daily), fluticasone (250 mcg per inhalation; 1 to 2
inhalations twice daily)
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:Timothy grass (Phleum pratense) GRAZAX tablet 75,000 SQ-T once daily
Co-interventions: not reported
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Dahl 2006 (Continued)
Outcomes Average daily asthma medication and symptom scores before and during the grass pollen
season, average daily rhinoconjunctivitis symptom and medication scores during the
grass pollen season
Notes Type of publication: peer reviewed
Funding: ALK-Abello A/S, Denmark
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double-blind’, placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double-blind’, placebo-controlled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10% dropout in both groups
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk None noted
Eifan 2009
Methods Design: randomised, open-label, parallel, pharmacotherapy-controlled trial
Duration: 52 weeks
Setting: 1 paediatric allergy centre in Istanbul, Turkey
Participants Population: 48 children were randomly assigned to house dust mite SLIT (16), usual
pharmacotherapy (16) and 1 other treatment that was not relevant to this review (sub-
cutaneous immunotherapy, 16)
Age: 5 to 10 years; mean age 6.5 (SLIT) years and 7.6 (placebo) years
Inclusion criteria: 5 to 10 years of age, suffering from mild persistent asthma/rhinitis
according to GINA guidelines, having HDM-related asthma/rhinitis symptoms, strictly
mono-sensitised to Dermatophagoides pteronyssinus and Dermatophagoides farina as con-
firmed by a positive skin prick test and HDM specific IgE level greater than or equal to 0.
35 IU/mL, who were prospectively followed up and received inhaled/intranasal steroids
for at least 2 years with no reduction of symptoms
Exclusion criteria: systemic immunological disorders, severe asthma with FEV1 < 70%,
54Sublingual immunotherapy for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eifan 2009 (Continued)
severe atopic dermatitis, previous use of allergen immunotherapy
Percentage withdrawn: SLIT 6.25%, placebo 12.5%
Percentage with asthma: 85% (41/48)
Co-morbidities: rhinitis
Allowed medication: rescue medications, inhaled/intranasal corticosteroids, antihis-
tamines and oral steroids
Disallowed medication: not reported
Interventions Control group: usual pharmacotherapy only
SLIT group: house dust mite SLIT (D. pteronyssinus and D. farinae), cumulative 1-year
dose ~ 73,876.8 SU (standard units)
Co-interventions: not reported
Outcomes Symptom score diary for asthma and rhinitis symptoms, medication use, VAS symptom
score, skin prick testing, nasal provocation tests, lung function test, methacholine chal-
lenge and immunoglobulin E levels, peripheral blood mononuclear cell isolation and
detection of secreted cytokines
Notes Type of publication: peer reviewed
Funding: The Marmara University Scientific Research Committee
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a computer-generated randomisa-
tion method”
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Open-label’
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ’Open-label’
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% attrition in treatment group, 12% in
control group
Selective reporting (reporting bias) High risk Data for several outcomes (lung function,
bronchial hyper-reactivity, skin prick test,
blood markers) were not reported in full (i.
e. significance only), and others and other
data were reported only in graphical form
Other bias Low risk None noted
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Fadel 2010
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: not reported
Setting: university hospital, Syria
Participants Population: 55 participants randomly assigned to grass pollen SLIT group (41) and
placebo group (14)
Age: 18 to 50 years; mean age not reported
Inclusion criteria: 18 to 50 years with allergic asthma due to grass pollens
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: grass pollen SLIT, dose progression phase then 3 times per week. Dose
2400 IR
Co-interventions: not applicable
Outcomes Symptoms, medication scores, global assessment of efficacy
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no specific details about
sequence generation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind - no specific details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind - no specific details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract only. No useable nu-
merical data and minimal details regarding
the conduct of the study
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Fadel 2010 (Continued)
Other bias Low risk None noted
Gomez Vera 2005
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 26 weeks
Setting: regional hospital allergy clinic in Mexico
Participants Population: 60 participants were randomly assigned to SLIT (30) and placebo (30)
Age: 13 to 45 years; mean age 21.4 (whole population) years
Inclusion criteria: mild and moderate persistent asthma, according to clinical and
spirometry criteria (GINA); differences in pre and post FEV1 salbutamol spirometry
equal to or greater than 14%; age between 13 and 45 years; prick test and intradermal
skin tests positive to Dermatophagoides pteronyssinus; total IgE higher than 200 IU
Exclusion criteria: other diseases that might alter results; diagnosed by chest, paranasal
sinus and oesophageal x-rays; exacerbation of asthma that needed oral steroids
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: Salbutamol and antihistamines were used as rescue treatment.
For mild persistent asthma, ICS were NOT used. For moderate asthma, ICS at doses
recommended by GINA were included
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (D. pteronyssinus), cumulative dose of 10,469 UBE.
710 UBE 3 times/wk
Co-interventions: conventional pharmacological treatment
Outcomes Spirometry before and after salbutamol (FEV1), secondary effects, number of asthma
crises admitted to Emergency Department, rescue treatment with salbutamol, inhaled
steroids or systemic steroids, asthma symptoms (requested from participants every
month), lack of ability to carry out daily tasks, night symptoms
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
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Gomez Vera 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind - no specific details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind - no specific details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Not all outcomes reported and few numer-
ical data presented
Other bias Low risk None noted
Hanna 2013
Methods Design: prospective, randomised, placebo-controlled trial
Duration: 13 weeks
Setting: not reported
Participants Population: 60 participants were randomly assigned to house dust mite SLIT (30),
placebo (15) and 1 other treatment that was not relevant to this review (subcutaneous
immunotherapy, 15)
Age: no details
Inclusion criteria: allergic asthma to D. farinae
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (D. farinae), maintenance dose 5 drops of 10 BU/
mL 3 times a week
Co-interventions: not reported
Outcomes Symptoms, medication scores and D. farinae specific IgE, IL-4, IL-10 and IFN-gamma
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Hanna 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’No mention of blinding’; ’prospective,
randomised 3 parallel groups’
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ’No mention of blinding’; ’prospective,
randomised 3 parallel groups’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract, no full paper. Min-
imal study characteristics and no useable
data
Other bias Low risk None noted
Inal 2009
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 52 weeks
Setting: Turkey
Participants Population: 32 participants were randomly assigned to house dust mite SLIT and
placebo (unclear how many in each group)
Age: no details
Inclusion criteria: mite allergic children with asthma and rhinitis
Exclusion criteria: not reported
Percentage withdrawn: 6.7% overall (not given per group); 93% (28/30) completed
the study
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinitis
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (dosing not stated)
Co-interventions: not reported
Outcomes Symptom scores, medication scores, VAS scores, QoL
Notes Type of publication: conference abstract
Funding: not reported
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Inal 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomization to treatment groups was
based on disease severity assessed with
symptom score for rhinitis and asthma in
the baseline year, gender and age’. Sequence
generation not described
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy but no spe-
cific details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy but no spe-
cific details
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93% (28/30) completed the study
Selective reporting (reporting bias) High risk Minimal study information or data pre-
sented in the abstract, and only P values
provided
Other bias Low risk None noted
Ippoliti 2003
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 26 weeks (with 3-month run-in)
Setting: Italy
Participants Population: 86 participants were randomly assigned to house dust mite SLIT (47) and
placebo (36)
Age: 5 to 12 years; median age of 9 in both groups
Inclusion criteria: children 5 to 12 years old, history of mild/moderate asthma, positive
skin prick test with wheal diameter > 5mm to house dustmites (HDM) (D. pteronyssinus)
and specific IgE to HDM at least of class 3, FEV1 greater than 70%
Exclusion criteria: positive skin test to other inhalant allergens, clinical history of other
allergies such as seasonal asthmadue topollens, history of immunotherapy in the previous
year or severe asthma
Percentage withdrawn: 0% SLIT, 0% placebo
Percentage with asthma: 100%
Co-morbidities: rhinoconjunctivitis
Allowed medication: drugs for relief of symptoms, if needed, for no more than 7
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Ippoliti 2003 (Continued)
consecutive days: inhaled steroids (200 mcg/puff, 2 to 4 puffs) and inhaled salbutamol
(250 mcg/puff, 1 to 3 puffs) on demand
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (D. pteronyssinus), maintenance dose 5 drops of 10
BU/mL 3 times a week
Co-interventions: not reported
Outcomes Daily symptom scores on diary cards, clinical evaluation, FEV1, CD40 count, serum
ECP, IL-13, PRL and ACTH
Notes Type of publication: peer reviewed
Funding: Grant MURST, 1998
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind - no specific details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind - no specific details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk None noted
Karakoc-Aydiner 2011
Methods Design: parallel, pharmacotherapy-controlled trial
Duration: 156 weeks (3 years)
Setting: unclear
Participants Population: 31 participants were randomly assigned to house dust mite SLIT (9), phar-
macotherapy only (10) and one other treatment that was not relevant to this review
(subcutaneous immunotherapy, 12)
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Karakoc-Aydiner 2011 (Continued)
Age: children; mean age 10.0 (SLIT) years and 7.5 (pharmacotherapy) years
Inclusion criteria: children with mild to moderate persistent asthma
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: usual pharmacotherapy only
SLIT group: house dust mite SLIT (dosing not reported)
Co-interventions: not reported
Outcomes Total symptom scores, total medication scores, visual asthma score, skin reactivity and
laboratory outcomes including allergen-induced IL-4, IL-5, IL-13, IFN-gamma, IL-10,
LI-17 and TGF-beta
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nomentionof blinding; assume open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention of assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract, no full paper. Min-
imal study characteristics and no useable
data
Other bias Low risk None noted
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Keles 2009
Methods Design: parallel, pharmacotherapy-controlled trial
Duration: 17.3 weeks
Setting: unclear
Participants Population: 53 participants were randomly assigned toHDMSLIT (15), pharmacother-
apy only (12) or to 2 other treatments not relevant to this review
Age: not reported
Inclusion criteria: children with mild to moderate asthma
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: Usual pharmacotherapy only
SLIT group:HDM SLIT. Dosing not reported
Co-interventions: Not reported
Outcomes Symptom andmedication scores, lung function tests, skin-prick tests, bronchial and nasal
provocation tests and allergen-induced cytokine response (IL-5, IL-10, IL-13, TGF-beta
and IFN-gamma)
Notes Type of publication: Conference abstract
Funding: Nor reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nomentionof blinding; assume open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention of assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out not reported
Selective reporting (reporting bias) High risk Conference abstract, no full paper. Min-
imal study characteristics and no useable
data
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Keles 2009 (Continued)
Other bias Low risk None noted
Keles 2011
Methods Design: parallel, pharmacotherapy-controlled trial (8-week run-in period)
Duration: 52 weeks (26 weeks post-treatment follow-up)
Setting: pediatric allergy and immunology outpatient clinic, Turkey
Participants Population: 58 participants randomly assigned to HDM SLIT group (15), to pharma-
cotherapy only group (15) or to 2 other treatment arms not relevant to this group
Age: 5 to 12 years; mean age 8.6 (2.1) years in HDM SLIT group and 7.9 (2.8) years in
pharmacotherapy group
Inclusion criteria: children (5 to 12 years)withmild persistent/moderate asthma/rhinitis
according to Global Initiative for Asthma guidelines, mono-sensitised toHDM, received
inhaled/intranasal steroids for at least 2 years with no reduction in symptoms
Exclusion criteria: not reported
Percentage withdrawn: HDM SLIT 13.3%, pharmacotherapy 20%
Percentage with asthma: 100% (from abstract methods)
Co-morbidities: rhinitis
Allowed medication: rescue medications (beta2-agonists and antihistamines) as needed
and ICS or intranasal corticosteroids in a stepwise fashion depending on persistence and
severity of symptoms
Disallowed medication: not reported
Interventions Control group: usual pharmacotherapy only
SLIT group:HDMSLIT 1-month induction phase followed by maintenance of 5 drops
3 times a week. 1.5 mg and 52.8 mg of D. pteronyssinus (Der p1) and 1.5 mg and 52.8
mg of D. farinae (Der f1)
Co-interventions: not reported
Outcomes Medications, symptoms, visual analogue scale (VAS) score, number of asthma attacks,
dose of ICS and side effects, total serum and allergen-specific IgE, allergen-specific IgG4,
IL-5, IL-13, INF-gamma, IL-10, TGF-beta and IL-17
Notes Type of publication: peer reviewed
Funding: Marmara University Scientific Research Committee
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “By using the table randomisation method
patients were randomised into one of 4 par-
allel groups”
Allocation concealment (selection bias) Unclear risk No details
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Keles 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nomentionof blinding; assume open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention of assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Relatively low and balanced dropout; 13%
withdrawal in treatment group, 20% in
control group
Selective reporting (reporting bias) Low risk All stated outcomes reported numerically
or narratively but not possible to include
data in meta-analysis
Other bias Low risk None noted
La Grutta 2007
Methods Design: ’randomised’, open-label, parallel, pharmacotherapy-controlled trial
Duration: 52 weeks
Setting: Italy
Participants Population: 56 participants randomly assigned to HDM/Parietaria SLIT group (33)
and pharmacotherapy only (23)
Age: HDM/Parietaria SLIT group 15.4 (mean) years, 8 to 44 (range) years, pharma-
cotherapy only group 21.8 (mean) years, 7 to 68 (range) years
Inclusion criteria: mild persistent asthma with/without intermittent moderate rhinitis,
sensitised to HDM
Exclusion criteria: systemic or immunological disease, major anatomical alterations of
the upper airways, renal insufficiency, coronary heart disease, neurological or psychiatric,
receiving long-term corticosteroid or beta-blocking treatments, pregnant women, no
bronchial hyper-reactivity, no nasal inflammation
Percentage withdrawn: 0% from both groups
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinitis
Allowed medication: on demand rescue medication for short periods; cetirizine 10 mg,
beta2-agonist 100 mcg 2 puffs, intranasal fluticasone 50 mcg 1 spray per nostril, short
course of systemic steroid if severe symptoms unresponsive to standard treatment; 50
mg prednisolone for 3 days
Disallowed medication: long-term corticosteroid and/or beta-blockers
Interventions Control group: usual pharmacotherapy only
SLIT group:HDM/Parietaria SLIT initiation phase then twice/wk. Dose 1000 AU
Co-interventions: not reported
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La Grutta 2007 (Continued)
Outcomes Symptom scores, medication use, adverse events, bronchial provocation tests, nasal
eosinophilia
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated to allergoid SLIT or
pharmacotherapy according to a computer-
generated list with an active-controlled ra-
tio of 3:2
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Placebo not used, active comparison of
pharmacotherapy. Nomention of outcome
assessor blinding for some outcomes, but
nasal eosinophils were done by a blinded
operator (not involved in the clinical study)
who counted the various inflammatory
cells
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk Several outcomes were reported only with a
significance level and could not be included
in the meta-analysis
Other bias Low risk None noted
Leng 1990
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 7.14 weeks (13 weeks post-treatment follow-up)
Setting: unclear
Participants Population: 18 participants randomly assigned to Artemisia pollen SLIT group (9) and
placebo group (9)
Age: 15 to 56 years; Artemisia pollen SLIT group mean 34.8 years, placebo group mean
36.2 years
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Leng 1990 (Continued)
Inclusion criteria: Participants had to be in good health, history of asthma in the
Artemisia pollination season, positive skin prick and bronchial provocation test to
Artemisia, FEV1 at least 80% predicted
Exclusion criteria: previous immunotherapy to grass pollen extract in the preceding 5
years
Percentage withdrawn: 0% in both groups
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: hayfever
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT (Coca’s solution)
SLIT group: Artemisia pollen SLIT daily up-dosing to a maximum of 16416 PNU.
Cumulative dose 396,652.06 PNU
Co-interventions: not reported
Outcomes Bronchial provocation test, serum-specific IgE, adverse events
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, specifically mentions blind-
ing of participants and assessors. ’The color
and amounts [of SLIT and placebo] in-
gested of these two solutionswere the same.
The patients were not informed of the con-
tents of the oral solutions’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, specifically mentions blind-
ing of participants and assessors. ’The color
and amounts [of SLIT and placebo] in-
gested of these two solutionswere the same.
The patients were not informed of the con-
tents of the oral solutions’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Other bias Low risk None noted
Lewith 2002
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: 16 weeks
Setting: 38 general practices in Hampshire and Dorset, UK
Participants Population: 242 participants randomly assigned to homeopathic HDM SLIT group
(122) and placebo group (120)
Age: 18 to 55 years; homeopathic HDM SLIT groupmean 38.2 (9) years, placebo group
mean 37.9 (10.4) years
Inclusion criteria: positive result to house dust mite (wheal diameter > 3 mm > negative
control 15 minutes after test) that was greater than for other aero-allergen extracts tested,
considered to have asthma if > 15% improvement in FEV1 or PEF 15 minutes after
200 mcg inhalation of salbutamol before randomisation and 2 of 3 criteria of an asthma
symptom diary score > 1 on at least 7 of the 14 baseline days during run-in period or
diurnal variation in PEF > 15% on at least 7 of the 14 baseline days or a need for inhaled
salbutamol on at least 7 of the 14 baseline days
Exclusion criteria: recorded no impairment in quality of life in diaries during their run-
in period or filled in fewer than 10 out of 14 days, took part in another drug trial in the
preceding 30 days, had previously been treated with homeopathic immunotherapy, were
pregnant or lactating, were unlikely to comply with trial requirements, had a respiratory
infection in the preceding 3 weeks, changed their concurrent medication in the two
weeks before entry
Percentage withdrawn: homeopathic HDM SLIT group 17.2%, placebo group 15.8%
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: no changes made to background medications
Disallowed medication: Participants requiring OCS were withdrawn from the study
Interventions Control group: placebo SLIT
SLIT group: homeopathic HDM SLIT administered on 3 occasions over 24 hours.
Dose 30 dilutions of 1:100
Co-interventions: usual medication
Outcomes Questionnaires on negative and positive trait mood and quality of life specific to asthma
(the asthma bother profile), PEF, perceived asthma severity on a VAS, perceived mood
on a bipolar scale, bronchodilator consumption
Notes Type of publication: peer reviewed
Funding: Smith’s Charity, NHS Executive South and West Research and Development
Directorate, Boiron, Maurice Laing Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
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Lewith 2002 (Continued)
Random sequence generation (selection
bias)
Low risk First 10 randomly allocated using sealed en-
velopes followed by randomisation bymin-
imisation according to age, sex, smoking
status and asthma severity
Allocation concealment (selection bias) Low risk First 10 randomly allocated using sealed en-
velopes followed by randomisation bymin-
imisation according to age, sex, smoking
status and asthma severity
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Randomisation codes broken only after
study completed. ’The indistinguishable
preparations’. ’As a check for blinding, one
day after randomisation we asked partici-
pants and investigators to guesswhether the
treatment was homeopathic immunother-
apy or placebo’. ’Neither participants nor
investigators were better than chance at
guessing treatment (114 (47%) partici-
pants and 116 (48%) investigators guessed
correctly)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation codes broken only after
study completed. ’The indistinguishable
preparations’. ’As a check for blinding, one
day after randomisation we asked partici-
pants and investigators to guesswhether the
treatment was homeopathic immunother-
apy or placebo’. ’Neither participants nor
investigators were better than chance at
guessing treatment (114 (47%) partici-
pants and 116 (48%) investigators guessed
correctly)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Balanced dropout (17% in homeopathy
group and 16% in placebo group), but all
participants were followed up
Selective reporting (reporting bias) High risk Several outcomes were reported only with
a significance level or visually in line graphs
and data could not be included in themeta-
analysis
Other bias Low risk None noted
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Lue 2006
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: 24 weeks (2 weeks post-treatment follow-up)
Setting:Outpatient Clinic of the Pediatric Allergy and Immunology Division of Chung-
Shan Medical University Hospital, Taiwan
Participants Population: 20 participants randomly assigned to HDM SLIT group (10) and placebo
group (10)
Age: 6 to 12 years; HDM SLIT group mean 7.7 (1.8) years and placebo group mean 8.
6 (1.8) years
Inclusion criteria: at least 1-year histories of mildly persistent to moderately persistent
asthma, sensitised to HDM only. Diagnosis was based on clinical history, positive skin
tests and presence of specific IgE (3+, as detected by MAST CLA allergen testing).
Children were enrolled only if their FEV1 was greater than 70% of predicted value and
their reversibility of PEFR exceeded 15% after administration of an inhaled b2-agonist
Exclusion criteria: sensitive to any other airborne allergens by standardised prick test
or specific IgE; received prior immunotherapy; treated with oral or parenteral corticos-
teroids (> 15 consecutive days), ICS at dosage greater than 1000 mcg/d (beclomethasone
dipropionate) and inhaled beta2-agonists more than 4 times per day; contraindications
to specific allergen immunotherapy (e.g. immunodepression, autoimmune disease, pro-
gressive nephropathy, malignancy of any organ system)
Percentage withdrawn: 0% for both groups
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowedmedication: ICS (Pulmicort Turbuhaler), inhaled beta2-agonist (Bricanyl Tur-
buhaler) and OCS (prednisolone, 5 mg)
Disallowed medication: oral or parenteral corticosteroids (> 15 consecutive days), ICS
at dosage greater than 1000 mcg/d (beclomethasone dipropionate) and inhaled beta2-
agonists more than 4 times per day
Interventions Control group: placebo SLIT
SLIT group: HDM SLIT daily with 3 week initiation phase. Maximum 20 drop dose
of 300 IR/mL. Cumulative dose of 41,824 IR
Co-interventions: not reported
Outcomes Asthma symptom scores, medication scores, PEFR, skin prick test, lung function tests,
serum total IgE, ECP, eosinophil count, mite-specific IgE and IgG4, adverse events
Notes Type of publication: peer reviewed
Funding: Stallergenes provided the Staloral used in this study. “This study did not receive
any support from the pharmaceutical industry”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Enrolled and randomly assigned” - no fur-
ther details
Allocation concealment (selection bias) Unclear risk No details
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Lue 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, no specific details. Placebo
was given ’in the same glycerosaline dilu-
ents’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, no specific details. Placebo
was given ’in the same glycerosaline dilu-
ents’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk All stated outcome reported
Other bias Low risk None noted
Marcucci 2003
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 52 weeks
Setting: Italy
Participants Population: 24 children were randomly assigned to house dust mite SLIT (13) and
placebo (11)
Age: 4 to 16 years; mean age 7.7 (SLIT) years and 7.3 (placebo) years
Inclusion criteria: eligible for the study if mono-sensitised to HDMs, with a clinical
history of at least 2 years of rhinitis and/or asthma related to perennial allergens
Exclusion criteria: no previous specific immunotherapy treatment
Percentage withdrawn: 0
Percentage with asthma: 84.6% (SLIT), 81.8% (placebo)
Co-morbidities: rhinoconjunctivitis
Allowed medication: oral antihistamines, nasal corticosteroids, ICS, cromolyn and
salbutamol
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT (D. pteronyssinus and D. farinea) daily with 3 week initiation
phase, maximum 20 drop dose of 300 IR (cumulative dose 41,824 IR)
Co-interventions: not reported
Outcomes ECP and tryptase in sputum, nasal and serum mite-specific IgE, nasal ECP, allergen-
specific nasal challenge
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Marcucci 2003 (Continued)
Random sequence generation (selection
bias)
Low risk ’Randomised by means of a computer-gen-
erated code’. ’The randomisation key fol-
lowed did not allow for a good balancing
for gender between groups but we believe
that this had little or no effect on the final
outcomes’
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled trial.
’The placebo treatment had the same com-
position and presentation of the active
treatment’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled trial.
Placebo was given ’in the same glyceros-
aline diluents’
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) Unclear risk Mainly non-clinical outcomes, but well re-
ported. Did not report trial registration to
check whether all prespecified outcomes
were included in the write-up
Other bias Low risk None noted
Marogna 2005
Methods Design: ’randomised’, open-label, parallel, pharmacotherapy-controlled trial
Duration: 156 weeks with 52 weeks post-treatment follow-up
Setting: Outpatient Allergy Unit, Cuasso al Monte Hospital, Varese, Italy
Participants Population: 79 (enrolled) participants were randomly assigned to birch pollen SLIT
group (39) and pharmacotherapy only group (40)
Age: 18 to 65 years; birch pollen SLIT group mean 27.8, pharmacotherapy only group
mean 29.0
Inclusion criteria: clinical history of rhinitis with or without mild intermittent or per-
sistent asthma due to birch pollen in the past 2 years; positive skin prick test response (>
5 mm) and positive CAP-RAST assay result (class III or greater) for birch pollen only;
age between 18 and 65 years; FEV1 within normal limits (> 79% of predicted value)
Exclusion criteria: sensitised to other common inhalant allergens, moderate persistent
asthma, anatomic abnormalities of the upper respiratory tract, long-term treatment with
systemic steroids, malignancies, systemic immunological disorders
During the study, participants with onset of nasal eosinophilia, bronchial hyperreactivity
out of the pollen season or new sensitisations
Percentage withdrawn: birch pollen SLIT group 25.6%, pharmacotherapy only group
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Marogna 2005 (Continued)
42.5%
Percentage with asthma: 100%
Co-morbidities: rhinitis
Allowed medication: All participants received the following continuous pharmacolog-
ical treatment during pollen seasons: cetirizine or loratadine (10 mg once daily) and
nasal cromolyn (10 mg/d). Inhaled salbutamol (2 puffs) on demand for asthma attacks.
Intranasal beclomethasone dipropionate, 2 puffs per nostril twice daily (400 mg/d) by
physician prescription only if poor response to antihistamines and cromolyn
Disallowed medication: In birch season, participants were advised to discontinue use
of intranasal nasal steroids (if any) at least 10 days before the nasal scraping
Interventions Control group: usual pharmacotherapy only
SLIT group: birch pollen SLIT initiation phase of 50 days then daily for 3 years. Dose
was reduced by one-third during the pollen season. Cumulative dose of 102 mcg per
year
Co-interventions: none reported
Outcomes Symptom scores (nasal itching, sneezing, rhinorrhoea, nasal obstruction, cough, wheez-
ing and eye itching-redness), medication use, lung function tests, methacholine chal-
lenge, nasal eosinophils
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk 25% dropout from treatment group, 42%
from control group; only completers were
analysed
Selective reporting (reporting bias) High risk All stated outcomes reported but several
only in graphical form or with inexact P
values (i.e. not in a format that could be
meta-analysed)
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Other bias Low risk None noted
Mosbech 2014
Methods Design: block randomised, parallel, double-blind, placebo-controlled trial
Duration: 52 weeks
Setting: 81 centres in Denmark, Germany, Italy, Spain, United Kingdom, Sweden,
France and Poland
Participants Population: 604 participants randomly assigned to HDM SLIT group 1 (146), HDM
SLIT group 2 (159), HDM SLIT group 3 (156) and placebo group (143)
Age: 14 years and above (mean age/age range not reported but across groups 6% were
reported to be adolescents)
Inclusion criteria: 14 years of age or older with controlled (based on ACQ score), mild
to moderate (steps 2 and 3 in GINA 2002 Guideline), HDM-allergic asthma of at least
1 year duration requiring ICS use (100 to 800 mg/d) and mild to severe HDM-allergic
rhinitis, positive diagnostic test results to HDM (i.e. skin prick tests with wheal size
> 3 mm to D. farinae, D. pteronyssinus or both and specific IgE test results against D.
farinae extract, D. pteronyssinus extract or both) > CAP class 2 and documented history
of reversible airway obstruction
Exclusion criteria: FEV1 < 70% of predicted value with appropriate medication; clinical
history of allergy with symptoms to a perennial allergen or a seasonal allergen causing
symptoms in the pretreatment ICS adjustment and/or stable periods; clinical history of
severe asthma within the past 2 years before enrolment; immunotherapy with HDM
allergenwithin previous 5 years before randomisation; concurrent or previous (within the
past 6 months before randomisation) immunotherapy with other allergens than HDM;
history of anaphylactic shock or angio-oedema
Percentage withdrawn: SLIT group 1 10%, SLIT group 2 16%, SLIT group 3 10%,
placebo group 12%
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: allergic rhinitis
Allowed medication: Before treatment initiation, use of ICS was standardised and ta-
pered to the lowest dose providing asthma control. Symptomatic medication was pro-
vided as rescue medication to all
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group 1: HDM SLIT 1 DU daily
SLIT group 2: HDM SLIT 3 DU daily
SLIT group 3: HDM SLIT 6 DU daily
Co-interventions: ICS
Outcomes Reduction in ICS dose, FEV1, PEF, exacerbation frequency, asthma control question-
naire, asthma QoL questionnaire, adverse events, withdrawals
Notes Type of publication: peer-reviewed
Funding: ALK-Abello, Denmark, assumed overall responsibility for the trial and has
been involved in both trial design and conduct
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Mosbech 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization was performed in blocks
of 8 by the sponsor by using the SAS system
for Windows which generates random as-
signment of treatment groups to random-
ization numbers. The randomization list
was generated by a trial-independent statis-
tician, and the list was reviewed by another
trial-independent person’
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tablets (active and placebo) were manufac-
tured andprovided by the sponsor andwere
oral lyophilisates, containing standardised
extracts of Dermatophagoides pteronyssinus
andDermatophagoides farinae in a 1:1 ratio
or a placebo that was similar in appearance,
smell and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation codes were kept strictly
confidential and accessible only to autho-
rised persons until un-blinding.Only when
the trial had been completed was the data
file verified, and the
protocol violations determined were the
randomisation codes broken and made
available for data analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and balanced (9.6% to
15.7% across groups). ’Imputation for pre-
maturely discontinued subjects was done
by using the last-observation-carried-for-
ward method, and the analysis thus fol-
lowed the ICH intent-to-treat principle’
Selective reporting (reporting bias) High risk Multiple outcomes, including AQLQ,
ACQ, lung function tests, not reported
numerically or only significant results re-
ported numerically, so unable to include
in meta-analysis. Reduction in ICS dose
reported only for 1-dose group and for
placebo group
Other bias Low risk None noted
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Mosges 2010
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: 0.015 weeks (90 minutes)
Setting: 14 centres in Germany
Participants Population: 116 (54 with asthma) randomly assigned to ultra-rush birch pollen SLIT
group (27) and placebo group (27)
Age: 6 to 14 years; ultra-rush birch pollen SLIT group mean 10.2 (2.64) years, placebo
group mean 10.5 (2.55) years
Inclusion criteria: 6 to 14 years, medical history of allergic rhinitis or rhinoconjunctivitis
with or without mild to moderate asthma because of tree pollens (birch and possibly
alder and/or hazel), positive skin prick tests and presence of specific IgE ≥ 0.7 IU/
L to respective tree pollens, Retrospective Rhinoconjunctivitis Total Symptom Score
(RRTSS) ≥ 8
Exclusion criteria: previous immunotherapy within the past 3 years, perennial allergic
rhinitis, perennial allergic asthma, absolute or relative contraindications to immunother-
apy, any other condition that could compromise participant safety during the study
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinitis and/or conjunctivitis
Allowed medication: The following symptomatic drugs were allowed for the treatment
of allergic reactions during titration: local (nasal and ocular) levocabastine (step 1),
oral cetirizine (step 2), nasal fluticasone (step 3) and eventually an OCS (step 4). In
participants with asthma, previous medication with corticosteroids for inhalation and/
or selective beta2-adrenoceptor agonists for inhalation was continued at the same dose
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: ultra-rush high-dose birch pollen (Betula alba) SLIT titration regimen
reaching maintenance dose of 300 IR within 90 minutes (30-90-150-300 IR)
Co-interventions: not reported
Outcomes Lung function tests, laboratory safety measures (RBC, haemoglobin, haematocrit,
platelets, WBC including differential, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), bilirubin, lactate dehydrogenase (LDH) andC-reactive protein (CRP)
, adverse events
Notes Type of publication: peer reviewed
Funding: Stallergenes GmbH, Kamp-Lintfort, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk No details
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Mosges 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, no specific details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, no specific details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not clearly reported
Selective reporting (reporting bias) High risk Most outcomes reported narratively; al-
most no supporting data
Other bias Low risk None noted
Mungan 1999
Methods Design: ’randomised’ (unclear), single-blind, parallel, placebo-controlled trial
Duration: 52 weeks
Setting: Turkey
Participants Population: 36 participants were randomly assigned to HDM SLIT group (15), to
placebo group (11) and to 1 other treatment arm not relevant to this review
Age: 18 to 46 years; HDM SLIT group mean 31.7 (7.28) years, placebo group mean
33.3 (8.45) years
Inclusion criteria: hypersensitivity to inhaledHDMwith history of asthma and rhinitis
symptoms for at least 3 consecutive years, presence of symptoms despite optimal treat-
ment and environmental controlling procedures, FEV1 > 70% predicted, positive skin
prick test for D. pteronyssinus and D. farinae, positive in vitro specific IgE test for D.
pteronyssinus and D. farinae
Exclusion criteria: hypersensitivty to any other air-bourne allergen on skin prick test,
previous immunotherapy, active immunological or systemic disease or malignancy
Percentage withdrawn: 0% in both groups
Percentage with asthma: 88%
Co-morbidities: rhinitis
Allowed medication: salbutamol and antihistamines only for symptomatic treatment,
ICS
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT initiation phase followed by twice per week. Cumulative dose
11,316 IR/y
Co-interventions: not reported
Outcomes Rescue medication use, symptom scores, skin prick test, bronchial challenge test, total
IgE, specific IgE, IgG4
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Mungan 1999 (Continued)
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Separated’ into 3 groups; possibly not ran-
domly assigned? “patients with rhinitis and
asthma due to mite allergy were randomly
divided into three groups”
Allocation concealment (selection bias) Unclear risk ’Separated’ into 3 groups; possibly not ran-
domly assigned?
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo controlled’, “single blind”, but no
details about exactly who was blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Placebo-controlled but no details about ex-
actly who was blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk Many outcomes reported only narratively
and compared with baseline rather than
placebo. Symptom and medication scores
reported but without variance
Other bias Low risk None noted
Muratore 1993
Methods Design: ’randomised’, double-blind, parallel, placebo-controlled trial
Duration: 52 weeks
Setting: Italy
Participants Population: 28 participants randomly assigned toHDMSLIT group and placebo group
(number for each group not reported)
Age: 4 to 9 years (mean age for each group not reported)
Inclusion criteria: children suffering from bronchial asthma
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: all participants allowed ’bronchodilating and anti-inflammatory
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Muratore 1993 (Continued)
medication as required’
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM (Dermatophagoides antigen extract) SLIT incremental dosing sched-
ule then 3 times/wk maintenance dose of 2.5 UB
Co-interventions: not reported
Outcomes Clinical symptoms on a 3-point scale and drug consumption
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly allocated’ but no specific details
Allocation concealment (selection bias) Unclear risk ’Randomly allocated’ but no specific details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, no specific details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, no specific details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract only. No useable nu-
merical data and minimal details regarding
the conduct of the study
Other bias Low risk None noted
NCT00633919
Methods Design: ’randomised’, double-blind, parallel, multi-centre, placebo-controlled trial
Duration: 104 weeks
Setting: Spain
Participants Population: 124 participants randomly assigned to SLIT group (63) and placebo group
(61)
Age: 18 to 65 years; HDM SLIT group mean 32.0 (8.0) years, placebo group mean 30.
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NCT00633919 (Continued)
0 (9.0) years
Inclusion criteria: clinical history of house dust mite induced persistent mild to moder-
ate asthma, with or without concurrent rhinoconjunctivitis, of at least 1 year duration,
positive specific serum IgE test to Dermatophagoides during the year before the screen-
ing visit (CAP class 2 or higher or equivalent), positive skin prick test response (wheal
diameter ≥ 3 mm) to Dermatophagoides mix; if premenopausal female of childbearing
potential, participant must test negative on standard urine pregnancy test, willingness
to comply with this protocol
Exlusion criteria: FEV1 < 70% predicted, asthma controlled at randomisation without
need for inhaled corticosteroids or with dose higher than 1000 mcg/d of beclometasone
or equivalent, clinical history of symptomatic perennial allergic asthma caused by other
allergens, chronic sinusitis, aspirin or sulfite intolerance, COPD, severe asthma or atopic
dermatitis, previous immunotherapy with HDM allergens within previous 10 years; cur-
rent symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute
otitis media or other relevant infectious process, cystic fibrosis, malignancy, insulin-de-
pendent diabetes, malabsorption or malnutrition, renal or hepatic insufficiency, chronic
infection, drug dependency or alcoholism, ischaemic heart disease or angina requiring
current daily medication or with any evidence of disease, making implementation of the
protocol or interpretation of protocol results difficult, or jeopardising the safety of the
participant
Percentage withdrawn: HDM SLIT group 42.8%, placebo group 36.1%
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinoconjunctivitis
Allowed medication: SABA, LABA, ICS, OCS, antihistamines, nasal steroids
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT (Dermatophagoidesmix) 200 STU daily for 2 years
Co-interventions: during the 2 evaluation periods, participants were provided with
standardised medication to use as required/according to symptom severity: desloratadine
(5 mg), budesonide nasal spray (64 mcg per puff ), salbutamol inhaler (200 mcg per
puff ), budesonide/formoterol inhaler (80/4.5 mcg per inhalation), oral prednisolone (5
mg per tablet)
Outcomes Average daily asthmamedication score, global evaluation of efficacy by participant, global
evaluation of efficacy by investigator, adverse events
Notes Type of publication: clinical trials website only; no peer-reviewed article identified
Funding: ALK-Abelló A/S
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no further details
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (participant, caregiver, in-
vestigator), placebo-controlled; ’SLITone
placebo’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind (participant, caregiver, in-
vestigator), placebo-controlled; ’SLITone
placebo’
Incomplete outcome data (attrition bias)
All outcomes
High risk High dropout in both arms; 42.8% in SLIT
group and 36.0% in control group; ef-
ficacy outcomes reported only for those
with available data; no imputation done for
missing data
Selective reporting (reporting bias) Low risk All started outcomes reported numerically
Other bias Low risk None noted
Niu 2006
Methods Design: randomised, double-blind, parallel, placebo-controlled trial
Duration: 24 weeks (+ 2 week off-treatment follow-up)
Setting: 5 medical centres in Taiwan
Participants Population: 110 children were randomly assigned to house dust mite SLIT (56) and
placebo (54)
Age: 6 to 12 years; mean age 7.9 (SLIT) years and 8.2 (placebo) years
Inclusion criteria: Patients with at least 1-year history of mildly persistent to moderately
persistent (GINA-global initiative for asthma, steps 2 and 3) asthma were enrolled in
this study. They were allergic to HDM only. Children were enrolled in this study only
if their FEV1 was > 70% of that predicted, and if reversible PEFR exceeded 15% after
inhalation of beta2-agonists
Exclusion criteria: Patients were excluded if theywere sensitive to cockroach,Alternaria,
Cladosporium, dog/cat danders or pollens by skin prick tests (wheal ≥ 5 mm), or had
allergen-specific IgE antibodies (≥ 1 +) against above allergens. Patients who had previ-
ously been treated with immunotherapy, oral or parenteral corticosteroids for more than
15 consecutive days, depot steroids, ICS in doses > 1000 mcg/d (beclomethasone dipro-
pionate), inhaled beta2-agonists more than 4 times/d and those suffering from other
respiratory diseases that were not suitable for immunotherapy, such as anatomical abnor-
mality of upper respiratory tract and congenital cardiovascular diseases, were excluded
Percentage withdrawn: 12.5% SLIT, 11.1% placebo
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: During the trial, participants were allowed to take the follow-
ing rescue medications if needed: ICS (budesonide turbuhaler), inhaled beta2-agonist
(terbutaline aerosol), OCS (prednisolone 5 mg)
Disallowed medication: not reported
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Interventions Control group: placebo SLIT
SLIT group: HDM SLIT (D. pteronyssinus and D. farinae), incremental dosing up to
maintenance dose (cumulative dose ~ 41824 IR, which was equivalent to 1.7 mg D.p.
and 3.0 mg D.f.)
Co-interventions: not reported
Outcomes Daily asthma scores, drug consumption, PEFR, lung function tests, skin prick tests, total
serum and specific IgE, global assessment by blinded physician, adverse events
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly assigned’ but no specific details
Allocation concealment (selection bias) Unclear risk ’Randomly assigned’ but no specific details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’The extract and placebo were dispensed in
the same glycerosaline dilutents’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Before and after 24 weeks of therapy, par-
ticipants were interviewed and physically
examined by an attending physician who
had no previous knowledge of participant
treatments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout in both groups (12.5% in
intervention group and 11.1% in control
group)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk None noted
Orefice 2004
Methods Design: randomised, parallel, open-label, pharmacotherapy-controlled trial
Duration: 156 weeks (3 years)
Setting: Italy
Participants Population: 47 participants were randomly assigned to HDM SLIT (23) or pharma-
cotherapy alone (24)
Age: no details
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Inclusion criteria: patients with mild/moderate allergic asthma sensitive to HDM
Exclusion criteria: patients with a symptom score less than 12 and/or needing a dose
of budesonide greater than 400 mcg/d for longer than 2 weeks were excluded - not clear
whether this was baseline exclusion or occurred during the study
Percentage withdrawn: 8.7% SLIT, 20.8% pharmacotherapy alone
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: usual pharmacotherapy alone
SLIT group:HDM SLIT (no details of dosing)
Co-interventions: not reported
Outcomes Bronchial provocation tests, symptom scores and morning and evening PEFR
Notes Type of publication: conference abstract
Funding: “self funded”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk ’Randomised’ but no details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced dropout and concerns re: ex-
clusion of participants with more severe
asthma during trial: “Patients with a symp-
tom score less than 12 and/or needing a
dose of budesonide greater than 400 mcg/
day for more than 2 weeks were excluded”
- not clear whether this was baseline exclu-
sion or occurred during the study (dropout
rate 8% in treatment group, 20% in con-
trol group)
83Sublingual immunotherapy for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Orefice 2004 (Continued)
Selective reporting (reporting bias) High risk Conference abstract, no full paper. Min-
imal study characteristics and no useable
data
Other bias Low risk None noted
Pajno 2000
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 104 weeks (2 years)
Setting: Italy
Participants Population: 24 children were randomly assigned to HDM SLIT (12) and placebo (12)
Age: 8 to 15 years; mean age 11 (SLIT) years and 12 (placebo) years
Inclusion criteria: history of mild to moderate asthma with methacholine PC20 (con-
centration of inhaled methacholine that causes a 20% decrease in FEV1 not below 2mg/
mL, positive skin prick test (wheal diameter > 5 mm) to HDM, specific IgE to HDM
of at least class 3
Exclusion criteria: positive skin response to at least 1 other inhalant allergen of the
standard panel for southern Italy, clinical history of other allergies such as seasonal asthma
due to pollens, history of immunotherapy in previous years, history of cardiovascular or
other medical or immunological diseases, severe asthma
Percentage withdrawn: 0% SLIT, 25% placebo
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: Only rescue drugs (beta2-agonist and OCS or ICS) were allowed
during the study
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (D. pteronyssinus), incremental dosing schedule
followed by maintenance 2.4 mg Der P 1 and 1.2 mg Der P 2 per week (in 3 doses/wk)
Co-interventions: not reported
Outcomes Drug consumption; asthma scores on a VAS; specific IgE, IgG and IgG4; adverse events
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned sepa-
rately to active or placebo group according
to a keyed code
84Sublingual immunotherapy for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pajno 2000 (Continued)
Allocation concealment (selection bias) Unclear risk “Keyed code” may imply concealed but not
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled trial.
Placebo was indistinguishable from active
treatment in flavour and appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All data were gathered in a double-blind
fashion in accordance with the clinical pro-
tocol. The co-ordinator, who was blinded
as to the group each child was assigned
to, was in charge of participant supervision
and adjusted rescue treatment according to
symptoms; was also responsible for report-
ing any reactions and/or side effects
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced dropout (0% in treatment
group, 25% in control group). Not in-
cluded in the analysis
Selective reporting (reporting bias) Low risk All started outcomes reported narratively
or numerically
Other bias Low risk None noted
Pajno 2003
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 56 weeks (with 52 week off-treatment follow-up)
Setting: Italy
Participants Population: 30 children were randomly assigned to Parietaria SLIT (15) and placebo
(15)
Age: 8 to 14 years; mean age 11 years
Inclusion criteria: history of seasonal asthma and rhinoconjunctivitis. Diagnosis of
asthmawas established on the basis of at least 3 doctor-diagnosed episodes separated by at
least 1 week of wheezing/breath difficulty during the 2 previous Parietaria pollen seasons
in a clinical setting in which asthma was likely and conditions other than allergy had
been excluded; poor symptom control in previous years despite antiallergic treatment
including antihistamines, ICS and nedocromil sodium for 3 to 4 months (i.e. almost the
full pollen season); positive skin prick test result (wheal diameter > 5 mm) to Parietaria
pollen extract (Parietaria judaica); specific IgE to P. judaica levels in sera of at least class
2 was determined by means of the RAST technique
Exclusion criteria: appreciable clinical history of sensitisation to other inhalant aller-
gens (confirmed by skin prick test and/or in vitro IgE analysis), history of previous im-
munotherapy; severe asthma (FEV1 < 70% of predicted values); history of cardiovascular
or other medical or immunological disease. Children showing at baseline a methacholine
PC20 (concentration of inhaled methacholine that caused a 20% decrease in FEV1) <
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Pajno 2003 (Continued)
2 mg/mL were also excluded so that only children with mild or no specific bronchial
hyperreactivity outside the pollen season of Parietaria were included
Percentage withdrawn: 6.7% SLIT, 13.3% placebo
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinoconjunctivitis
Allowed medication: Both SLIT groups (active and placebo) were prescribed and in-
structed to use rescue drugs (nedocromil sodium eye drops and nasal spray, loratadine,
salbutamol) during the peak of the following pollen season of Parietaria (i.e. from April
to June 2000). They also inhaled fluticasone propionate (50 mg per actuation) twice
daily. If symptoms developed that were not controlled by regular drugs, the co-ordinator
could prescribe a 5-day course of prednisone (1 mg/kg/d)
Disallowed medication: intranasal steroids
Interventions Control group: placebo SLIT
SLIT group: Parietaria pollen SLIT (Parietaria judaica), incremental dosing schedule
followed by maintenance twice/wk (cumulative Par j ~ 20.3 mcg)
Co-interventions: inhaled fluticasone propionate 50 mcg twice daily April to June of
first pollen season
Outcomes Symptom and drug scores, VAS asthma scores, early and late skin prick responses, adverse
events, bronchial hyperreactivity, lung function tests
Notes Type of publication: peer reviewed
Funding: University Hospital of Messina
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment to active (15 children)
, placebo (15 children) or control (8 chil-
dren) group was obtained by means of a
computer-generated key code
Allocation concealment (selection bias) Unclear risk “Keyed code” may imply concealed but not
clear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was indistinguishable from active
treatment for appearance, colour and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The co-ordinator, who was blinded as to
the group to which each child was assigned,
was in charge of participant supervision and
adjustment of rescue medications accord-
ing to symptoms; was also responsible for
reporting any reaction and/or side effects
certainly or possibly related to treatment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Relatively low dropout in both groups (6%
in treatment group, 13% in control group),
although dropouts not included in efficacy
analysis
Selective reporting (reporting bias) Unclear risk Several outcomes reported only narratively
or ’ranges’ of P values given. Discrepancies
between different reports appear to be re-
lated to same participant group
Other bias Low risk None noted
Pham-Thi 2007
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 78 weeks
Setting: Department of Paediatric Pneumology and Allergy, Hopital Necker-Enfants
Malades, Paris, France
Participants Population: 111 children were randomly assigned to house dust mite SLIT (55) and
placebo (56)
Age: 5 to 16 years; mean age 9.6 (SLIT) years and 9.5 (placebo) years
Inclusion criteria: asthma, with or without perennial rhinitis, for at least 2 years, receiv-
ing treatment with an ICS (> 200 and ≤ 1000 mcg/d/equivalent budesonide) daily and
continuously for at least 6 months during the previous 12 months; reversible bronchial
obstruction, as assessed by salbutamol inhalation test (increase in FEV1 ≥ 15% after
inhaled salbutamol) during the past 2 years; sensitised to dust mites, as proved by positive
skin tests to HDM extract and HDM-specific IgE level ≥ class 2 (CAP RAST)
Exclusion criteria: concomitant sensitisation to perennial allergens such as cockroach,
Alternaria or Cladosporium mould species, cat, dog (if animal at home) and to seasonal
pollen allergens, inducing allergic symptoms lasting longer than 4 months/y. Sensitisa-
tions were based on a clear-cut clinical history, positive skin tests and specific IgE (CAP
RAST ≥ class 2). Previous immunotherapy with HDM extracts within 3 years from
the date of inclusion; contraindications to SIT, according to international guidelines
(WHO)
Percentage withdrawn: 20% SLIT, 14.3% placebo
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinitis
Allowed medication: Terbutaline (MDI, 250 mcg per actuation) was used as a short-
acting bronchodilator. Budesonide (MDI, 100 or 200 mcg per actuation) was used as
a regulatory ICS. In case of asthma exacerbation, the investigator prescribed a short
course of prednisolone (20 mg per tablet). No other antiasthma drugs were allowed.
Intake of antiasthma drugs was recorded as the number of puffs per day. Pharmacological
treatment was adjusted every 3 months following a step-down approach
Disallowed medication: antiasthma medication not mentioned in allowed list
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT (D. pteronyssinus and D. farinae), up-dosing for 2 weeks up to
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300 IR concentration once daily (average cumulative dose was 155,000 IR, correspond-
ing to 6.9 mg Der P 1 and 14.7 mg Der f 1)
Co-interventions: terbutaline, budesonide
Outcomes Asthma symptom scores, reduction in use of ICS and inhaled beta2-agonists, rhinitis
symptoms, lung function tests, skin sensitivity toHDM,dustmite-specific immunoglob-
ulin E and IgG4, QoL
Notes Type of publication: peer reviewed
Funding: Stallergenes SA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Children were then randomly assigned 1:
1 to receive SLIT or placebo with stratifi-
cation based on ICS daily intake (sequence
generation method not described)
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind, placebo-controlled trial”.
“Placebo tablets were identical to the active
extract in appearance, presentation, taste
and colour”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Among the 19 participants who withdrew,
10 in the SLIT group (all but 1) and 7 in
the placebo group (all but 1) were consid-
ered evaluable for the intent-to-treat anal-
ysis (ITT), which included 54 participants
in the SLIT group and 55 participants in
the placebo group
Selective reporting (reporting bias) High risk QoL total score comparison was not prop-
erly reported, just non-significance be-
tween groups stated
Other bias Low risk None noted
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Radu 2007
Methods Design: ’randomised’, single-blind, parallel, placebo-controlled trial
Duration: 26 weeks
Setting: Romania
Participants Population: 106 participants were randomly assigned to HDM SLIT group (55) and
placebo group (51)
Age: 5 to 13 years; HDM SLIT group range 5 to 12 years, placebo group range 5 to 13
years
Inclusion criteria: stable asthma and taking ICS
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinitis
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT, dose not reported
Co-interventions: not reported
Outcomes Symptom scores, rescue medication use, PEFR
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
Allocation concealment (selection bias) Unclear risk Drugs and sealed codes were delivered di-
rectly to the pharmacy department of Glas-
gow Royal Infirmary
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blind but not clear who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Single-blind but not clear who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported, study stopped after
6 months
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Selective reporting (reporting bias) High risk Conference abstract only. Minimal numer-
ical data or details regarding the conduct of
the study
Other bias Unclear risk Planned for 36 months but stopped after
6 months because of statistically signifi-
cant differences in outcome favouring ac-
tive treatment
Reilly 1994
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 4 weeks (with 4 weeks ’optional’ post-treatment follow-up)
Setting: asthma outpatient clinic, Scotland
Participants Population: 28 participants were randomly assigned to homeopathic SLIT group (13)
and placebo group (15)
Age: minimum age 16 years; mean age of homeopathic SLIT group 40 (16.3) years,
placebo group 37 (14.3) years
Inclusion criteria: 16 years of age and older; asthma with > 15% improvement in FEV1
with bronchodilators; > 1 year history of asthma; atopic and reactive to inhaled allergens
and positive skin tests
Exclusion criteria: deterioration during the grass pollen season, allergen avoidance
within past 6 weeks, previous homeopathic immunotherapy for asthma, respiratory in-
fection, severe concomitant disease, pregnancy, antihistamines in the past 4 weeks, par-
enteral steroids in the past 6 months. Both doctors (homeopathic and asthma clinic
doctor) could veto inclusion of any patient they considered unsuitable
Percentage withdrawn: 15.39% homeopathic SLIT group, 13.33% placebo group
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: ’unaltered conventional care’
Disallowed medication: antihistamines in past 4 weeks, parenteral steroids in past 6
months
Interventions Control group: placebo SLIT
SLIT group: homeopathic SLIT (allergen varied, decided on case-by-case basis; HDM
(84.6% of participants); feathers (7.7%); mixed moulds (7.7%)). 3 doses in 24 hours
then optionally repeated at 4 weeks (according to patient choice)
Co-interventions: 77% taking ICS plus usual medication in homeopathic SLIT group,
67% taking ICS plus usual medication in placebo group
Outcomes Lung function tests, skin testing, allergen-specific IgE, symptom scores, PEFR
Notes Type of publication: peer reviewed
Funding: RCCM Research Fellowship for Complementary Medicine, Blackie Founda-
tion Trust, Foundation Francaise pour le Recherche en Homeopathie
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned by a restricted tech-
nique of permuted blocks, stratified for in-
tended allergen and daily dose of steroid
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind; placebo vials were prepared
with globules impregnated with the same
batch of dilutant, which, without the ad-
dition of antigen, had been identically di-
luted and vibrated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Both study doctors and statisticians were
blinded to participant allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Balanced, reasonably low dropout (15% in
treatment group, 13% in placebo group)
. “Analysis was intention to treat”. “4 pa-
tients did not attend for follow-up: 3
(2 homeopathy gave social reasons and
reported no marked change in symp-
toms; 1 (placebo) was withdrawn by her
GP…Thus, 24 of 28 patients’ data were
used in the principal analyses”. Dropouts
were not accounted for in the analyses, but
dropout was balanced and was less than
20% in both groups
Selective reporting (reporting bias) Low risk All named outcomes were reported but
were not relevant to the review and used
non-parametric tests
Other bias High risk “Both doctors (homeopathic and asthma
clinic doctor) could also veto any patient
they considered unsuitable”; may represent
high risk of selection bias
Rodriguez 2012
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: not reported
Setting: Cuba
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Participants Population: 40 participants were randomly assigned to HDM SLIT group and placebo
group (number for each group not reported)
Age: ’adult’
Inclusion criteria: adult patients with mild or moderate asthma and specific sensibility
preponderant to this mite
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT (D. pteronyssinus), up-dosing to 2000 BU
Co-interventions: not reported
Outcomes Clinical symptoms, medication use, skin reactivity, PERF variability
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details (does not specifically state ran-
domised but double-blind, placebo-con-
trolled)
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled but no
further details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled but no
further details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract only. Minimal numer-
ical data or details regarding the conduct of
the study
Other bias Low risk None noted
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Rodriguez Santos 2004
Methods Design: ’randomised’, open-label, parallel, pharmacotherapy-controlled trial
Duration: 104 weeks
Setting: outpatient clinic, Cuba
Participants Population: 50 participants were randomly assigned to HDM SLIT group (25) and
pharmacotherapy group (25)
Age: 6 to 15 years (mean age not reported)
Inclusion criteria: children aged 6 to 15 years with asthma and elevated IgE, personal
and family history of atopy
Exclusion criteria: not reported
Percentage withdrawn: 0% withdrawal in both groups
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: pharmacotherapy only
SLIT group: HDM SLIT (D. pteronyssinus). Daily for 24 months. Dose 500, 1000,
2000, 5000, 8000, 10,000 BU
Co-interventions: not reported
Outcomes PEFR, emergency department attendance, steroid consumption
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly divided according to ’severity of
attacks’ - not clear whether this was ran-
dom stratification, or if participants were
purposely allocated on the basis of ’attack
severity’
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
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Selective reporting (reporting bias) Unclear risk Stated outcomes reported but numeri-
cal data not well presented; appears that
within-group outcomes reported rather
than comparisons with control
Other bias Low risk None noted
Shao 2014
Methods Design: ’randomised’, open-label, parallel, pharmacotherapy-controlled trial
Duration: 52 weeks
Setting: 6 centres located in 4 provinces in China
Participants Population: 264 participants were randomly assigned to HDM SLIT group (168) and
pharmacotherapy group (96)
Age: 3 to 13 years; mean age of HDM SLIT group 6.4 (2.59) years, pharmacotherapy
group 5.9 (3.037) years
Inclusion criteria: moderate to severe/persistent allergic rhinitis without severe/uncon-
trolled asthma according to Allergic Rhinitis and Its Impact on Asthma and the Global
Initiative for Asthma, clinical history of mite allergy and sensitisation to D. farinae con-
firmed by positive skin prick test and serum-specific IgE > 0.7I U/L and FEV1 ≥ 70%
predicted
Exclusion criteria: not reported
Percentage withdrawn: HDM SLIT group 16%, pharmacotherapy group 19.8%
Percentage with asthma: 82% (218/264)
Co-morbidities: rhinitis
Allowed medication: oral antihistamines, nasal corticosteroids, ICS, antileukotrienes,
beta2-agonists
Disallowed medication: not reported
Interventions Control group: pharmacotherapy only
SLIT group:HDM SLIT (D. farinae) daily. Dose not reported
Co-interventions: standard pharmacotherapy
Outcomes Symptom scores, medication consumption, adverse events, serum-specific IgE and IgG4,
lung function tests
Notes Type of publication: peer reviewed
Funding: Zhejiang Wolwo Bio-Pharmaceutical Co. Ltd.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no details
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Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Balanced dropout (16% in SLIT group,
19% in control group) but only completers
were analysed
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk None noted
Stelmach 2009
Methods Design: ’randomised’, double-blind, placebo-controlled trial
Duration: 104 weeks
Setting: specialty clinic setting, Poland
Participants Population: 50 participants randomly assigned to grass pollen SLIT group (25) and
placebo group (25)
Age: 6 to 17 years; mean age of participants in grass pollen group who completed study
9.1 (2.4) years, placebo group who completed study 8.5 (2.8) years
Inclusion criteria: children sensitive only to grass pollen (positive skin prick tests and
presence of specific IgE), clinical diagnosis of asthma with duration of at least 2 years
before the first study visit, with and without current symptoms of seasonal allergic
rhinoconjunctivitis. Diagnosis of asthma was established by symptoms of asthma and
by improvement in prebronchodilator FEV1 ≥ 12% after administration of salbutamol
200 mcg
Exclusion criteria:participantswith asthma and/or rhinitis allergic to perennial allergens
or severe intermittent or persistent asthma; active upper respiratory tract infection within
1month before the first visit and between first and second visits; known contraindications
of SIT according to the EAACI; clinically significant pulmonary, haematological, hepatic,
gastrointestinal, renal, endocrine, neuronal, cardiovascular and/or psychiatric disease or
malignancy that put the participant at risk when participating in the study or may have
influenced results of the study as judged by the investigator
Percentage withdrawn: grass pollen SLIT group 20%, placebo group 40%
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinoconjunctivitis
Allowed medication: All children in pollen season received budesonide 200 mcg twice
daily and salbutamol 100 mg/dose as quick reliever. Other permissible treatments: stan-
dard treatments for infections and exacerbations of asthma and standard treatments for
allergic rhinoconjunctivitis during pollen seasons (local cromones, local and/or systemic
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antihistamines and nasal steroids)
Disallowedmedication:Excludedmedicationswere systemic corticosteroids or immune
suppressive drugs, used within 4 weeks before the study
Interventions Control group: placebo SLIT
SLIT group: grass pollen SLIT (Dactylis glomerata, Anthoxanthum odoratum, Lolium
perenne, Poa pratensis, Phleum pretense). Ultra-rush induction: 1-3-6-12 (10-30-60-120
IR) drops separated by a 30minute observation period (total of 240 IR). At the beginning
of the next day, every morning before breakfast, received 4 puffs (120 IR) for 6 months.
Cumulative dose 43,800 IR
Co-interventions: budesonide 200 mcg twice daily and salbutamol 100 mcg/dose as
required during pollen season
Outcomes Symptom scores, lung function tests, nasal provocation tests, bronchial provocation tests,
serum IgE and IgG4, adverse events
Notes Type of publication: peer reviewed
Funding: Stallergenes Pharmaceutical Company supplied verum and placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All suitable participants were randomly as-
signed to the 2 treatment arms according to
a computer-generated allocation schedule
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo group received identical-looking
placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Immunotherapy was administered blindly
by a treatment team that was also respon-
sible for assessment and treatment of any
adverse reactions
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced and high dropout (20% from
SLIT group and 40% from placebo group
by end of study)
Selective reporting (reporting bias) Low risk All stated outcomes reported narratively or
numerically
Other bias Low risk None noted
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Tian 2014
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 48 weeks
Setting: asthma special outpatient centre in China
Participants Population: 60 children were randomly assigned to house dust mite SLIT (30) and
placebo (30)
Age: 4 to 18 years; mean age 11.1 (SLIT) years and 10.8 (placebo) years
Inclusion criteria: diagnosed with mild to moderate allergic asthma according to diag-
nostic criteria for bronchial asthma in children, and without allergic rhinitis, allergic to
D. farinae as confirmed by skin prick test (++ or greater), serum IgE detection (> 2) with
species of allergen not > 3
Exclusion criteria: other cardiovascular or autoimmune disease
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: SABA, ICS, antihistamines, LTRA, OCS
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (D. farinae), titrated up over the first 4 weeks to 333
mcg/mL once daily
Co-interventions: not reported
Outcomes Symptom scores, medication scores, ratio of Th17 and CD4+CD25+Treg cells
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk ’Divided into treatment group and control
group in order of admission’ - not clear
whether truly random
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-
controlled. Appearance, smell, packaging,
volume, storage conditions and modes and
methods of administration were identical
between placebo and drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind; no further details about out-
come assessors
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Tian 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Data for all time points were reported for
the active treatment group, but not for the
control group. Data not consistently re-
ported for each arm, most graphically or
just with levels of statistical significance
Other bias Low risk None noted
Troise 2009
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 104 weeks
Setting: single centre
Participants Population: 24 participants were randomly assigned to birch pollen SLIT (14) and
placebo (10)
Age: no information
Inclusion criteria: severe rhinitis and mild to moderate asthma
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100%
Co-morbidities: severe rhinitis
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group: birch pollen SLIT (Betula alba), no details of dosing
Co-interventions: not reported
Outcomes Rhinorrhoea, nasal obstruction, median days with asthma, severe adverse events
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details
Allocation concealment (selection bias) Unclear risk No details
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Troise 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind but no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind but no further details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract only. Minimal numer-
ical data or details regarding the conduct of
the study
Other bias Low risk None noted
Virchow 2014
Methods Design: randomised, double-blind, placebo-controlled trial (’MITRA’ trial)
Duration: 78 weeks
Setting: ’13European countries’ includingAustria, Croatia,Denmark, France,Germany,
Lithuaina, Netherlands, Poland, Serbia, Slovakia, Spain, United Kingdom
Participants Population: 834 participants randomly assigned to 3 groups; HDM SLIT 6 SQ, 12 SQ
and placebo SLIT (numbers randomly assigned to each arm not reported)
Age: adults
Inclusion criteria: clinically relevant history consistent with HDM-induced asthma of
at least 1 year before trial entry; use of an appropriate amount of ICS in accordance with
the GINA Guideline steps 2 to 4 for a period of at least 6 months within the past year
(in a range of budesonide 400 to 1200 mcg); documented reversible airway obstruction;
asthma control level ≥ 1.0 (asthma control questionnaire (ACQ) ≥ 1.0) at screening;
asthma control level between 1.0 and 1.5 (1.0 ≤ ACQ≤ 1.5) at visit 3 (randomisation)
; FEV1 ≥ 70% of predicted value; clinical history consistent with mild to severe HDM-
induced allergic rhinitis for at least 1 year; positive SPT response to HDM; positive
specific IgE against HDM (≥ IgE class 2; ≥ 0.70 KU/L)
Exclusion criteria: clinical history of persistent allergic asthma and/or rhinitis caused by
an allergen to which the participant is regularly exposed and sensitised (except HDM);
clinical history of intermittent allergic asthma and/or rhinitis if the seasonal allergenmay
cause symptoms in the ICS reduction period; previous treatment with immunotherapy
with HDM allergen for longer than 1 month within the past 5 years; hospitalisation for
longer than 12 hours due to asthma exacerbation within the last 3 months before the
screening visit
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: allergic rhinitis
Allowed medication: not reported
Disallowed medication: not reported
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Virchow 2014 (Continued)
Interventions Control group: placebo SLIT daily
SLIT group 1: HDM SLIT 6 SQ daily
SLIT group 2: HDM SLIT 12 SQ daily
Co-interventions: ICS 400 to 1200 budesonide or equivalent
Outcomes First moderate or severe asthma exacerbation during the ICS reduction period (ICS was
reduced in the past 6 months - 50% for 3 months and 100% for 3 months) analysed by
time-to-event, immunological measures; asthma symptoms; use of symptomatic medi-
cation; lung function; AQLQ; ACQ; adverse events
Notes Type of publication: conference abstract; protocol on European Trials Register (2010-
018621-19)
Funding: ALK-Abello
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled but no
further details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled but no
further details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract and European trials
register protocol. Minimal numerical data
presented
Other bias Low risk None noted
Vourdas 1998
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 104 weeks (2 years)
Setting: Greece
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Vourdas 1998 (Continued)
Participants Population: 66 children were randomly assigned to olive pollen SLIT (34) and placebo
(32)
Age: 7 to 17 years; mean age 12 years
Inclusion criteria: rhinoconjunctivitis and/or mild asthma due to olive pollen sensiti-
sation proved by positive skin prick test and RAST class II and above
Exclusion criteria: uncontrolled asthma or polysensitisation
Percentage withdrawn: 2.9% SLIT, 3.1% placebo
Percentage with asthma: 90.6%
Co-morbidities: rhinoconjunctivitis
Allowed medication: cetirizine, salbutamol, terbutaline, theophylline, sodium cromo-
glycate, budesonide, prednisolone
Disallowed medication: beta-blockers and ’retard’ corticosteroids
Interventions Control group: placebo SLIT
SLIT group:olive pollen SLIT, daily up-dosing then eachmorningpre- and co-seasonally
from January to July for 2 years up to a maximum of 20 drops of 300 IR (total 30,000
IR/y)
Co-interventions: not reported
Outcomes Symptom and medication scores, physician and participant overall evaluation of treat-
ment, PEFR, skin prick tests, allergen-specific IgE and IgG4, adverse events
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was a glycerinated phenolated
saline solution with an appearance similar
to that of the active agent
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind but no further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant from each group dropped
out and was not included in the efficacy
analysis (3% of total population). “All 66
patients were included in the tolerance
analysis”
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Selective reporting (reporting bias) High risk Most measures were reported only with
level of statistical significance, or in other
ways that could not be meta-analysed
Other bias Low risk None noted
Wang 2014
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 52 weeks (+ 12 week baseline period before randomisation)
Setting: 14 centres in cities, China
Participants Population: 484 participants were randomly assigned to house dust mite SLIT (322)
and placebo (162)
Age: 16 to 50 years; mean age 31.2 (SLIT) years and 31.3 (placebo) years
Inclusion criteria: adult patients (aged 16 to 50) with mild or moderate, persistent,
HDM-induced asthma for at least previous 12 months. Asthma was diagnosed with a
bronchial reversibility test (12% after inhalation of beta2-agonist) or a positive metha-
choline challenge within the previous year or at screening
Exclusion criteria: Main exclusion criteria were previous AIT, severe asthma, co-sensi-
tisation to confounding aero-allergens and smoking history of more than 10 pack-years
Percentage withdrawn: 4.3% SLIT, 3.1% placebo
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: allergic rhinitis
Allowed medication: budesonide dry powder 100 mcg (controller), salbutamol, pred-
nisolone (for asthma exacerbations) and loratadine (for allergic rhinitis)
Disallowed medication: The only authorised medications are listed under ’Allowed
medication’
Interventions Control group: placebo SLIT
SLIT group:HDM SLIT (D. pteronyssinus and D. farinae), approximately 28 mcg Der
P 1 and 50 mcg Der f 1 daily (300 IR)
Co-interventions: ICS
Outcomes Well-controlled asthma for at least 16 of the last 20 weeks of treatment, ICS use, Asthma
Control Questionnaire, lung function test, skin prick test, laboratory tests, treatment-
related serious adverse events
Notes Type of publication: peer reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomized 2:1 to active treatment or
placebo’ but no further details
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Wang 2014 (Continued)
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled but no
further details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, placebo-controlled but no
further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and balanced 4% from
SLIT and 2% from placebo groups; 96%
were included in the full analysis set (14
excluded from SLIT group and 5 from
placebo group) because of lack of assessable
weeks during treatment period
Selective reporting (reporting bias) High risk Lack of clarity with outcome reporting;
reporting of participants with moderate
asthma separately; numerical data not al-
ways presented. KK: some important out-
comes (ACQ and ICS dose reduction) re-
ported only for subgroups with statistically
significant results
Other bias Low risk None noted
Wood 2014
Methods Design: randomised, parallel, double-blind, placebo-controlled trial
Duration: 13 weeks
Setting: multiple centres in the USA and the UK
Participants Population: 89 children were randomly assigned to low dose (31) and high dose cock-
roach SLIT (30) and placebo (28)
Age: 5 to 17 years; mean age 11 (low SLIT) years, 10 (high SLIT) years and 11 (placebo)
years
Inclusion criteria:history of perennial rhinitis, asthmaor both and sensitivity toGerman
cockroach (positive SPT response and cockroach-specific IgE level > 0.35 kUA/L)
Exclusion criteria: not reported
Percentage withdrawn: 9.7% (low SLIT), 10% (high SLIT), 25% (placebo)
Percentage with asthma: 80%
Co-morbidities: rhinitis
Allowed medication: not reported
Disallowed medication: not reported
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Wood 2014 (Continued)
Interventions Control group: placebo SLIT
SLIT group (low): Greer German cockroach extract SLIT, 1 day escalation up to 3685
BAU (approx 4.2 mcg Bla g 2 and 50 mcg Bla g 1 daily)
SLIT group (high):Greer German cockroach extract SLIT, 1 day escalation then 4 week
escalation to 14740 BAU (approx 16.8 mcg Bla g 2 and 202 mcg Bla g 1 daily)
Co-interventions: not reported
Outcomes Changes in cockroach IgE, IgG and IgG4 levels and FAB activity, safety assessments and
adherence
Notes Type of publication: peer reviewed
Funding: supported in whole or in part with federal funds from the National Institute
of Allergy and Infectious Diseases, National Institutes of Health and National Center for
Research Resources and National Center for Advancing Translational Sciences, National
Institutes of Health. Immunological extracts were donated for some studies by Greer
Pharmaceuticals (Lenoir, NC)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind but no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind but no further details
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced dropout (10% in both treat-
ment arms, 25% in control group)
Selective reporting (reporting bias) Unclear risk Adverse event outcomes not clearly re-
ported
Other bias Low risk None noted
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Yukselen 2013
Methods Design: randomised, parallel, double-blind, double-dummy, placebo-controlled trial
Duration: 52 weeks
Setting: outpatient clinic in Turkey
Participants Population: 32 participants were randomly assigned to house dust mite SLIT (11),
placebo (10) and 1 other treatment that was not relevant to this review (subcutaneous
immunotherapy, 11)
Age: no information
Inclusion criteria: clinical history of at least 1 year of rhinitis with asthma related to
symptomswith house dustmites andnoprevious treatmentwith specific immunotherapy
Exclusion criteria: no previous immunotherapy
Percentage withdrawn: 9.1% (SLIT), 0% (placebo)
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: rhinitis
Allowed medication: inhaled budesonide 100 to 800 mcg/d and inhaled salbutamol as
required for control of asthma. Intranasal mometasone and antihistamines were given as
needed to alleviate symptoms of rhinitis
Disallowed medication: None of the participants were treated with OCS or LTRA
Interventions Control group: placebo SLIT
SLIT group: house dust mite SLIT (D. pteronyssinus and D. farinae), initiation phase
then 3 times/wk maintenance up to 28 drops of 1000 TU/mL (cumulative 2 year dose
for SLIT approx 347466 TU)
Co-interventions: inhaled budesonide 100 to 800 mcg/d
Outcomes Symptom and medication scores, nasal provocation tests, nasal eosinophils, sputum
eosinophils; serum-specific IgE, IgG4, IL-10 and IFN-gamma; assessment of clinical
efficacy
Notes Type of publication: peer reviewed
Funding: Allergopharma and Allergo provided allergen solutions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Based on computer generated randomisa-
tion’
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double dummy; ’All study
personnel and participants were blinded to
treatment assignment for the first year of
the immunotherapy’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double dummy; ’All study
personnel and participants were blinded to
treatment assignment for the first year of
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Yukselen 2013 (Continued)
the immunotherapy’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Unbalanced but low dropout (< 10% in
both groups). Only 2 randomly assigned
participants were not included in the effi-
cacy analyses (6.25%)
Selective reporting (reporting bias) High risk Many outcomes not reported at the end
of the controlled portion of the study and
compared with run-in/baseline rather than
with placebo
Other bias Low risk None noted
Zeldin 2013
Methods Design: randomised, parallel, double-blind, placebo-controlled dosing trial
Duration: 10 days (1.4 weeks)
Setting: France
Participants Population: 63 participants were randomly assigned to 4 doses of house dust mite SLIT
(11, 12, 12, 12) and placebo (16)
Age: adults; no specific details of age
Inclusion criteria: adults with > 1 year history of HDM-associated allergic asthma
controlled with therapies consistent with GINA treatment step 2, 3 or 4; positive skin
prick test to HDM; HDM-specific serum IgE 0.7 kU/L
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: placebo SLIT
SLIT group 1: HDM SLIT 300 IR daily
SLIT group 2: HDM SLIT 500 IR daily
SLIT group 3: HDM SLIT 800 IR daily
SLIT group 4: HDM SLIT 1000 IR daily
Co-interventions: not reported
Outcomes Adverse events, physical examination, vital signs, spirometry, ECG and safety laboratory
tests
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias
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Zeldin 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomized 3:1 within dose-regimen
groups’ but no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind but no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind but no further details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported
Selective reporting (reporting bias) High risk Conference abstract only. Minimal numer-
ical data or details regarding the conduct of
the study
Other bias Low risk None noted
Zhang 2013
Methods Design: randomised, parallel, open-label, pharmacotherapy controlled trial
Duration: 104 weeks (2 years)
Setting: Taiwan
Participants Population: 128 children were randomly assigned to house dust mite SLIT (64) and
pharmacotherapy only (64)
Age: 4 to 14 years (mean not reported)
Inclusion criteria: mild to moderate asthma symptoms
Exclusion criteria: not reported
Percentage withdrawn: not reported
Percentage with asthma: 100%
Co-morbidities: not reported
Allowed medication: not reported
Disallowed medication: not reported
Interventions Control group: pharmacotherapy only - patients were treated “according to the manu-
facturer’s instructions”
SLIT group:HDM SLIT (D. farinae), dosing not reported
Co-interventions: not reported
Outcomes Asthma symptom scores, PEFR, adverse events
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Zhang 2013 (Continued)
Notes Type of publication: English abstract of a Chinese article
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly assigned to treatment group
and control group’ but no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk ’Of the 128 children, 5 cases dropped out
before the study completion’
Selective reporting (reporting bias) High risk Conference abstract only. Minimal numer-
ical data or details regarding the conduct of
the study
Other bias Low risk None noted
Zheng 2012
Methods Design: randomised, parallel, open-label, pharmacotherapy controlled trial
Duration: 104 weeks but outcomes reported at 25 weeks
Setting: single-centre hospital asthma centre in China
Participants Population: 106 children randomly assigned to HDM SLIT group (53) and conven-
tional treatment group (53)
Age: range 4 to 14 years; mean 10 (5) years
Inclusion criteria: cough variant asthma and a positive skin prick test to Der-
matophagoides farinae, PEFR not less than 70% predicted; no use of beta2-agonists, H1
receptor blockers or corticosteroids before treatment
Exclusion criteria: not reported
Percentage withdrawn: 0
Percentage with asthma: 100% (from inclusion criteria)
Co-morbidities: not reported
Allowed medication: ’conventional therapy’
Disallowed medication: No use of beta2-agonists, H1 receptor blockers or corticos-
teroids before treatment
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Zheng 2012 (Continued)
Interventions Control group: ’conventional therapy’
SLIT group:HDM (D. farinae) SLIT drops
Co-interventions: inhaled fluticasone
Outcomes Improvement in cough/asthma symptom score; time taken until improvement in symp-
toms; serum eosinophil level; peak expiratory flow
Notes Type of publication: peer-reviewed; published in Chinese only
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly divided’ - no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears all randomly assigned participants
were reported on in safety and efficacy out-
comes
Selective reporting (reporting bias) Unclear risk Adverse event outcomes not clearly re-
ported
Other bias Low risk None noted
ACQ: Asthma Control Questionnaire;ACTH: adrenocorticotrophic hormone;AE: adverse events;AU: allergy units;BAE: bioequiv-
alent allergy units; BU: biological units; CAP-RAST: immunocap-radioallergosorbent test; CD: cluster of differentiation; ECG:
electrocardiogram; ECP: eosinophil cationic protein;DU: developmental units; EAACI: European Academy of Allergy and Clinical
Immunology; FEV1: forced expiratory volume in 1 second; GINA: Global Initiative for Asthma; GP: general practitioner; HDM:
house dust mite; ICS: inhaled corticosteroids; IFN: interferon; IgE: immunoglobulin E: IgG: immunoglobulin G; IL: interleukin;
IR: index units of reactivity; IU: international units; kU/L: kilounits per litre;LABA: long-acting beta2-agonist; LTRA: leukotriene
receptor antagonist; MDI: metered dose inhaler; OCS: oral corticosteroids; PEFR: peak expiratory flow rate; PD20: provocative
dose of methacholine required to produce a 20% fall in forced expiratory volume in 1 second; PC20: provocative concentration
of methacholine required to produce a 20% fall in forced expiratory volume in 1 second; PEFR: peak expiratory flow rate; PNU:
protein nitrogen units; PRL: prolactin; RAST: radioallergosorbent test; SABA: short-acting beta2-agonist; SLIT: sublingual im-
munotherapy; SQ-T: standardised quality tablet; STU: specific treatment units; TGF: transforming growth factor; Th: T-helper
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cells; Treg: T-regulatory cells; TU: therapeutic units; UBE: equivalent biologic units; UK: United Kingdom of Great Britain and
Northern Ireland; USA: United States of America; VAS: visual analogue score.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdou 1993 Design - not randomised
Agostinis 2009 Population mixed - only 60% had asthma
Andre 2000 Design - not an RCT (review paper)
Andre 2003 Population did not have asthma
Ariano 1998 Design - not randomised
Ariano 2001 Population mixed - only 15% (3/20) had asthma
Ariano 2005 Design - not randomised
Bergmann 2014 Population mixed - only 30% of participants had asthma
Bernstein 2011 Population mixed - unclear how many had asthma (study author contacted, no reply)
Blaiss 2011 Population mixed - only 26% (89/344) had asthma
Bommarito 2009 Population mixed - unclear how many had asthma (study author contacted, no reply)
Buchanan 2004 Population did not have asthma - egg allergy
Bufe 2004 Population mixed - only 42% (68/161) had asthma
Bufe 2009 Population mixed - only 42% (105/243) had asthma
Bush 2011 Population mixed - only 32% (10/31) had asthma
Cadario 2008 Wrong comparator - continuous vs intermittent SLIT
Cao 2007 Population mixed - unclear how many had asthma (study author contacted, no reply)
Clavel 1998 Population mixed - only 9% (26/136) had asthma
Cortellini 2010 Population mixed - only 14% (4/27) had asthma
Cosmi 2006 Population mixed - only 45% (9/20) had asthma
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Cox 2012 Population mixed - only 20% of participants had asthma
Creticos 2014 Population mixed - only 8% (36/429) had asthma
D’Ambrosio 1996 Population mixed - only 23% (7/30) of completers had asthma
D’Anneo 2008 Population mixed - unclear how many had asthma (study author contacted, no reply)
D’Anneo 2010 Population mixed - only 50% (15/30) had asthma
de Blay 2007 Population mixed - only 28% (29/104) had asthma
de Bot 2008 Population mixed - only 37% (93/251) had asthma
Deb 2012 Design - not randomised
Di Rienzo 2003 Design - not randomised
Di Rienzo 2006 Population did not have asthma
Didier 2011 Population mixed - only 14% (81/581) had asthma
Drachenberg 2001 Population mixed - only 22% had asthma
Durham 2012 Population mixed - only 24% (151/634) had asthma
Fancello 2008 Population mixed - unclear how many had asthma (study author contacted, no reply)
Feliziani 1995 Population mixed - unclear how many had asthma (study author contacted, no reply)
Ferrer 2003 Wrong intervention - subcutaneous immunotherapy
Germouty 1986 Wrong intervention
Giovane 1994 Population did not have asthma
Gozalo 1997 Design - not randomised
Hedlin 1999 Wrong intervention - subcutaneous immunotherapy
Hirsch 1997 Population mixed - only 73% (22/30) had asthma
Holt 2013 Population did not have asthma (prevention study)
Ibañez 2007 Population mixed - only 40% (24/60) had asthma
111Sublingual immunotherapy for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Leonardi 2009 Population did not have asthma (retrospective study)
Leonardi 2010 Population mixed - only 64% (21/33) had asthma
Lombardi 2001 Design - not randomised (alternate allocation)
Ma 2010 Wrong comparator
Maksimovic 2002 Population mixed - unclear how many had asthma (study author contacted, no reply)
Malling 2005 Population did not have asthma
Malling 2009 Population mixed - across groups, only 8.8% to 11% had asthma
Maloney 2014 Design - post hoc analysis, not an RCT
Marappan 2007 Population mixed - unclear how many had asthma (study author contacted, no reply)
Marappan 2008 Population mixed - unclear how many had asthma (study author contacted, no reply)
Maria 2004 Design - not randomised
Marogna 2004 Population mixed - only 61% (311/511) had asthma
Marogna 2010 Population mixed - rhinitis and intermittent asthma
Marogna 2012 Wrong comparator
Mauro 2004 Wrong comparator - head-to-head SLIT vs SCIT (no placebo)
Mayorga 2004 Wrong comparator - head-to-head SLIT vs SCIT (no placebo)
Melarnanci 2004 Design - not randomised
Moreno-Ancillo 2007 Population mixed - only 61% (64/105) had asthma
Murphy 2013 Population mixed - only 27% (89/329) had asthma
Mussler 2009 Design - no control group (trial extension)
NCT02014623 Methods - non-randomised, not asthma
Nelson 2011 Population mixed - only 24% (104/438) had asthma
Nettis 2007 Population mixed - only 25% (10/40) had asthma
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Nolte 2014 Population mixed and did not all have asthma (study author confirmed the study was not designed to
assess asthma and should not be included)
O’Hehir 2009 Population mixed - only 78% (21/27) had asthma
Oppenheimer 1994 Population did not have asthma
Osipova 2003 Population did not have asthma (latex allergy)
Ozdemir 2007 Design - not randomised
Palma-Carlos 2007 Population did not have asthma
Passalacqua 1998 Population mixed - only 30% (6/20) had asthma
Passalacqua 1999 Population mixed - only 43% (13/30) had asthma
Passalacqua 2006 Population mixed - only 23% (13/56) of completers had asthma
Peter 2009 Population mixed - unclear how many had asthma (study author contacted, no reply)
Pfaar 2008 Population mixed - only 29% (54/185) had asthma
Pozzan 2010 Population mixed - only 33% (17/52) had asthma
Pradalier 1999 Population mixed - only 34% (42/123) had asthma; the study excluded patients taking daily medications
Purello-D’Ambrosio 1999 Population mixed - only 50% (15/30) had asthma
Queiros 2012 Population mixed - only 51% (36/70) of completers had asthma
Quercia 2011 Population mixed - only 44% (14/32) had asthma
Reich 2011 Population mixed - only 41% (113/276) had asthma
Reinert 1983 Population did not have asthma
Rodriguez 2006 Wrong comparator
Rodriguez Santos 2008 Population mixed - only 70% had asthma (or asthma and rhinitis)
Romano 2006 Design - not randomised
Romo 1996 Wrong comparator
Sambugaro 2003 Design - not randomised
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(Continued)
Sanchez 1989 Design - not randomised
Scordamaglia 1997 Population mixed - only 43% had asthma
Shore 1980 Design - not randomised
Srivastava 2007 Wrong intervention - subcutaneous immunotherapy
Stelmach 2012 Population mixed - only 33% (20/60) had asthma
Stevenson 1984 Wrong intervention
Stosovic 2011 Design - ’adequate matched controls’
Sánchez 2001 Design - not randomised
Tabar 2008 Wrong intervention - subcutaneous immunotherapy
Tari 1990 Population mixed - unclear how many had asthma (study author contacted, no reply)
Taudorf 1987 Population mixed - only 38% (15/39) had asthma
TePas 2004 Population did not have asthma
Tomic-Spiric 2010 Population mixed - only 44% had asthma (confirmed by study authors)
Urbanek 1982 Population mixed - unclear how many had asthma (confirmed by translator)
Valovirta 2006 Population mixed - only 41% (36/88) had asthma
Wahn 2009 Population mixed - only 21% (57/266) had asthma
Wahn 2012 Population mixed - only 31% (64/207) had asthma
Wang 2006 Wrong intervention - subcutaneous immunotherapy
Worm 2006 Population mixed - only 28% (52/185) had asthma
Worm 2014 Population mixed - only 24.6% of participants had asthma
Wüthrich 2003 Population mixed - only 50% (14/28) had asthma
Yuksel 1999 Population mixed - only 28% (11/39) had asthma
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Characteristics of studies awaiting assessment [ordered by study ID]
EUCTR2008-03906-32-CZ
Methods Randomised, double-blind, placebo-controlled, multi-national, phase 3 study
Participants Adults aged 18 to 65 years with grass pollen-related allergic rhinoconjunctivitis for at least the last 2 grass pollen
seasons. Patients with moderate or persistent asthma, or requiring doses of ICS greater than 400 mcg budesonide (or
equivalent), were excluded
(full inclusion and exclusion criteria at http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-003906-
32-CZ)
Interventions ORALAIR Grasses 300 IR sublingual tablets vs placebo
Outcomes Average adjusted symptom score (AASS), average rhinoconjunctivitis total symptom score (ARTSS), average rescue
medication score (ARMS), average combined score (ACS) (taking into account the RTSS and rescue medication
score (RMS)), average rhinoconjunctivitis symptom score (ARSS), proportion of symptom-controlled days (PSCD)
, global evaluation of the efficacy of sublingual tablets of grass pollen allergen extract by the patient, adverse events
Notes Not clear if ongoing or completed, no results published, unable to link to a peer-reviewed full text. Unlikely to have
recruited sufficient patients with asthma for inclusion
Kozhem’iaka 1979
Methods Unknown, conducted in 1979
Participants Children with allergies, no other information
Interventions Peroral house dust mite vaccine
Outcomes Unknown
Notes Title only, unable to find additional information but no indication the children had asthma
Ma 2014
Methods Randomised, parallel, open-label trial
Participants 120 children aged 5 to 14 years with asthma and allergic rhinitis
Interventions HDM SLIT
Outcomes ACQ, specific IgE, rhinitis symptoms, monthly medication use, adverse reactions
Notes Identified in prepublication search. Abstract only available in English; full text translation will be obtained for review
update
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NCT00172341
Methods Randomised, parallel, double-blind trial at the National Taiwan University Hospital
Participants Children between 5 and 15 years of age with mild to moderate asthma for at least 1 year and with sensitisation to
domestic mites (positive skin prick test to D. pt and D. f )
(full inclusion and exclusion criteria at https://clinicaltrials.gov/ct2/show/NCT00172341)
Interventions Staloral (house dust mite SLIT) vs placebo
Outcomes “Change of asthmatic scores from baseline”
Notes First received: September 12, 2005
Last updated: November 2, 2005
Last verified: July 2004
Li-Chieh Wang, MD
886-2-23123456 ext 5127
lcwang5@ha.mc.ntu.edu.tw
Clinicaltrials.gov record: NCT00172341
No study results found
NCT00501527
Methods Randomised, double-blind, placebo-controlled, safety/efficacy study
Participants Ages 12 to 50 years with confirmed Phleum pratense allergy and clinical history of allergic rhinoconjunctivitis and/or
asthma
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT00501527)
Interventions 2 different doses of P. pratense pollen SLIT vs placebo
Outcomes Symptom scores, nasal provocation tests, dose-response skin prick tests, Asthma Quality of Life Questionnaire,
Rhinitis Quality of Life Questionnaire, medication scores, visual scales, ’in vitro’ immunological tests, adverse events
Notes Study completed in 2010 but no results published on Clinical Trials website and unable to link to a peer-reviewed
full text
NCT00623701
Methods Randomised, double-blind, placebo-controlled, multi-centre, multi-national, efficacy/safety study
Participants Aged 18 to 65 years with allergic rhinoconjunctivitis attributable to grass pollen
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT00623701 and https://www.
clinicaltrialsregister.eu/ctr-search/trial/2007-000823-16/DE)
Interventions Grass pollen SLIT vs placebo
Outcomes Primary endpoint: difference between active treatment and placebo in the change of the area under the curve of the
symptom - medication - score (SMS) from the baseline season to the season after 1 year of treatment
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NCT00623701 (Continued)
Notes Study completed in 2011 but no results published on Clinical Trials website and unable to link to a peer-reviewed
full text
NCT00803244
Methods Randomised, double-blind, placebo-controlled, multi-national, phase 3 efficacy/safety study
Participants Aged 12 to 65 years with grass pollen-related allergic rhinoconjunctivitis for at least the last 2 grass pollen seasons.
Patientswithmoderate or persistent asthma, or requiringdoses of ICS greater than400mcgbudesonide (or equivalent)
, were excluded
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT00803244)
Interventions Grass pollen SLIT vs placebo
Outcomes Average adjusted symptom score, proportion of symptom-controlled days, global patient evaluation of the efficacy
of treatment, adverse events
Notes Not clear if ongoing or completed, no results published, unable to link to a peer-reviewed full text. Unlikely to have
recruited sufficient patients with asthma for inclusion
NCT01052610
Methods Randomised, double-blind, placebo-controlled
Participants Children aged 6 to 18 years with bronchial asthma and/or allergic rhinitis allergic to house dust mites first diagnosed
at least 2 years before the study
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT01052610)
Interventions HDM SLIT vs placebo
Outcomes Clinical symptoms of asthma and allergic rhinitis and use of rescue medication, change in percent of regulatory
lymphocytes in peripheral blood, assessment of inflammatory markers in exhaled breath condensate and FeNO, non-
specific bronchial hyperreactivity
Notes Staus of study unknown, no results published on Clinical Trials website, unable to link to a peer-reviewed full text
NCT01529437
Methods Randomised, double-blind, placebo-controlled phase 1 safety study
Participants Aged 5 years and older with timothy grass and Dermatophagoides farinae sensitivity and allergic rhinoconjunctivitis
with or without asthma perennially or during grass pollen season
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT01529437)
Interventions HDM and/or Timothy grass pollen SLIT vs placebo
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NCT01529437 (Continued)
Outcomes Adverse events
Notes Study reported as completed but no study results published on Clinical Trials website and unable to link to a peer-
reviewed full text
NCT01603056
Methods Randomised, double-blind, placebo-controlled, multi-centre, efficacy/safety study
Participants Aged 5 to 55 years with history of HDM-induced allergic rhinitis. Patients with severe asthma excluded
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT01603056)
Interventions HDM SLIT vs placebo
Outcomes Rhinoconjunctivitis symptoms and medication scores, asthma symptom scores, number of healthy days in the study,
AsthmaQuality of Life Questionnaire, Rhinitis Quality of Life Questionnaire, rescuemedication use, nasal complaint
scores on visual analogue scale
Notes Large study reporting enrolment of 617 participants but no results published on Clincal Trials website and unable
to link to peer-reviewed full text
Novembre 1991
Methods “Controlled study”
Participants Children with allergic asthma
Interventions Sublingual immunotherapy (no other details)
Outcomes Unknown
Notes Title only, unable to find additional information
Potter 2003
Methods Unknown
Participants Unknown
Interventions Sublingual immunotherapy (no other details)
Outcomes Unknown
Notes Title only, unable to find additional information
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Characteristics of ongoing studies [ordered by study ID]
EUCTR2012-005678-76
Trial name or title 24-month, multi-centre, prospective, randomised, double-blind, placebo-controlled, parallel-group study to
evaluate the efficacy, safety, tolerability and cost-effectiveness of allergen-specific sublingual immunotherapy
(SLIT) in combination with standard of care (SoC) in paediatric allergic asthma
Methods Multi-centre, prospective, randomised, double-blind, placebo controlled, parallel-group study
Participants Outpatient children aged 5 to < 18 years, clinically stable allergic asthma diagnosed by physician according
to the GINA guidelines (2) at least 1 year before study entry, with/without concomitant allergic rhinocon-
junctivitis; mono-sensitisation to HDM, assessed by skin prick testing (wheal diameter > 3 mm) and/or by
ImmunoCAP (specific IgE > 3.5 kU/L)
(full inclusion and exclusion criteria at http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-
005678-76-IT)
Interventions HDM SLIT vs placebo
Outcomes Reduction from baseline of at least 50% in inhaled CS (ICS) doses or withdrawal of asthma-controller med-
ications, Asthma Control Test-ACT and Childhood-ACT, asthma exacerbations requiring OCS, rhinocon-
junctivitis symptoms and signs, adverse events, QoL, changes in skin test reactivity, SLIT adherence, cost-
effectiveness
Starting date 30/08/2013
Contact information Clinical Pharmacology & Trials
Address:
via G. Gaslini 3-5
16147
Genova
Italy
Telephone:
+390105636461
Email:
ornelladellacasa@ospedale-gaslini.ge.it
Notes Ongoing study, highly likely to be relevant and including important and validated outcomes
Hassan 2010
Trial name or title Efficacy of sublingual immunotherapy in patient with bronchial asthma with allergic rhinitis
Methods Double-blind randomised controlled trial conducted at the National Institute of Diseases of Chest and
Hospital (NIDCH), Dhaka, Bangladesh
Participants 60 patients with bronchial asthma and allergic rhinitis
Interventions Mite allergen SLIT
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Hassan 2010 (Continued)
Outcomes Not stated
Starting date February 2009 to January 2010
Contact information None
Notes Conference abstract
NCT01700192
Trial name or title Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust
Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
Methods Randomised, double-blind, placebo-controlled safety and efficacy study
Participants Aged 12 years and over with history of AR/ARC to house dust of 1 year duration or more (with or without
asthma). Patients with unstable or severe asthma or requiring high doses of ICS in the 6 months before
enrolment excluded
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT01700192)
Interventions HDM SLIT vs placebo
Outcomes Average total combined rhinitis score (TCRS), adverse events, average rhinitis daily symptom score (Rhinitis
DSS), average total combined rhinoconjunctivitis score (TCS), average rhinitis daily medication score (Rhini-
tis DMS), average allergic rhinitis/rhinoconjunctivitis symptoms assessed by visual analogue scale (VAS)
Starting date 01/2013
Contact information Responsible party: Merck Sharp & Dohme Corp
Notes Unlikely to recruit sufficient patients with asthma to meet inclusion criteria for this review
NCT01930461
Trial name or title Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-
associated Allergic Asthma
Methods Randomised, double-blind, placebo-controlled, dose-ranging efficacy/safety study
Participants Aged 18 to 50 years, diagnosed asthma and rhinitis with medical history consistent with HDM-induced
allergic asthma and rhinitis. Asthma must be stable at time of enrolment
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT01930461)
Interventions 3 different doses of HDM SLIT vs placebo
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NCT01930461 (Continued)
Outcomes Asthma control test (ACT) score, rhinoconjunctivitis symptoms and rescue medication use, Asthma Quality
of Life (AQLQ), number of asthma exacerbations, adverse events
Starting date 09/2013
Contact information Pascal Demoly, MD, Montpellier, France. Responsible party: Stallergenes
Notes Ongoing study, highly likely to be relevant and including important and validated outcomes
NCT02005627
Trial name or title Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study (Pollen+)
Methods Randomised, double-blind, placebo-controlled, efficacy/safety study
Participants Aged 18 to 65 years with grass pollen-induced allergic rhinoconjunctivitis for at least 2 years with peak
symptoms in May-July, with or without mild seasonal asthma. Patients with perennial asthma requiring
regular inhaled corticosteroids excluded
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT02005627)
Interventions Grass pollen SLIT vs placebo
Outcomes Early phase response (EPS) after nasal allergen challenge (NAC), the area under the curve (AUC) of the early
phase response (total nasal symptom score (TNSS) 0 to 60 minutes) following grass pollen nasal allergen
challenge, early phase (EP) and late phase response (LPR) to intradermal grass pollen allergen, blood basophil
activation, combined symptom + medication score, change from proportion of allergen-specific T reg cells
Starting date 12/2013
Contact information Esther H Steveling, MD
Tel: +44(0)7872850275
e.steveling@imperial.ac.uk
Notes Unlikely to recruit sufficient patients with asthma to meet inclusion criteria for this review
NCT02277483
Trial name or title Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House
Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma
Methods Randomised, open-label, safety/efficacy study
Participants Aged 60 years or older with a history of at least 2 years of house dust mite (HDM)-induced allergic rhinitis
and/or allergic rhinoconjunctivitis with or without mild to moderate controlled asthma
(full inclusion and exclusion criteria at https://www.clinicaltrials.gov/ct2/show/NCT02277483)
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NCT02277483 (Continued)
Interventions HDM SLIT vs standard pharmacotherapy
Outcomes Total combined score (TCS) (TCS = rhinoconjunctivitis total symptom score (RTSS) and total rescue medi-
cation score (RTMS)), Total rescue medication score (RTMS)
Starting date 10/2014
Contact information Yun-Kyoung Kim
Tel: 82-31-219-4467
forsake326@gmail.com
Notes Unlikely to recruit sufficient patients with asthma to meet inclusion criteria for this review
RPCEC00000125
Trial name or title Therapeutic effect and security of the sublingual vaccines of house-dust mites, with different posological
regimens in asthmatic children sensitive to those mites
Methods Randomised, double-blind, placebo controlled trial
Participants Aged 5 to 15 years with allergic asthma provoked by house dust mite (D. pteronyssinus or B. tropicalis). Only
patients with mild or moderate asthma included; those with intermittent or severe asthma excluded
(full inclusion and exclusion criteria at http://apps.who.int/trialsearch/Trial2.aspx?TrialID=
RPCEC00000125)
Interventions HDM SLIT vs placebo
Outcomes Symptom score (dyspnoea, cough, expectoration, wheeze and tightness), medication scores, PEFR, skin
reactivity, QOL, allergen-specific antibodies, adverse events
Starting date 16/10/2013
Contact information R. Castro Almarales
National Center of Bioproducts (BIOCEN), Allergen Department
Carretera de Beltran Km 1 1/2
CP 13050, Box 6048
Bejucal, Mayabeque
Cuba
Tel: 53-047-066-82201 - 07, ext 2100, 2101
rcastro@biocen.cu
Notes Likely to meet inclusion criteria for this review
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D A T A A N D A N A L Y S E S
Comparison 1. SLIT vs control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbation requiring ED or
hospital visit
1 47 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Quality of life Other data No numeric data
3 Serious adverse events 22 2560 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.01, 0.01]
4 Exacerbation requiring OCS 2 77 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 All adverse events 19 1755 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.21, 2.38]
6 Bronchial provocation 4 139 Std. Mean Difference (IV, Random, 95% CI) 0.69 [-0.04, 1.43]
6.1 PD20 1 52 Std. Mean Difference (IV, Random, 95% CI) 1.46 [0.84, 2.08]
6.2 PC20 3 87 Std. Mean Difference (IV, Random, 95% CI) 0.40 [-0.26, 1.05]
7 ICS use 2 174 Mean Difference (IV, Random, 95% CI) 35.10 [-50.21, 120.
42]
8 Unvalidated asthma symptom
scores
Other data No numeric data
9 Unvalidated medication use
scores
Other data No numeric data
Comparison 2. Subgroup and sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events by age 19 1755 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.21, 2.38]
1.1 Children (mean age < 18
years)
8 626 Odds Ratio (M-H, Random, 95% CI) 2.13 [0.83, 5.47]
1.2 Teenagers and adults
(mean age > 18 years)
8 964 Odds Ratio (M-H, Random, 95% CI) 1.48 [1.06, 2.06]
1.3 Mixed age study
population or age range not
specified
3 165 Odds Ratio (M-H, Random, 95% CI) 2.06 [0.47, 9.05]
2 Adverse events by allergen 18 1726 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.21, 2.38]
2.1 HDM SLIT 10 1386 Odds Ratio (M-H, Random, 95% CI) 1.47 [1.10, 1.97]
2.2 Pollen SLIT 6 251 Odds Ratio (M-H, Random, 95% CI) 5.48 [1.99, 15.05]
2.3 Other/mixed allergens 2 89 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events by study duration 19 1815 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.21, 2.38]
3.1 Duration less than 52
weeks
7 427 Odds Ratio (M-H, Random, 95% CI) 1.53 [0.38, 6.19]
3.2 Duration 52 weeks and
longer
12 1388 Odds Ratio (M-H, Random, 95% CI) 1.77 [1.22, 2.58]
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4 Adverse events (sensitivity for
risk of bias: blinded studies
only)
14 1329 Odds Ratio (M-H, Random, 95% CI) 1.47 [1.10, 1.96]
5 Adverse events (sensitivity
analysis removing studies with
mixed population of asthma
and rhinitis)
13 1293 Odds Ratio (M-H, Random, 95% CI) 1.42 [1.06, 1.91]
Analysis 1.1. Comparison 1 SLIT vs control, Outcome 1 Exacerbation requiring ED or hospital visit.
Review: Sublingual immunotherapy for asthma
Comparison: 1 SLIT vs control
Outcome: 1 Exacerbation requiring ED or hospital visit
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Calderon 2006 (1) 0/36 0/11 Not estimable
Total (95% CI) 36 11 Not estimable
Total events: 0 (SLIT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLIT Favours control
(1) 4 different dose arms combined
Analysis 1.2. Comparison 1 SLIT vs control, Outcome 2 Quality of life.
Quality of life
Study Outcome name Scoring Data type SLIT Control
Bousquet 1999 Short-Form Health
Status Survey;
physical pain
22 items divided into
7 scales measuring
physical
functioning, limita-
tions in role func-
tioning due to
physical health prob-
lems,social function-
ing,
general
Means,
no variance
86.2 (n=18) 68.3 (n=20)
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Quality of life (Continued)
mental health, gen-
eral health percep-
tion,
physical pain and vi-
tality. Each scale is 0
to 100 with
lower score for
poorer health. Mea-
sured at 25
months.
Bousquet 1999 Short-Form Health
Status Survey;
general mental
health domain
22 items divided into
7 scales measuring
physical
functioning, limita-
tions in role func-
tioning due to
physical health prob-
lems,social function-
ing,
general
mental health, gen-
eral health percep-
tion,
physical pain and vi-
tality. Each scale is 0
to 100 with
lower score for
poorer health. Mea-
sured at 25
months.
Means,
no variance
79.7 (n=18) 60.7 (n=20)
Bousquet 1999 Short-Form Health
Status Survey;
general perception of
health domain
22 items divided into
7 scales measuring
physical
functioning, limita-
tions in role func-
tioning due to
physical health prob-
lems,social function-
ing,
general
mental health, gen-
eral health percep-
tion,
physical pain and vi-
tality. Each scale is 0
to 100 with
lower score for
Means,
no variance
76.5 (n=18) 56.8 (n=20)
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Quality of life (Continued)
poorer health. Mea-
sured at 25
months.
Lewith 2002 Diary quality of life
assessment
Proportion of days in
each of the assess-
ment periods
when no problem
was reported in six
categories of
life. Mean improve-
ment scores at end of
treatment
Means (SD) 0.090 (-0.096
to 0.150)
0.117
(-0.096 to
0.150)
Analysis 1.3. Comparison 1 SLIT vs control, Outcome 3 Serious adverse events.
Review: Sublingual immunotherapy for asthma
Comparison: 1 SLIT vs control
Outcome: 3 Serious adverse events
Study or subgroup SLIT Control
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alvarez-Cuesta 2007 0/17 0/16 0.7 % 0.0 [ -0.11, 0.11 ]
Calderon 2006 (1) 0/36 0/11 0.6 % 0.0 [ -0.12, 0.12 ]
Corzo 2014 (a) (2) 0/54 0/17 1.2 % 0.0 [ -0.08, 0.08 ]
Corzo 2014 (b) (3) 0/54 0/18 1.4 % 0.0 [ -0.08, 0.08 ]
Criado Molina 2002 0/16 0/16 0.6 % 0.0 [ -0.11, 0.11 ]
Dahl 2006 0/61 0/32 3.6 % 0.0 [ -0.05, 0.05 ]
Eifan 2009 0/15 0/14 0.5 % 0.0 [ -0.12, 0.12 ]
Fadel 2010 0/41 0/14 0.9 % 0.0 [ -0.10, 0.10 ]
Lue 2006 0/10 0/10 0.3 % 0.0 [ -0.17, 0.17 ]
Mosbech 2014 (4) 15/461 4/143 8.0 % 0.00 [ -0.03, 0.04 ]
NCT00633919 2/63 2/61 2.1 % 0.00 [ -0.06, 0.06 ]
Niu 2006 1/49 4/48 1.0 % -0.06 [ -0.15, 0.02 ]
-0.1 -0.05 0 0.05 0.1
Favours SLIT Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup SLIT Control
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pajno 2000 0/12 1/12 0.2 % -0.08 [ -0.29, 0.12 ]
Shao 2014 0/168 0/96 29.4 % 0.0 [ -0.02, 0.02 ]
Stelmach 2009 0/20 0/15 0.7 % 0.0 [ -0.11, 0.11 ]
Troise 2009 (5) 0/14 0/10 0.3 % 0.0 [ -0.15, 0.15 ]
Vourdas 1998 0/34 0/32 2.4 % 0.0 [ -0.06, 0.06 ]
Wang 2014 4/322 1/162 27.3 % 0.01 [ -0.01, 0.02 ]
Wood 2014 (6) 0/61 0/28 2.9 % 0.0 [ -0.05, 0.05 ]
Zeldin 2013 (7) 0/47 0/16 1.1 % 0.0 [ -0.09, 0.09 ]
Zhang 2013 0/64 0/64 8.8 % 0.0 [ -0.03, 0.03 ]
Zheng 2012 0/53 0/53 6.1 % 0.0 [ -0.04, 0.04 ]
Total (95% CI) 1672 888 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 22 (SLIT), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.54, df = 21 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
-0.1 -0.05 0 0.05 0.1
Favours SLIT Favours control
(1) 4 different dosing arms combined
(2) 4 different dosing arms combined
(3) 4 different dosing arms combined
(4) 3 different dosing arms combined
(5) ”Severe” adverse events
(6) High dose and low dose combined
(7) 4 different dose arms combined
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Analysis 1.4. Comparison 1 SLIT vs control, Outcome 4 Exacerbation requiring OCS.
Review: Sublingual immunotherapy for asthma
Comparison: 1 SLIT vs control
Outcome: 4 Exacerbation requiring OCS
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Calderon 2006 (1) 0/36 0/11 Not estimable
Pajno 2003 0/15 0/15 Not estimable
Total (95% CI) 51 26 Not estimable
Total events: 0 (SLIT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLIT Favours control
(1) 4 different dose arms combined
Analysis 1.5. Comparison 1 SLIT vs control, Outcome 5 All adverse events.
Review: Sublingual immunotherapy for asthma
Comparison: 1 SLIT vs control
Outcome: 5 All adverse events
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alvarez-Cuesta 2007 0/17 0/16 Not estimable
Bahceciler 2001 0/8 0/7 Not estimable
Bousquet 1999 15/42 14/43 11.8 % 1.15 [ 0.47, 2.82 ]
Caffarelli 2000 0/24 0/20 Not estimable
Calderon 2006 (1) 36/36 10/11 1.1 % 10.43 [ 0.40, 275.32 ]
Eifan 2009 0/15 0/14 Not estimable
Gomez Vera 2005 0/30 0/30 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours SLIT Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ippoliti 2003 0/47 0/39 Not estimable
Keles 2011 0/13 0/12 Not estimable
La Grutta 2007 0/33 0/23 Not estimable
Leng 1990 1/9 0/9 1.0 % 3.35 [ 0.12, 93.83 ]
Marogna 2005 4/29 0/23 1.3 % 8.29 [ 0.42, 162.48 ]
Mosbech 2014 (2) 290/461 77/143 37.4 % 1.45 [ 0.99, 2.12 ]
Mungan 1999 2/15 0/11 1.1 % 4.26 [ 0.18, 98.07 ]
NCT00633919 (3) 24/63 21/61 16.4 % 1.17 [ 0.56, 2.44 ]
Niu 2006 6/49 7/48 7.5 % 0.82 [ 0.25, 2.64 ]
Shao 2014 39/168 9/96 15.0 % 2.92 [ 1.35, 6.34 ]
Troise 2009 11/14 4/10 3.4 % 5.50 [ 0.91, 33.18 ]
Vourdas 1998 8/34 2/32 4.0 % 4.62 [ 0.90, 23.70 ]
Total (95% CI) 1107 648 100.0 % 1.70 [ 1.21, 2.38 ]
Total events: 436 (SLIT), 144 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.52, df = 10 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours SLIT Favours control
(1) 4 different dosing arms combined
(2) 3 different dosing arms combined
(3) Adverse events only reported if over 5% of participants were affected
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Analysis 1.6. Comparison 1 SLIT vs control, Outcome 6 Bronchial provocation.
Review: Sublingual immunotherapy for asthma
Comparison: 1 SLIT vs control
Outcome: 6 Bronchial provocation
Study or subgroup SLIT Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PD20
Marogna 2005 29 1020 (430.8132) 23 410 (383.6665) 26.7 % 1.46 [ 0.84, 2.08 ]
Subtotal (95% CI) 29 23 26.7 % 1.46 [ 0.84, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.62 (P < 0.00001)
2 PC20
Keles 2011 13 3.2 (3.9) 12 2.7 (4) 24.0 % 0.12 [ -0.66, 0.91 ]
Pajno 2003 14 9.1 (7.7) 13 2.46 (2.26) 23.4 % 1.12 [ 0.30, 1.94 ]
Stelmach 2009 20 4.05 (1.0897) 15 4 (1.3724) 25.9 % 0.04 [ -0.63, 0.71 ]
Subtotal (95% CI) 47 40 73.3 % 0.40 [ -0.26, 1.05 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 4.49, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 76 63 100.0 % 0.69 [ -0.04, 1.43 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 12.58, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Chi2 = 5.35, df = 1 (P = 0.02), I2 =81%
-2 -1 0 1 2
Favours control Favours SLIT
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Analysis 1.7. Comparison 1 SLIT vs control, Outcome 7 ICS use.
Review: Sublingual immunotherapy for asthma
Comparison: 1 SLIT vs control
Outcome: 7 ICS use
Study or subgroup SLIT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bousquet 1999 (1) 32 348 (410) 33 308 (408) 18.4 % 40.00 [ -158.89, 238.89 ]
Pham-Thi 2007 (2) 54 257 (232) 55 223 (270) 81.6 % 34.00 [ -60.45, 128.45 ]
Total (95% CI) 86 88 100.0 % 35.10 [ -50.21, 120.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours SLIT Favours control
(1) ICS use (mcg beclomethasone/day)
(2) ICS use (mcg budesonide/day)
Analysis 1.8. Comparison 1 SLIT vs control, Outcome 8 Unvalidated asthma symptom scores.
Unvalidated asthma symptom scores
Study Outcome name Scoring Data type SLIT Control
Alvarez-Cuesta
2007
Bronchial symptom
scores during cat ex-
posure
0 (absent) to 3 (se-
vere), multiple mea-
surements
Mean area under the
curve (CI)
45.74 (10.8 to 80.
67) n=17
143.44 (61.98 to
224.9) n=16
Bousquet 1999 Daytime asthma
score
0 (no symptoms) to
3 (severe symptoms)
Mean change (SD) 0.17 (0.5) n=32 0.19 (0.44) n=33
Bousquet 1999 Nighttime asthma
score
0 (no symptoms) to
3 (severe symptoms)
Mean change (SD) 0.17 (0.51) n=32 0.11 (0.35) n=33
Caffarelli 2000 Bronchial symptom
score
0 (no symptoms) to
3 (severe symptoms)
, weekly mean of
daily ratings during
pollen season
Weekly mean (SD) 2.4 (2.7) n=24 4.6 (3.5) n=20
Cooper 1984 Days with asthma
symptoms
Num-
ber of days during
pollen season (max
70)
Means, no variance 34.3, n=11 40.3, n=8
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Unvalidated asthma symptom scores (Continued)
Cooper 1984 Asthma symptom
severity score
0 (none) to 3 (se-
vere)
Means, no variance 40.5, n=11 58.2, n=8
Dahl 2006 Asthma symptom
score (before pollen
season)
0 (no symptoms) to
3 (severe symptoms)
, rated daily
Mean (SD) 0.23 (0.34) n=73 0.33 (0.33) n=40
Dahl 2006 Asthma symptom
score (during pollen
season)
0 (no symptoms) to
3 (severe symptoms)
, rated daily
Mean (SD) 0.44 (0.68) n=68 0.74 (0.92) n=39
Dahl 2006 Percentage well days Defined post hoc as
a day during the
pollen season with a
symptom score 2 or
less and no rescue
medication required
Mean (SD) 58.9 (27.6) n=61 38.2 (32.9) n=32
Eifan 2009 Vi-
sual analogue score
for asthma/rhinitis
symptoms
0
cm (no symptoms)
to 10 cm (highest
level of symptoms)
Mean (SD) 2.7 (2.1) n=15 4.6 (1.5) n=14
Eifan 2009 Asthma symptom
score
0 (no symptoms) to
3 (severe symptoms)
, rated daily
Mean (SD) 0.2 (0.4) n=15 2.5 (1.6) n=14
Ippoliti 2003 Asthma symptom
score
0 (no symptoms) to
3 (severe symptoms)
, mean of daily rat-
ings throughout 6
months of therapy
Means, no variance 1.28, n=47 3.15, n=39
Lewith 2002 Visual analogue
scale, asthma sever-
ity
Higher scores in-
dicate more severe
asthma
Mean (SE), read
from graph
2.44 (0.32) n=101 2.62 (0.31) n=101
Lewith 2002 Number of asthma
symptoms
Unclear Mean (SE), read
from graph
0.99 (0.14) n=101 1.14 (0.15) n=101
Lue 2006 Daytime asthma
symptom score
0 (no symptoms) to
3 (severe symptoms)
, rated daily
Mean (SD) 0.13 (0.19) n=10 0.49 (0.38) n=10
Lue 2006 Nighttime asthma
symptom score
0 (no symptoms) to
3 (severe symptoms)
, rated daily
Mean (SD) 0.16 (0.15) n=10 0.50 (0.47) n=10
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Unvalidated asthma symptom scores (Continued)
Marogna 2005 Composite asthma
symptom score
Monthly individual
symptom ratings 0
(absent) to 3 (se-
vere) combined
Mean (SEM), read
from graph
50 (15) n=29 150 (25) n=23
Mungan 1999 Asthma symptom
score
0 (no symptoms) to
3 (severe symptoms)
, rated daily during
second 6 months of
treatment
Means, no variance 0.41, n=15 0.88, n=11
Niu 2006 Daily asthma symp-
tom score
Combined daytime
andnighttime score,
each rated 0 (no
symptoms) to 3 (se-
vere symptoms)
Means and p-val-
ues for within group
change
-0.07 (p=0.108) n=
49
0.01 (p=0.998) n=
48
Pajno 2000 Nighttime asthma
symptom score
Number per month
during last year of
treatment
Means (p<0.
0001 for difference
between groups)
6, n=12 13.2, n=9
Pham-Thi 2007 % asthma-free days Number of
days when day and
nighttime score was
0 (no symptoms)
Mean (SD) 85.8 (23.8) n=54 91.1 (15.4) n=55
Pham-Thi 2007 Nighttime asthma
score
0 (no symptoms) to
3 (severe symptoms)
Mean (SD) 0.10 (0.19) n=54 0.07 (0.16) n=55
Pham-Thi 2007 Daytime asthma
score
0 (no symptoms)
to 3 (severe symp-
toms),mean of daily
scores from past 3
weeks
Mean (SD) 0.15 (0.26) n=54 0.08 (0.17) n=55
Reilly 1994 Visual
analogue scale for
asthma symptoms
Minimum=
fine, maximum=ter-
rible (measured in
mm)
Mean change
(SEM)
-7.2 (3.2) n=11 7.8 (3.0) n=13
Stelmach 2009 Asthma symptom
score (second pollen
season)
As for first pollen
season
Mean weekly score
(SD)
7.15 (5.43) n=20 11.99 (7.32) n=15
Stelmach 2009 Asthma
symptom score (first
pollen season)
Day, night and beta-
agonist use rated 0
to 3 and combined
0 (no symptoms and
no use of b-ago-
Mean weekly score
(SD)
18.07 (11.58) n=20 16.13 (9.34) n=15
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Unvalidated asthma symptom scores (Continued)
nists use) to 9 (se-
vere symptoms dur-
ing day and night,
and > 3
beta2-agonists),
rated daily
Zheng 2012 Cough/asthma
symptom score
0 (no symptoms) to
3 (severe symptoms)
; assessed for both
night and day
Mean decrease in
score after 25 weeks
treatment
3.3 (2.1)
n=53
1.3 (2.1)
n=53
Analysis 1.9. Comparison 1 SLIT vs control, Outcome 9 Unvalidated medication use scores.
Unvalidated medication use scores
Study Outcome name Scoring Data type SLIT Control
Bousquet 1999 Inhaled
corticosteroid use
mcg
beclomethasone/day
Mean (SD) 348 (410) n=32 308 (408) n=33
Dahl 2006 Asthma medication
score (during season)
Average daily com-
posite score of beta2-
agnoist, ICS use and
OCS use; maximum
daily score 16
Daily mean (SD) 0.71 (1.28) n=68 0.66 (1.08) n=39
Dahl 2006 Asthma medication
score (before season)
Average daily com-
posite score of beta2-
agnoist, ICS use and
OCS use; maximum
daily score 16
Daily mean (SD) 0.09 (0.23) n=73 0.09 (0.14) n=40
Eifan 2009 Total medication
score
1
point: beta2-agnoists
and antihistamines;
2 points: inhaled/in-
tranasal steroids
3 points: one tablet
of corticosteroid
Mean (SD) 1.2 (0.9) n=15 2.8 (1.1) n=14
Lewith 2002 Short acting bron-
chodilator use
Puffs/week Mean (SD), read
from graph
3.35 (0.48) n=101 3.4 (0.5) n=101
Lue 2006 Medication score Mean daily use of
corti-
costeroids, beta2-ag-
noist, antihistamines
Mean (SD) 1.0 (0.94) n=10 1.1 (1.15) n=10
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Unvalidated medication use scores (Continued)
- scoring unclear
Marogna 2005 Salbutamol use Puffs/month at end
of treatment
Mean (SD), read
from graph
2 (0.5) n=29 11.5 (1) n=23
Mungan 1999 Medication scores
(second 6 months of
treatment)
ICS, beta2-agnoists
and antihistamines
scored 1 to 4 de-
pend-
ing on dose and/
or frequency (maxi-
mum score 12)
Means, no variance 1.97, n=15 5.24, n=11
NCT00633919 Average
Daily Asthma Med-
ication Score Dur-
ing a 2-months Eval-
uation Period Au-
tumn 2008 (later
time point)
1 to 2 inhalations
twice daily of salbu-
tamol (200 mcg per
in-
halation) = 2 scores;
1 to 2 inhalation
twice daily of budes-
onide/formoterol 80
(4.5 mcg per in-
halation) = 4 scores;
1 inhalation twice
daily of budesonide/
formoterol 160 (4.5
mcg per inhalation)
= 8 scores; up to 10
tablets once daily of
prednisone (5 mg) =
1.6 scores. The to-
tal maximum daily
scores were 40
Mean (SD) 4.4 (5.9)
n=36
4.7 (5.4)
(n=)39
Niu 2006 Short acting bron-
codilator use
Puffs/day Mean change (SD) -0.04 (0.32) n=49 0.02 (0.27) n=48
Niu 2006 Oral corticosteroid
use
Tablets/day Mean change (SD) -0.08 (0.42) n=49 0 (0.27) n=48
Niu 2006 Inhaled
corticosteroid use
Puffs/day Mean change (SD) -0.23 (0.67) n=49 -0.1 (1.08) n=48
Pajno 2000 Total med-
ication score (end of
treatment)
1: bronchodilators;
2: ICS; 4:
7-day course of OCS
Means (SD imputed
from p-value)
82.68 (55) n=12 205.2 (55) n=9
Pham-Thi 2007 Inhaled
corticosteroid use
mcg budesonide/day Mean (SD) 257 (232) n=54 223 (270) n=55
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Unvalidated medication use scores (Continued)
Pham-Thi 2007 Short acting bron-
chodilator use
Puffs/day Mean (SD) 0.55 (0.6) n=54 0.47 (0.5) n=55
Stelmach 2009 Medication
score (second pollen
season)
Mean weekly med-
ication score dur-
ing second pollen
season, adjusted for
pollen concentration
Mean (SD) 6.22 (2.45) n=20 7.37 (2.7) n=15
Stelmach 2009 Medication score
(first pollen season)
Mean weekly medi-
cation score during
first pollen season,
adjusted for pollen
concentration
Mean (SD) 5.1 (1.77) n=20 7.48 (2.78) n=15
Analysis 2.1. Comparison 2 Subgroup and sensitivity analyses, Outcome 1 Adverse events by age.
Review: Sublingual immunotherapy for asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 1 Adverse events by age
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Children (mean age < 18 years)
Bahceciler 2001 0/8 0/7 Not estimable
Caffarelli 2000 0/24 0/20 Not estimable
Eifan 2009 0/15 0/14 Not estimable
Ippoliti 2003 0/47 0/39 Not estimable
Keles 2011 0/13 0/12 Not estimable
Niu 2006 6/49 7/48 7.5 % 0.82 [ 0.25, 2.64 ]
Shao 2014 39/168 9/96 15.0 % 2.92 [ 1.35, 6.34 ]
Vourdas 1998 8/34 2/32 4.0 % 4.62 [ 0.90, 23.70 ]
Subtotal (95% CI) 358 268 26.6 % 2.13 [ 0.83, 5.47 ]
Total events: 53 (SLIT), 18 (Control)
Heterogeneity: Tau2 = 0.35; Chi2 = 4.06, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 1.58 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours SLIT Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 Teenagers and adults (mean age > 18 years)
Alvarez-Cuesta 2007 0/17 0/16 Not estimable
Calderon 2006 (1) 36/36 10/11 1.1 % 10.43 [ 0.40, 275.32 ]
Gomez Vera 2005 0/30 0/30 Not estimable
Leng 1990 1/9 0/9 1.0 % 3.35 [ 0.12, 93.83 ]
Marogna 2005 4/29 0/23 1.3 % 8.29 [ 0.42, 162.48 ]
Mosbech 2014 (2) 290/461 77/143 37.4 % 1.45 [ 0.99, 2.12 ]
Mungan 1999 2/15 0/11 1.1 % 4.26 [ 0.18, 98.07 ]
NCT00633919 (3) 24/63 21/61 16.4 % 1.17 [ 0.56, 2.44 ]
Subtotal (95% CI) 660 304 58.2 % 1.48 [ 1.06, 2.06 ]
Total events: 357 (SLIT), 108 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.74, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
3 Mixed age study population or age range not specified
Bousquet 1999 15/42 14/43 11.8 % 1.15 [ 0.47, 2.82 ]
La Grutta 2007 0/33 0/23 Not estimable
Troise 2009 11/14 4/10 3.4 % 5.50 [ 0.91, 33.18 ]
Subtotal (95% CI) 89 76 15.2 % 2.06 [ 0.47, 9.05 ]
Total events: 26 (SLIT), 18 (Control)
Heterogeneity: Tau2 = 0.70; Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI) 1107 648 100.0 % 1.70 [ 1.21, 2.38 ]
Total events: 436 (SLIT), 144 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.52, df = 10 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.66, df = 2 (P = 0.72), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours SLIT Favours control
(1) 4 different dosing arms combined
(2) 3 different dosing arms combined
(3) Adverse events only reported if over 5% of participants were affected
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Analysis 2.2. Comparison 2 Subgroup and sensitivity analyses, Outcome 2 Adverse events by allergen.
Review: Sublingual immunotherapy for asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 2 Adverse events by allergen
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 HDM SLIT
Bahceciler 2001 0/8 0/7 Not estimable
Bousquet 1999 15/42 14/43 11.8 % 1.15 [ 0.47, 2.82 ]
Gomez Vera 2005 0/30 0/30 Not estimable
Ippoliti 2003 0/47 0/39 Not estimable
Keles 2011 0/13 0/12 Not estimable
Mosbech 2014 (1) 290/461 77/143 37.4 % 1.45 [ 0.99, 2.12 ]
Mungan 1999 2/15 0/11 1.1 % 4.26 [ 0.18, 98.07 ]
NCT00633919 (2) 24/63 21/61 16.4 % 1.17 [ 0.56, 2.44 ]
Niu 2006 6/49 7/48 7.5 % 0.82 [ 0.25, 2.64 ]
Shao 2014 39/168 9/96 15.0 % 2.92 [ 1.35, 6.34 ]
Subtotal (95% CI) 896 490 89.2 % 1.47 [ 1.10, 1.97 ]
Total events: 376 (SLIT), 128 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.11, df = 5 (P = 0.40); I2 =2%
Test for overall effect: Z = 2.61 (P = 0.0090)
2 Pollen SLIT
Caffarelli 2000 0/24 0/20 Not estimable
Calderon 2006 (3) 36/36 10/11 1.1 % 10.43 [ 0.40, 275.32 ]
Leng 1990 1/9 0/9 1.0 % 3.35 [ 0.12, 93.83 ]
Marogna 2005 4/29 0/23 1.3 % 8.29 [ 0.42, 162.48 ]
Troise 2009 11/14 4/10 3.4 % 5.50 [ 0.91, 33.18 ]
Vourdas 1998 8/34 2/32 4.0 % 4.62 [ 0.90, 23.70 ]
Subtotal (95% CI) 146 105 10.8 % 5.48 [ 1.99, 15.05 ]
Total events: 60 (SLIT), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00097)
3 Other/mixed allergens
Alvarez-Cuesta 2007 0/17 0/16 Not estimable
La Grutta 2007 0/33 0/23 Not estimable
0.02 0.1 1 10 50
Favours SLIT Favours control
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(. . . Continued)
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 50 39 Not estimable
Total events: 0 (SLIT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1092 634 100.0 % 1.70 [ 1.21, 2.38 ]
Total events: 436 (SLIT), 144 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.52, df = 10 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 6.00, df = 1 (P = 0.01), I2 =83%
0.02 0.1 1 10 50
Favours SLIT Favours control
(1) 3 different dosing arms combined
(2) Adverse events only reported if over 5% of participants were affected
(3) 4 different dosing arms combined
Analysis 2.3. Comparison 2 Subgroup and sensitivity analyses, Outcome 3 Adverse events by study duration.
Review: Sublingual immunotherapy for asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 3 Adverse events by study duration
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Duration less than 52 weeks
Bahceciler 2001 0/8 0/7 Not estimable
Caffarelli 2000 0/24 0/20 Not estimable
Calderon 2006 (1) 36/36 10/11 1.1 % 10.43 [ 0.40, 275.32 ]
Gomez Vera 2005 0/30 0/30 Not estimable
Gomez Vera 2005 0/30 0/30 Not estimable
Ippoliti 2003 0/47 0/39 Not estimable
Leng 1990 1/9 0/9 1.0 % 3.35 [ 0.12, 93.83 ]
0.05 0.2 1 5 20
Favours SLIT Favours control
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(. . . Continued)
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Niu 2006 6/49 7/48 7.5 % 0.82 [ 0.25, 2.64 ]
Subtotal (95% CI) 233 194 9.5 % 1.53 [ 0.38, 6.19 ]
Total events: 43 (SLIT), 17 (Control)
Heterogeneity: Tau2 = 0.39; Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Duration 52 weeks and longer
Alvarez-Cuesta 2007 0/17 0/16 Not estimable
Bousquet 1999 15/42 14/43 11.8 % 1.15 [ 0.47, 2.82 ]
Eifan 2009 0/15 0/14 Not estimable
Keles 2011 0/13 0/12 Not estimable
La Grutta 2007 0/33 0/23 Not estimable
Marogna 2005 4/29 0/23 1.3 % 8.29 [ 0.42, 162.48 ]
Mosbech 2014 (2) 290/461 77/143 37.4 % 1.45 [ 0.99, 2.12 ]
Mungan 1999 2/15 0/11 1.1 % 4.26 [ 0.18, 98.07 ]
NCT00633919 (3) 24/63 21/61 16.4 % 1.17 [ 0.56, 2.44 ]
Shao 2014 39/168 9/96 15.0 % 2.92 [ 1.35, 6.34 ]
Troise 2009 11/14 4/10 3.4 % 5.50 [ 0.91, 33.18 ]
Vourdas 1998 8/34 2/32 4.0 % 4.62 [ 0.90, 23.70 ]
Subtotal (95% CI) 904 484 90.5 % 1.77 [ 1.22, 2.58 ]
Total events: 393 (SLIT), 127 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 8.76, df = 7 (P = 0.27); I2 =20%
Test for overall effect: Z = 3.01 (P = 0.0026)
Total (95% CI) 1137 678 100.0 % 1.70 [ 1.21, 2.38 ]
Total events: 436 (SLIT), 144 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.52, df = 10 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.05 0.2 1 5 20
Favours SLIT Favours control
(1) 4 different dosing arms combined
(2) 3 different dosing arms combined
(3) Adverse events only reported if over 5% of participants were affected
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Analysis 2.4. Comparison 2 Subgroup and sensitivity analyses, Outcome 4 Adverse events (sensitivity for
risk of bias: blinded studies only).
Review: Sublingual immunotherapy for asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 4 Adverse events (sensitivity for risk of bias: blinded studies only)
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alvarez-Cuesta 2007 0/17 0/16 Not estimable
Bahceciler 2001 0/8 0/7 Not estimable
Bousquet 1999 15/42 14/43 10.6 % 1.15 [ 0.47, 2.82 ]
Caffarelli 2000 0/24 0/20 Not estimable
Calderon 2006 (1) 36/36 10/11 0.8 % 10.43 [ 0.40, 275.32 ]
Gomez Vera 2005 0/30 0/30 Not estimable
Ippoliti 2003 0/47 0/39 Not estimable
Leng 1990 1/9 0/9 0.8 % 3.35 [ 0.12, 93.83 ]
Mosbech 2014 (2) 290/461 77/143 59.2 % 1.45 [ 0.99, 2.12 ]
Mungan 1999 2/15 0/11 0.9 % 4.26 [ 0.18, 98.07 ]
NCT00633919 (3) 24/63 21/61 15.8 % 1.17 [ 0.56, 2.44 ]
Niu 2006 6/49 7/48 6.2 % 0.82 [ 0.25, 2.64 ]
Troise 2009 11/14 4/10 2.6 % 5.50 [ 0.91, 33.18 ]
Vourdas 1998 8/34 2/32 3.2 % 4.62 [ 0.90, 23.70 ]
Total (95% CI) 849 480 100.0 % 1.47 [ 1.10, 1.96 ]
Total events: 393 (SLIT), 135 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.63, df = 8 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours SLIT Favours control
(1) 4 different dosing arms combined
(2) 3 different dosing arms combined
(3) Adverse events only reported if over 5% of participants were affected
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Analysis 2.5. Comparison 2 Subgroup and sensitivity analyses, Outcome 5 Adverse events (sensitivity
analysis removing studies with mixed population of asthma and rhinitis).
Review: Sublingual immunotherapy for asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 5 Adverse events (sensitivity analysis removing studies with mixed population of asthma and rhinitis)
Study or subgroup SLIT Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bahceciler 2001 0/8 0/7 Not estimable
Bousquet 1999 15/42 14/43 10.9 % 1.15 [ 0.47, 2.82 ]
Calderon 2006 (1) 36/36 10/11 0.8 % 10.43 [ 0.40, 275.32 ]
Gomez Vera 2005 0/30 0/30 Not estimable
Ippoliti 2003 0/47 0/39 Not estimable
Keles 2011 0/13 0/12 Not estimable
La Grutta 2007 0/33 0/23 Not estimable
Leng 1990 1/9 0/9 0.8 % 3.35 [ 0.12, 93.83 ]
Marogna 2005 4/29 0/23 1.0 % 8.29 [ 0.42, 162.48 ]
Mosbech 2014 (2) 290/461 77/143 61.0 % 1.45 [ 0.99, 2.12 ]
NCT00633919 (3) 24/63 21/61 16.3 % 1.17 [ 0.56, 2.44 ]
Niu 2006 6/49 7/48 6.4 % 0.82 [ 0.25, 2.64 ]
Troise 2009 11/14 4/10 2.7 % 5.50 [ 0.91, 33.18 ]
Total (95% CI) 834 459 100.0 % 1.42 [ 1.06, 1.91 ]
Total events: 387 (SLIT), 133 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.57, df = 7 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours SLIT Favours control
(1) 4 different dosing arms combined
(2) 3 different dosing arms combined
(3) Adverse events only reported if over 5% of participants were affected
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A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study ID Total N Allergen Comparator Age range Country Duration % with asthma
Almarales
2012
120 HDM Placebo Not reported Cuba 52 weeks 100
Alvarez-
Cuesta 2007
50 Cat dander Placebo 14-55 Spain 52 weeks 81.8
Bahceciler
2001
15 HDM Placebo 7-18 Turkey 26 weeks* 100
Bousquet
1999
85 HDM Placebo 7-42 France 108 weeks* 100
Caffarelli
2000
48 Grass pollen Placebo 4-14 Italy 13 weeks* 89.6
Calderon
2006
43 Grass pollen Placebo 18-65 Unclear 4 weeks* 100
Corzo 2014
(a)
71 HDM Placebo 18-65 UK and Den-
mark
4 weeks 100
Corzo 2014
(b)
72 HDM Placebo 5-14 Spain 4 weeks 100
Cooper 1984 19 Grass pollen Placebo 5-15 UK > 8 but < 16
weeks*
100
Criado
Molina 2002
44 Alternaria Pharmacother-
apy
18-65 Spain 52 weeks 100
Dahl 2006 114 Timothy grass Placebo 18-65 Denmark and
Sweden
19.5 weeks 100
Eifan 2009 48 HDM Pharmacother-
apy
5-10 Turkey 52 weeks 85
Fadel 2010 55 Grass pollen Placebo 18-50 Syria Not reported 100
Gomez Vera
2005
60 HDM Placebo 13-45 Mexico 26 weeks 100
Hanna 2013 60 HDM Placebo Not reported Not reported 13 weeks 100
Inal 2009 32 HDM Placebo Not reported Turkey 52 weeks 100
Ippoliti 2003 86 HDM Placebo 5-12 Italy 26 weeks* 100
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Table 1. Summary of study characteristics (Continued)
Karakoc-
Aydiner 2011
31 HDM Pharmacother-
apy
’Children’ Unclear 156 weeks 100
Keles 2009 53 HDM Pharmacother-
apy
Not reported Unclear 17.3 weeks 100
Keles 2011 58 HDM Pharmacother-
apy
5-12 Turkey 52 weeks* 100
La Grutta
2007
56 HDM/
Parietaria
Pharmacother-
apy
7-68 Italy 52 weeks 100
Leng 1990 18 Artemisia
pollen
Placebo 15-56 Unclear 7.14 weeks* 100
Lewith 2002 242 Homeopathic
HDM
Placebo 18-55 UK 16 weeks 100
Lue 2006 20 HDM Placebo 6-12 Taiwan 24 weeks* 100
Marcucci
2003
24 HDM Placebo 4-16 Italy 52 weeks 84.6
Marogna
2005
79 Birch pollen Pharmacother-
apy
18-65 Italy 156 weeks* 100
Mosbech
2014
604 HDM Placebo 14+ Denmark, Ger-
many, Italy,
Spain, United
Kingdom, Swe-
den, France,
Poland
52 weeks 100
Mosges 2010 116 Ultra-rush
birch pollen
Placebo 6-14 Germany 0.015 weeks 100
Mungan 1999 36 HDM Placebo 18-46 Turkey 52 weeks 88
Muratore
1993
28 HDM Placebo 4-9 Italy 52 weeks 100
NCT00633919
124 HDM Placebo 18-65 Spain 104 weeks 100
Niu 2006 110 HDM Placebo 6-12 Taiwan 24 weeks* 100
Orefice 2004 47 HDM Pharmacother-
apy
Not reported Italy 156 weeks 100
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Table 1. Summary of study characteristics (Continued)
Pajno 2000 24 HDM Placebo 8-15 Italy 104 weeks 100
Pajno 2003 30 Parietaria Placebo 8-14 Italy 56 weeks* 100
Pham-Thi
2007
111 HDM Placebo 5-16 France 78 weeks 100
Radu 2007 106 HDM Placebo 5-13 Romania 26 weeks 100
Reilly 1994 28 Home-
opathic HDM/
feathers/
mixed moulds
Placebo 16+ Scotland 4 weeks* 100
Rodriguez
2012
40 HDM Placebo ’Adults’ Cuba Not reported 100
Rodriguez
Santos 2004
50 HDM Pharmacother-
apy
6-15 Cuba 104 weeks 100
Shao 2014 264 HDM Pharmacother-
apy
3-13 China 52 weeks 82
Stelmach
2009
50 Grass pollen Placebo 6-17 Poland 104 weeks 100
Tian 2014 60 HDM Placebo 4-18 China 48 weeks 100
Troise 2009 24 Birch pollen Placebo Not reported Unclear 104 weeks 100
Virchow 2014 834 HDM Plaecbo Not reported Austria, Croa-
tia, Denmark,
France,
Germany,
Lithuaina,
Netherlands,
Poland, Serbia,
Slovakia, Spain,
United
Kingdom
78 weeks 100
Vourdas 1998 66 Olive pollen Placebo 7-17 Greece 104 weeks 90.6
Wang 2014 484 HDM Placebo 16-50 China 52 weeks* 100
Wood 2014 89 Greer German
cockroach
Placebo 5-17 USA and UK 13 weeks 80
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Table 1. Summary of study characteristics (Continued)
Yukselen 2013 32 HDM Placebo Not reported Turkey 52 weeks 100
Zeldin 2013 63 HDM Placebo ’Adults’ France 1.4 weeks 100
Zhang 2013 128 HDM Pharmacother-
apy
4-14 Taiwan 104 weeks 100
Zheng 2012 106 HDM Pharmacother-
apy
4-14 China Out-
comes reported
at 25 weeks
100
*Studies that included post-treatment follow-up periods.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
American Academy of Allergy Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
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7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Administration, Sublingual
#6 sublingual*
#7 tongue*
#8 oral*
#9 #5 or #6 or #7 or #8
#10 MeSH DESCRIPTOR immunotherapy Explode All
#11 immunotherap*
#12 hyposensit*
#13 desensit*
#14 #10 or #11 or #12 or #13
#15 #9 and #14
#16 SLIT:ti,ab
#17 #4 and (#15 or #16)
[Note: in search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
C O N T R I B U T I O N S O F A U T H O R S
RN and KMK sifted the search results and compiled the list of included studies.
RN, KMK and ALB extracted data and entered them into the review.
RN and KMK performed and interpreted the analyses.
RN wrote the Background, Methods and Discussion sections with substantial input from KMK and ALB.
RN and ALB wrote the Results section with substantial input from KMK.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• RN, KK, UK.
St George’s, University of London
External sources
• RN, KK, UK.
National Institute for Health Research. Evidence to guide care in adults and children with asthma, 13/89/14
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Wedid not anticipate identifying somany trials that included participants with asthma and/or rhinitis and did not provide disaggregated
data for participants with asthma. As a pragmatic change to our protocol, we decided to include studies in which 80% or more of the
participants were diagnosed with asthma. We have taken this into account in our GRADE assessments of the quality of the evidence and
have performed a sensitivity analysis removing the ’mixed population’ trials from the adverse events outcome. Furthermore, we specified
in our protocol that studies should cite a specific guideline for the purpose of asthma diagnosis. If no guideline was cited we specified
that trialists should provide sufficient information to allow us to establish the diagnosis according to an established guideline. However,
we found insufficient description in most of the studies identified by our search and accepted that if participants were described as
having asthma, we would consider this as meeting our inclusion criteria.
In view of the large number of included studies, we attempted to contact study authors only to clarify whether or not the study met
our inclusion criteria; we did not attempt to obtain further information regarding trial methods or results. Furthermore, because of the
large number of manufacturers of SLIT, we did not search individual company websites for relevant trials.
We chose to extract data for all adverse events as well as serious adverse events because of the paucity of events in the latter outcome.We
included all adverse events in our summary of findings table, rather than asthma symptoms, as we were not able to perform a meta-
analysis for asthma symptoms.
We decided to use risk differences (RDs) rather than odds ratios (ORs) to analyse serious adverse events to account for trials with no
events in either arm.
None of our primary outcomes had sufficient data for subgroup or sensitivity analyses to be carried out; as a result, we performed these
analyses on the all adverse events outcome.We were not able to perform a subgroup analysis according to baseline asthma severity as the
majority of studies included participants with mild or intermittent symptoms, or did not describe baseline asthma severity in sufficient
detail. We did not include any unpublished data in the review so this sensitivity analysis was not required. As described above, we
included an additional sensitivity analysis excluding studies which recruited a ’mixed population’ of participants with asthma and/or
rhinitis.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Asthma [∗therapy]; Pollen; Pyroglyphidae; Randomized Controlled Trials as Topic; Sublingual Immunotherapy [adverse effects;
∗methods]
MeSH check words
Adult; Animals; Child; Humans
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